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Regenerative medicine offers great hope for therapeutic innovation in many 
diseases, including those with defective skin, such as the group of inherited 
blistering skin diseases known as epidermolysis bullosa. The work in this 
thesis addresses some of the important pre-clinical approaches to generating 
keratinocytes (the main cell of the outer skin layer, epidermis) from 
pluripotent stem cells (human embryonic stem cells, hESCs). 
Undifferentiated hESCs were exposed to a complex microenvironment in 
organotypic cultures (to mimic conditions for epidermal stem cell 
development and maintenance); this yielded epidermis-like structures which 
stained positively for basal keratin 14 and several extracellular matrix 
molecules, although a stratified epidermis was not produced. To refine the 
protocol, hESCs were differentiated to an epidermal cell fate in monolayer 
cultures in vitro prior to subjecting them to organotypic culture. The most 
efficient technique involved culture of hESCs on native de-cellularized 
extracellular matrix produced by normal human dermal fibroblasts as a 
substrate for differentiation. Large epithelial-like sheets positive for keratin 
14 and p63 expression were observed. On subculture, these cells retained 
their morphological and immunocytochemical characteristics for up to 5 
passages and could be successfully cryo-preserved and recovered. Overall, 
this study explored the potential of pluripotent stem cells as a source of 
epidermal progenitors, with results that provide proof-of-concept for future 
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1.1 OVERVIEW OF SKIN FUNCTION 
Skin provides a defensive barrier against pathogens and environmental 
stresses, such as dehydration and temperature fluctuations, as well as 
mechanical resistance to trauma. The epidermis is a highly specialized 
epithelium that has evolved to provide a stable environmental barrier to 
prevent dehydration, resist mechanical and chemical stress and participate 
in immune responses. This barrier is generated, in part, by keratinocytes, 
the main cells of the epidermis, which form an adhesive network organized 
into multiple layers, or ‘strata’ (Fuchs and Raghavan, 2002, Candi et al., 
2005) (Figure 1). However, despite its remarkable stability, epidermis is 
amongst the most dynamic tissues in human body, which allows for tissue 
regeneration every 3-4 weeks. This function is supported by epidermal stem 
cells, which are responsible for constantly renewing the epidermis and 







Figure 1 Structure of epidermis within the skin.  
Skin is composed of two layers: the epidermis and dermis, separated by a basement 
membrane (BM). The epidermis is a stratified squamous epithelia that is composed of 
several cell layers. Attached to the BM is the basal layer (BL), consisting of highly 
proliferating cells. The BL stratifies to give rise to differentiated cell layers of the spinous 







1.2 STEM CELLS WITHIN THE SKIN 
Skin harbours several adult stem cell populations, each with a specific 
location and molecular characteristics; these are summarized in Figure 2. 
"
"
Figure 2 Location of adult stem cells in normal human skin and their role in 
homeostasis. 
Inserts indicate various locations within skin that harbour stem cells, arrows on the right 
indicate the contribution of a particular stem cell population to maintenance of skin 
homeostasis 1) Interfollicular epidermal stem cells; 2) Bulge epidermal stem cells; 3) 
Isthmus epidermal stem cells; 4) Hair follicle dermal-sheath stem cells; 5) Skin-derived 
precursors; 6) Dermal mesenchymal stem cells. 
"
1.2.1 Epidermal stem cells 
Adult stem cells can be defined by certain criteria: they are relatively 
undifferentiated, both morphologically and functionally; they provide a self-




slow-cycling in vivo but possess high proliferative potential which can be 
triggered in response to tissue injury and to certain growth stimuli. In 
addition, adult stem cells are normally located in a sheltered 
microenvironment, referred to as a “niche”, which contributes to, and 
regulates stem cell activity and behaviour (Lavker and Sun, 1982, Potten 
and Loeffler, 1990). Slow-cycling stem cells within skin have been identified 
experimentally as “label-retaining cells” (Bickenbach, 1981, Potten, 1987). 
Using this approach, two populations of epidermal stem cells (EpSCs) have 
been identified: the first was localized to the basal layer of epidermis; the 
second was shown to reside in the bulge area of hair follicles. More recently, 
a third population of EpSCs was localized to the upper isthmus, a region 
between the bulge and the sebaceous gland. 
 
1.2.1.1 Interfollicular EpSCs.  
In 1987, the heterogeneity of human EpSCs was demonstrated when three 
different types of clonal expansion were observed in human primary 
keratinocytes culture: holoclone, paraclone and meroclone (Barrandon and 
Green, 1987). The holoclone, the smallest colony-founding cell with the 
highest proliferative capacity, is considered to be the prototypic EpSC 
(Pellegrini et al., 1999, Jones and Watt, 1993). A single holoclone can double 
enough times within a few weeks to produce an area equivalent to the skin 
surface of an adult (~8x10"º cells). Subsequent studies have shown that 
human EpSCs firmly adhere to basement membrane and represent a minor 




(Bickenbach, 1981, Li et al., 1998). These cells are mitotically active and 
contribute to the homeostasis of the epidermis by their constant 
proliferation into rapidly dividing differentiated progeny (Alonso and Fuchs, 
2003). The first progeny of stem cell division has been termed transient 
amplifying cells, which have a limited proliferative potential, yet share 
many molecular markers with their parent cell population (Jones and Watt, 
1993). Some EpSCs may give rise to daughter cells that lack attachment to 
BM and which are already committed to terminal differentiation, a process 
known as asymmetrical cell division (Blanpain and Fuchs, 2009). 
Comprehensive efforts have been made to identify and isolate a pure 
population of both mouse and human EpSCs, including combined use of cell 
kinetic analysis and fluorescent-associated cell sorting (FACS) in vivo (Tani 
et al., 2000, Li et al., 1998). EpSCs display high levels of #6 integrin, and 
low-to-undetectable expression of the transferrin receptor, CD71. Use of 
FACS, however, introduces some limitations as cell viability is partially 
compromised. As a further approach, adhesion-selection methods can be 
used (Radu et al., 2002). These have shown that human EpSCs can be 
directly enriched from keratinocytes based on their rapid adherence to the 
$1-integrin ligand collagen type IV, and by their small size (5–7µm) (Chino 
et al., 2008). Despite the existence of enrichment approaches mentioned 
above, isolation of a pure and viable population of EpSCs has not yet been 
achieved. A number of other molecular markers have been suggested as 
putative EpSCs markers, including p63, (Pellegrini et al., 2001), a 
homologue of the p53 tumour suppressor gene which exists as six different 




alternative splicings leading to the production of %N- or TA-p63, and #, $ or 
& isoforms, respectively (Yang et al., 1998). The involvement of p63 has been 
implicated in both the development and maintenance of stratified epithelia 
in mice (Mills et al., 1999, Yang et al., 1999). Expression of p63 was shown 
to be indispensible for the initiation of epidermal stratification when the 
exogenous expression of p63 in single-layered lung keratin 8/keratin 18-
positive epithelial cells was able to initiate a stratification program, with 
formation of keratin 14-positive cells (Koster et al., 2004). Accordingly, 
absence of p63 results in premature termination of stem cell proliferation 
and failure to form stratified epithelium (Senoo et al., 2007). Other possible 
markers include P-glycoprotein, a multidrug resistance pump that mediates 
Hoechst 33342 dye exclusion, in murine keratinocytes (Sleeman et al., 
2000), while all keratins 15 (Lyle et al., 1998) and 19 (Stasiak et al., 1989) 
and raised levels of $ catenin (Zhu and Watt, 1999) have been implicated in 
human EpSCs. 
 
1.2.1.2 Bulge EpSCs.  
The hair follicle contains an outer root sheath that is contiguous with 
the epidermis, an inner root sheath and a hair shaft. The matrix 
surrounding the dermal papilla, in the hair root, contains actively dividing, 
relatively undifferentiated cells and therefore represents a source 
of mesenchymal cells that are essential for follicle formation. In mice, the 
bulge region, located below the sebaceous gland, is a niche for multipotent 




Subsets of these follicle-derived multipotent stem cells can be activated 
during injury and migrate out of hair follicles to the site of a wound to 
repair the damaged epithelium (Ito et al., 2005, Nowak et al., 2008); 
however, they contribute little to the homeostasis of intact epidermis. 
Instead these hair-follicle stem cells mostly contribute to the growth of 
follicles themselves and the sebaceous gland (Morris et al., 2004, Levy et al., 
2005). In addition, the bulge contains melanocyte stem cells (Steingrimsson 
et al., 2005). Furthermore, nestin-positive progenitor cells have been 
identified within the bulge region; these cells can differentiate into neurons 
(Amoh et al., 2008), glia, keratinocytes, smooth muscle cells, melanocytes 
and blood vessels (Amoh et al., 2005a, Amoh et al., 2005b). 
 
1.2.1.3 Isthmus EpSCs.  
A further putative EpSC population has recently been identified in the 
upper isthmus of the murine hair follicle, a region between the bulge and 
the sebaceous gland. These cells are positive for mTS24 and Lrig1 marker 
proteins (Nijhof et al., 2006), and can differentiate into all epidermal cell 
lineages after transplantation (Jensen et al., 2008). Recently, Lrg6-
expressing cells in the isthmus that can generate both hair follicles and 
sebaceous glands during development have been identified (Snippert et al., 
2010). Furthermore, Lrg-6 cells may also contribute to some cells of the 
interfollicular epidermis. Like isthmus cells, Lrg6-expressing cells 




lineages, and, like bulge cells, can be activated in injury to aid wound repair 
(Snippert et al., 2010).  
 
1.2.2 Dermal Stem Cells 
The dermis also contains several adult stem cell populations.  
 
1.2.3.1 Hair-follicle dermal-sheath stem cells.  
These cells contribute to the formation of dermal papilla cells and wound-
healing fibroblasts (Reynolds et al., 1999, Gharzi et al., 2003). One of the 
main advantages of hair-follicle-derived stem cells is their unique 
immunological profile: the virtual absence of major histocompatibility 
complex (MHC) class I expression and low numbers of associated immune 
cells (Paus et al., 2003). Furthermore, the presence of resident mesenchymal 
stem-cell-like cells has been reported in both rodent and human dermis 
(Jahoda and Reynolds, 2001). These cells not only contribute to mesodermal 
derivates of the dermis, but are also able to differentiate along 
mesenchymal stem cell pathways to produce adipocytes, chondrocytes, 
haematopoietic and neuronal precursors – both in vitro and in vivo (Gharzi 





1.2.3.2 Skin-derived precursors.  
The hair and whisker follicle dermal papillae have also been shown to 
harbour multipotent nestin- and fibronectin-positive precursors (Biernaskie 
et al., 2009, Toma et al., 2001). These cells, termed skin-derived precursors 
(SKPs), are distinct from mesenchymal stem cells and their capacity to 
differentiate into cells of neuroectodermal and mesodermal lineage was 
shown in both mice and human studies (Toma et al., 2001, Buranasinsup et 
al., 2006). SKPs share many characteristics with embryonic neural crest 
stem cells, including neural-crest-like differentiation potential in vitro and 
in vivo, and for whisker follicle dermal papillae, the cells are neural-crest-
derived (Fernandes et al., 2004). 
 
1.2.3.3 Dermal mesenchymal stem cells (D-MSCs).  
These cells can be obtained by adherent culture from low-temperature 
preserved human foreskin biopsies (Bartsch et al., 2005). The group has 
shown that D-MSCs are able differentiate into mesodermal lineages 
including adipocytes, osteocytes and myocytes. Recently, dermal fibroblasts 
themselves have been dissected based on clonal analysis of their 
differentiation potential (Chen et al., 2007). This study showed that nestin-
negative, vimentin-positive fibroblasts may represent a novel type of 
multipotent adult stem cells in human dermis. In addition, another 
multipotent MSC population has been isolated from within a population of 




termed Muse cells, are positive for pluripotency markers and able to 
differentiate into all three germ layers. 
The skin stem cell populations described co-operate together to replenish 
the epidermis and replace keratinocytes that are lost either through normal 
differentiation and tissue turnover, or through environmental insults, 
thereby maintaining skin integrity. However, this function can be severely 
compromised in certain skin conditions such as epidermolysis bullosa (EB). 
 
1.3 EPIDERMOLYSIS BULLOSA 
EB is a group of blistering skin disorders resulting from mutations in one of 
15 different genes encoding protein components of the cutaneous basement 
membrane zone (BMZ), keratinocyte or cell-cell adhesion complexes (Intong 
and Murrell, 2012). These mutations affect the organization of BMZ, 
causing the epidermis to separate from the dermis. The site of cleavage in 
the dermal-epidermal junction (DEJ) is dependent on which of the genes is 
defective (Figure 3). EB is classed according to the site of cleavage into four 
subtypes: EB simplex, dystrophic EB, junctional EB, and Kindler syndrome 
(Verneris et al., 2009, Fine et al., 2008). In EB simplex tissue separation is 
intraepidermal, the lamina lucida cleavage occurs in junctional EB, whereas 
in dystrophic forms of EB blistering is found below the lamina densa. 
Recessive dystrophic EB (RDEB) is one of the most severe forms of EB. The 
skin of RDEB patients can blister with a slightest touch and wound healing 




blistering and scarring is very common. The skin integrity is severely 
compromised, causing frequent infections due to loss of the protective 
function. The leading cause of death of patients with RDEB is squamous cell 
carcinomas (McGrath et al., 1991). 
The primary pathology of RDEB involves reduced or absent expression of 
the anchoring fibril protein type VII collagen at the DEJ leading to sub-
epidermal blistering (Bruckner-Tuderman et al., 1989, Hovnanian et al., 
1992, McGrath et al., 1993a). In RDEB, the level of blistering is below the 
BMZ which is likely to deplete the pool of interfollicular EpSCs, thereby 
disrupting skin homeostasis. Currently, there is no effective treatment for 
RDEB, although progress is being made in developing new therapies, 
including cell therapy approaches (Uitto, 2011, Uitto et al., 2012). It is 
important to remember that for a genetic skin disease, such as RDEB, 
correction of the underlying genetic defect or sustained allogeneic 
transplantation from healthy donors would be required in order to achieve 
successful cell therapy. Both keratinocytes and fibroblasts can synthesize 
and secrete type VII collagen (Stanley et al., 1985), and therefore both cell 
types might be beneficial for restoring the integrity of BMZ in RDEB. 
However, due to the constant turnover of skin, the ideal cell therapy would 
have to be aimed at resident skin stem cells in order to have a long-term 
sustainable therapeutic effect; alternative approaches in somatic cells might 







Figure 3 The classification of Epidermolysis Bullosa.  
Classification is based on the localization of the defective gene within the DEJ. EB- 
Epidermolysis Bullosa; BP Ag- Bullous Pemphigoid antigen 
"
1.4 POTENTIAL ADULT STEM CELL SOURCES FOR SKIN 
REGENERATIVE THERAPY 
With respect to treatment for skin fragility diseases, such as RDEB, several 
stem cell types have been studied and explored. These can be broadly 
divided into resident skin stem cells (Table 1) and stem cells from tissues 
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Table 1 Summary of different stem cell types within the skin that that could 
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Table 2 Summary of different stem cell types from tissues other than the skin 




1.4.1 Epidermal stem cells for skin regenerative therapy 
Despite numerous studies, the extent to which stem cells from the bulge 
region and the isthmus could contribute to epidermal regeneration remains 
unclear, thus impeding their potential application in cell therapy for EB. On 
the other hand, the importance of interfollicular stem cells in skin 
regenerative therapy has been confirmed by keratinocyte-mediated cell 
therapy in the treatment of full-thickness burns (Pellegrini et al., 1998). The 
first approaches for skin regeneration were mostly concerned with wound 
repair and utilized autologous (Simon et al., 1995) or allogeneic grafting 
systems, such as commercially available Apigraf® (Veves et al., 2001). 
Specifically, in RDEB skin grafting has been performed with cultured 
keratinocytes allografts (McGrath et al., 1993b), autologous cultured 
keratinocytes (Verplancke et al., 1997), allogeneic composite cultured skin 
grafts (Eisenberg and Llewelyn, 1998, Fivenson et al., 2003) and autologous 
epidermal grafts (Wollina et al., 2001). However, it is now clear that the 
long-term function of the graft is limited by the fact that grafted 
keratinocytes are on the path to terminal differentiation due to prolonged 
culture in vitro. It has been demonstrated that progenitor cells are superior 
over differentiated keratinocytes in the generation of engineered skin 
(Pellegrini et al., 1999). To date thousands of victims of third-degree burns 
have been treated by the means of cultured EpSCs as confirmed by follow-
up studies over a 20 year period (De Luca et al., 2006), thus confirming the 
capacity of EpSCs to maintain the clonogenic potential, growth rate and 




Despite the proof of their self-renewal and multipotency, EpSCs remain 
difficult to isolate due to the lack of well-defined markers thereby impeding 
their application for skin regenerative therapies. Recently, a first-in-man 
clinical trial in patient with non-Herlitz junctional EB showed a full 
functional correction of the disease through ex vivo correction of the 
underlying laminin-332 defect in autologous EpSCs (Mavilio et al., 2006). It 
should be noted, however, the authors were unable to obtain clonogenic and 
holoclone-forming cells from most of the patient’s skin. Increasing evidence 
suggests that in EB patients there is a depletion or a potential exhaustion of 
the endogenous EpSC population, thus implying that it would be a major 
technical challenge to obtain a sufficient amount of autologous EpSCs for 
further genetic correction and therapy. Therefore, alternative sources of 
stem cells should be explored. 
 
1.4.2 Dermal stem cells for skin regenerative therapy 
Dermal stem cells might prove to be useful in restoring the normal function 
of type VII collagen in RDEB. It has been shown that gene-corrected RDEB 
fibroblasts and normal human fibroblasts alone could restore type VII 
collagen expression at the BMZ in vivo (Woodley et al., 2003). Furthermore, 
a recent clinical has shown that intradermal injections of allogeneic 
fibroblasts can potentially benefit patients with RDEB (Wong et al., 2008). 
The main drawback of this approach is that the presence of multiple wounds 
in RDEB would require numerous intradermal injections which are both 




potentially avoided if dermal stem cells are utilized instead. Nevertheless, 
these remain difficult to isolate and are likely to represent a very rare 
population within the dermis. Moreover, the main defect in EB lies within 
the epidermis, strongly suggesting the importance of restoring the 
epidermal compartment of the skin. 
On the other hand, multipotent MSCs within dermis might provide a 
potential source for generating EpSCs. In addition, they have a practical 
advantage of easy accessibility compared to other MSCs. However, 
knowledge on resident skin MSC biology remains limited and the extent of 
their differentiation potential into keratinocytes remains unclear, thus for 
time being, alternative sources of multipotent progenitors should be 
considered. 
 
1.4.2 Mesenchymal Stem Cells (MSCs) for skin regenerative 
therapy 
1.4.2.1 Bone marrow-derived MSCs (BM-MSCs) 
These cells participate in the regeneration of mesenchymal lineages by 
providing fibroblast-like cells in the dermis and the number of these cells 
increases in skin wounding (Fathke et al., 2004, Ishii et al., 2005). 
Furthermore, several studies have shown that MSCs participate in the 
regeneration of skin in cutaneous wounds (Sasaki et al., 2008, Wu et al., 
2007, Mansilla et al., 2005, Deng et al., 2005, Badiavas and Falanga, 2003, 




transdifferentiate into keratin-14-positive cells and into keratinocytes, 
which are recruited to epidermis, hair follicles, and sebaceous glands 
(Sasaki et al., 2008, Krause et al., 2001, Kataoka et al., 2003, Inokuma et 
al., 2006). However, these BM-derived keratinocytes are rarely detected, 
and comprise only '0.0001–0.0003% of all keratinocytes in the new 
epidermis (Fan et al., 2006). Nevertheless, very recently, a specific subset of 
BM-MSCs with epithelial differentiation potential has been identified 
(Tamai et al., 2011). These platelet-derived growth factor receptor #-positive 
(Lin(/PDGFR#+) BM-MSCs were mobilized in response to elevated high 
mobility group box 1 (HMGB1) levels in serum following skin grafting, and 
were shown to significantly contribute to epidermal regeneration. 
A further mechanism by which BM-MSCs can promote wound healing is 
through release of pro-angiogenic factors, such as vascular endothelial 
growth factor (VEGF) and angiopoietin-1 (Wu et al., 2007). The use of an 
autologous BM-MSC/artificial dermis composite graft has also been shown 
to augment wound healing (Yoshikawa et al., 2008). Other findings 
demonstrate that BM-MSCs can also contribute to repair of skin 
appendages (Li et al., 2006). 
 
1.4.2.2 Adipose tissue-derived MSCs (A-MSC) 
Subcutaneous adipose tissue represents an alternative source of MSCs and 
is readily accessible from routinely performed liposuction or other plastic 
surgery procedures. Thus, A-MSCs have an advantage over BM-MSCs in 




retinoic acid can induce >80% of A-MSCs to undergo epithelial 
differentiation, as indicated by keratin 18 expression (Brzoska et al., 2005). 
 
1.4.2.3 Umbilical cord-derived MSC (UC-MSC) 
Umbilical cord blood cells also harbour multipotent MSCs (Lee et al., 2004). 
UC-MSCs can be isolated in large numbers from Wharton’s jelly, the tissue 
surrounding the umbilical cord vessels (Mitchell et al., 2003). These cells 
express similar set of markers to BM-MSCs (Troyer and Weiss, 2008) and 
can be painlessly isolated and successfully frozen and stored over a long 
period of time, and hence have the greatest potential for tissue banking 
(Kenneth and Moise, 2005), despite the high costs. 
 
1.4.2.4 Placenta-derived MSC (P-MSC) 
Human placenta has also been shown to contain multipotent progenitors 
that closely resemble MSCs in their plasticity and markers (Strom and 
Miki, 2003). P-MSCs have several advantages such as unlimited source of 
tissue and the non-invasive nature of isolation. However plancental 
cytotrophoblasts have shown to possess tumour-like properties, thus 
imposing some safety risks. Furthermore, the actual number and 
differentiation capacity of P-MSCs from a single placenta may be quite low 
(Matikainen and Laine, 2005). 
It is unlikely that either A-MSCs, UC-MSCs or P-MSCs would be able to 




they may give rise to type VII collagen-producing fibroblasts, theoretically 
they could be used to partially and/or temporarily ameliorate severity of the 
disease.  
 
1.4.3 Haematopoietic Stem Cells (HSCs) for skin regenerative 
therapy 
1.4.3.1 Bone marrow-derived-HSCs (BM-HSCs) 
BM-HSCs are among the best characterized adult stem cells. BM-HSCs 
have been shown to have the plasticity to regenerate various tissues after 
transplantation (Krause et al., 2001); although the true plasticity of BM-
HSCs remains arguable and might be due to a mechanism different from 
transdifferentiation (Ying et al., 2002). Nevertheless, besides differentiation, 
there are other potential mechanisms of action of BM-HSCs in injured 
tissues. These include secretion of various chemokines and cytokines, which 
stimulate regeneration by inhibiting apoptosis, suppressing immune 
reactions and increasing angiogenesis, enhancement of proliferation of 
resident tissue stem/progenitor cells, and cell fusion (Masson et al., 2004, 
Rabb, 2005, Terada et al., 2002). 
 
1.4.3.1 Umbilical cord blood-derived HSCs (UCB-HSCs) 
Umbilical cord blood is more readily available than bone marrow and is 
better tolerated than bone marrow due to the immunological immaturity of 




transplanted successfully even if the donor and the recipient are not a 
perfect match (Wagner et al., 2010b). However, the total number of HSCs is 
much lower compared to bone marrow (Verneris et al., 2009). Interestingly, 
when co-cultured with human adult keratinocytes on a fibrin 
glue/fibroblasts gel, UCB-HSCs can form a regular epithelial sheet 
consisting of three to four layers of cells (Kamolz et al., 2006). 
 
1.5 CURRENT STEM CELL THERAPY IN RDEB 
To date, a number of mouse and human studies have been conducted to 
evaluate the potential of extra-cutaneous stem cell sources for the treatment 
of RDEB. It has been shown that embryonic bone marrow transplantation 
(E-BMT) can ameliorate the pathological abnormalities underlying RDEB 
(Chino et al., 2008). In this mouse model, bone marrow transfer into the 
fetal circulation resulted in an increase in deposition of type VII collagen, 
particularly around developing hair follicles. The authors speculated that E-
BMT can potentially be used in utero in the human situation in which 
prenatal genetic diagnosis indicates COL7A1 mutations, with predicted 
severe phenotype. An additional merit of E-BMT is generation of tolerance 
to the new type VII collagen in a mouse completely lacking type VII collagen 
because of the inherent COL7A1 gene mutations. It should be noted, 
however, that in the above study E-BMT provided bone marrow-derived 
fibroblasts (BMDFs) to the skin preferentially around hair follicles, and the 
authors could not observe fully developed, mature anchoring fibrils at the 




shown that BM-HSC from a wild-type donor improves the basement 
membrane zone defect in a murine model of RDEB by inducing production of 
type VII collagen (Tolar et al., 2009). Interestingly, the authors also showed 
that the infusion of non-haematopoietic bone marrow stem cells failed to 
extend the life span of Col7a1-/- mice and correct murine RDEB. The first 
clinical trial of allogeneic whole bone marrow transplantation has been 
reported in 7 RDEB children (Wagner et al., 2010a). Following the infusion 
of bone marrow or umbilical cord blood, new type VII collagen was noted at 
the DEJ that continued to increase for at least one year after the bone 
marrow transplant, and clinical improvement was sustained thereafter in 
the initial follow up for up to 3 years. Further clinical trials are on-going at 
this and other centres in the USA (ClinicalTrials.gov identifiers: 
NCT00478244; NCT01033552; NCT00881556). These trials are looking to 
refine transplantation protocols, for example in assessing whether 
intradermal injections of BM-MSCs from the same donor as the 
transplanted cells might improve clinical response, as well as whether other 
types of EB might also benefit from bone marrow transplantation. Attempts 
to use alternative conditioning protocols, such as reduced intensity 
conditioning, are also being evaluated. Intradermal injection of allogeneic 
BM-MSCs has been performed in 2 individuals with RDEB (Conget et al., 
2010). The injections resulted in increased type VII collagen at the dermal-
epidermal junction and improved healing of chronic erosions. The BM 
correction lasted for ~4 months but there was no sustained clinical benefit 




ameliorate the severity of RDEB by providing an alternative source of type 
VII collagen-producing fibroblasts.  
While the bone marrow transplant work highlights the potential of bone 
marrow cells to correct the intrinsic skin pathology of RDEB, it is clear that 
much needs to be done in improving the safety and reducing the toxicity of 
current protocols. Furthermore, elucidating the mechanism involved is 
essential for improving clinical application of BM-MSCs. Recent 
experiments in a murine model demonstrate that significant damage to the 
epidermis due to type VII collagen deficiency and consequent sub-epidermal 
blistering results in rapid release of HMGB1, which can mobilize a 
Lin(/PDGFR#+ subset of BM-MSCs into the circulation and accelerate 
regeneration of the skin by recruiting these cells to the damaged skin and 
producing BMDKs (bone marrow-derived keratinocytes) and BMDFs in the 
epidermis and dermis respectively (Tamai et al., 2011). Despite recent 
findings, the understanding of underlying mechanisms through which the 
damaged epithelium signals to invoke mobilization and recruitment of BM-
MSCs is still limited. 
Further clinical trials of intradermal MSCs, from bone marrow or other 
sources, or sub-populations thereof, are planned in several countries. In 
addition, it should be remembered that cell therapy using somatic cells can 
provide clinical benefit for people with RDEB. Use of cultured allogeneic 
skin fibroblasts by intradermal injection can also lead to improved basement 
membrane structure and function in RDEB. Indeed, despite the fibroblasts 




expression at the DEJ can be seen for several weeks or months (Wong et al., 
2008). Another possibility for using somatic cells comes from observations 
on revertant mosaicism, in which there is a spontaneous correction of the 
primary genetic defect followed by expansion of the corrected cells (Jonkman 
et al., 1997). This phenomenon is not rare in EB, perhaps occurring in up to 
one-third of individuals with non-Herlitz junctional EB (Pasmooij et al., 
2007, Jonkman and Pasmooij, 2009, Pasmooij et al., 2005), and it has also 
been described in RDEB (Almaani et al., 2010, Pasmooij et al., 2010, van 
den Akker et al., 2012). The possibility of culturing the reverted 
keratinocytes and then using cultured autologous “naturally corrected” skin 
grafts has also been investigated (Gostynski et al., 2009) and represents an 
attractive therapeutic strategy in that it does not rely on genetic 
manipulation of the cells since the BM genetic defect has been corrected 
spontaneously.  
 
1.6 PLURIPOTENT STEM CELLS FOR SKIN REGENERATIVE 
THERAPY 
Pluripotent stem cells hold the most promising potential for regenerative 
cell therapies. One advantage is the capacity of such cells for immortality 
and self-renewal ad infinitum, which could provide an unlimited supply of 
epidermal cells for skin regeneration. In addition, pluripotent stem cells can 
also provide a source of other cell types required for skin engineering 




A pluripotent cell line is defined by two indispensible criteria: the ability to 
self-renew ad infinitum, and pluripotency, the ability to differentiate into 
tissue types from all three extra embryonic germ layers (Figure 4). True 
pluripotent cells will contribute to all somatic tissues in the fully developed 
organism, in addition to the germ line of the animal. Due to the combination 
of these two unique abilities of pluripotent stem cells are considered to be 
the most attractive cell type for the purpose of regenerative medicine. 
 
 
Figure 4 A schematic representation of the differentiation potential of 
pluripotent cells.  
ESCs- embryonic stem cells; iPSCs- induced pluripotent cells. Pluripotent cells are able to 
self-renew and differentiate towards three germ layers, ectoderm, mesoderm and 
endoderm, giving rise at first to multipotent tissue-specific stem cells. These multipotent 
stem cells are also able to self-renew and further differentiate into tissue progenitor cells, 






1.6.1 Human Embryonic Stem Cells 
Human embryonic stem cells (hESCs) were initially isolated from the inner 
cell mass of preimplantation blastocysts generated by in vitro fertilization 
(Thomson et al., 1998). hESCs can be expanded in culture and forced to 
undergo directed differentiation to a specified cell type by altering the 
culture substrate and growth conditions. An extensive collection of studies 
has shown in vitro derivation of somatic cells types of varying degrees of 
maturity, from hESCs. Differentiation of cells from the ectodermal, 
endodermal and mesodermal germ layers, has been achieved (Puceat, 2008, 
D'Amour et al., 2005, Zheng et al., 2006, Green et al., 2003, Levenberg et al., 
2002). Derivation of various specialized cell types, for example insulin-
producing cells (Segev et al., 2004), has also been accomplished. The biology 
of hESCs is discussed in detail in Chapter 2. 
 
1.6.2 Induced Pluripotent Stem Cells (iPSCs) 
The recent discovery that somatic stem cells can be reprogrammed into a 
pluripotent state opens new and exciting possibilities for regenerative 
medicine. This methodology avoids many of the ethical issues associated 
with the use of hESCs. Reprogramming opened an exciting perspective for 
generating disease- and patient-specific stem cells. Such cells can 
potentially provide a unique tool for investigating mechanism in various 
diseases, drug screening and exploring cell regenerative therapy. Using 
patient-specific iPSCs in cell regenerative therapy offers the possibility of 




rejection, although it remains unclear whether iPSCs will be able to evade 
an immune response completely. 
Initially, iPSCs were successfully derived from adult mouse fibroblasts 
through the ectopic co-expression of only four genes (Takahashi and 
Yamanaka, 2006). In this study, the researchers have shown that four 
factors were sufficient to reprogramme adult fibroblasts into a pluripotent 
state: Oct3/4, Sox2, Krüppel-like factor 4 (Klf4) and c-Myc. This study 
initiated extensive research in the field and successful reprogramming 
quickly progressed to human fibroblasts (Park et al., 2008b, Yu et al., 2007, 
Takahashi et al., 2007), and other cell types, such as pancreatic $ cells 
(Stadtfeld et al., 2008a), neural stem cells (Kim et al., 2008, Eminli et al., 
2008), mature B cells (Hanna et al., 2008), mouse stomach and liver cells 
(Aoi et al., 2008), adipose stem cells (Sun et al., 2009) and keratinocytes 
(Maherali et al., 2008). The reprogramming of dermal fibroblasts was also 
achieved in the absence of c-Myc (Nakagawa et al., 2008). Other work also 
demonstrated reprogramming of human fibroblasts into iPSCs using the 
same factors (Lowry et al., 2008) or Oct4, Sox2, Nanog and Lin28 (Ebert et 
al., 2009). Primary human fibroblasts have also been reprogrammed with 
only Oct3/4 and Sox2 and histone deacetylase (HDAC) inhibitor, valproic 
acid (VPA) (Huangfu et al., 2008b). Intriguingly, the reprogramming of 
human primary keratinocytes into iPSCs was shown to be at least 100-fold 
more efficient and twice as quick compared to fibroblasts (Aasen et al., 
2008). Moreover, transciptional profiling for stem cell-related genes revealed 
that keratinocytes are in fact more similar to hESCs than fibroblasts (Aasen 




transcripts expressed in keratinocytes, iPSCs and hESCs but not in 
fibroblasts. Flow cytometry analysis also revealed expression of putative 
stem cell markers, such as CD24, in primary keratinocytes but not in 
fibroblasts. Furthermore, keratinocytes contain higher levels of endogenous 
Klf4 and c-Myc transcripts compared to fibroblasts which are associated 
with transcriptional and epigenetic states favourable to reprogramming. 
Collectively, these intrinsic characteristics of keratinocytes make them a 
potentially more favourable cell type for reprogramming. Whether 
keratinocyte-derived iPSCs might also be more amendable to differentiation 
back towards epidermal cell lineages due to some epigenetic or 
transcriptional memory, however, is unknown.  
The iPSCs were shown to be indistinguishable from ESCs in morphology, 
proliferation, surface antigens, gene expression, pluripotency and 
telomerase activity, and were also capable of producing teratomas and germ 
line-competent chimeras. However, despite significant similarities between 
iPSCs and hESCs, distinct differences have also been reported. Using DNA 
methylation mapping, gene-expression profiling and a quantitative 
differentiation assay, a systematic comparison of 20 established ESC lines 
and 12 iPSC lines was carried out (Bock et al., 2011). This study produced a 
‘scorecard’ to evaluate the character of both pluripotent cell lines and 
predict their quality and functional consequences in a high-throughput 
manner. Despite overall similarities, transcriptional and epigenetic 
variation is common between pluripotent cell lines and the differences in 
global gene expression were more pronounced in earlier passages of iPSCs. 




some human iPSC lines were less predisposed to differentiate towards 
haematopoietic, neuroepithelial and neural lineages than hESCs (Miura et 
al., 2009, Feng et al., 2010, Hu et al., 2010a). While some researchers 
suggested that this indicates an intrinsically lower capacity of iPSCs for 
differentiation, an alternative explanation would be that iPSCs retain 
epigenetic memory of the donor tissue of origin which might influence the 
differentiation bias of iPSCs (Kim et al., 2010). For example, iPSCs derived 
from human retinal-pigment epithelial cells are more prone to differentiate 
back into this cell type than ESCs or iPSCs derived from other tissues (Hu 
et al., 2010b). The most exhaustive comparison of iPSCs to hESCs revealed 
loci that can reliably distinguish the two pluripotent cell types (Kim et al., 
2010). In addition, the residual iPSC-specific methylation was shown to link 
these cells to their tissue of origin, which is suggested to affect their 
differentiation propensity. For example, in iPSCs derived from non-
haematopoietic cells, such as fibroblasts and neural progenitors, there can 
be residual repressive methylation at loci that are required for 
haematopoietic fates, reducing the blood-forming potential in vitro (Kim et 
al., 2010). However, exogenous supplementation of neural-progenitor-
derived iPSCs with the cytokine WNT3A was shown to increase their blood-
forming potential, suggesting that incomplete reprogramming owing to 
epigenetic marks can be surpassed by manipulating culture conditions (Kim 
et al., 2010). These findings show that the ‘epigenetic memory’ of the donor 
cell can be exploited in order to manipulate iPSCs differentiation fate. 
In recent years, a variety of reprogramming methods have been 




reprogramming poses several problems and safety concerns, such as 
insertional mutagenesis and difficulty in storage and quality control. 
Therefore, several non-viral systems have been explored in inducing 
reprogramming. These include transposon systems (Soldner et al., 2009, 
Woltjen et al., 2009) and use of a single multiprotein expression vector (Kaji 
et al., 2009). It has also been shown that reprogramming can be achieved 
with the use of cell-penetrating recombinant proteins (Zhou et al., 2009). 
More recently a single transfer of ESC-derived proteins into primary 
cultured adult mouse fibroblasts has been shown to achieve full 
reprogramming to the pluripotent state (Cho et al., 2010). The non-viral 
systems are discussed in more detail in Chapter 3. 
Despite significant advances in the field of iPSC research, crucial criteria 
have to be met before clinical application of these cells can be accomplished. 
Firstly, an efficient protocol without the use of any potentially harmful 
components needs to be developed. Secondly, stringent standards for iPSCs 
characterization and analysis have to be devised. Understanding the exact 
genetic and epigenetic events that occur during reprogramming will be 
crucial for designing experimental approaches. And finally, refined 
differentiation protocols are needed to obtain the desired cell type that will 




1.7.3 Therapeutic potential of pluripotent stem cells for skin 
regeneration depends on understanding epidermal 
morphogenesis 
Although very much at a pre-clinical level, pluripotent stem cell sources 
such as hESCs and iPSCs offer new opportunities for the development of 
clinically relevant therapies. Disease-specific iPSC lines could be derived to 
study mechanisms at a molecular level and serve as a disease model for 
therapeutic drug discovery (Park et al., 2008a). With respect to RDEB, iPSC 
lines could be used to study developmental and signalling pathways 
underlying blister formation as well as the predisposition of people with 
RDEB to develop squamous cell carcinomas. In addition, genetically-
corrected iPSCs could be used to generate disease-free skin cell-progenitors 
with potential application in autologous cell therapy, and protocols to obtain 
genetically-corrected iPSCs from dermal fibroblasts and epidermal 
keratinocytes have been reported (Raya et al., 2010). Moreover, the 
phenomenon of revertant mosaicism could also be combined with iPSC 
technology, with the added advantage of not having to correct the BM gene 
abnormality (Pasmooij et al., 2010). The iPSC approach means that 
different cell types to restore type VII collagen could be created to be used in 
conjunction, such as bone marrow cells for systemic delivery and 
keratinocytes or fibroblasts for local treatment. However, all these goals can 
only be achieved if an efficient differentiation protocol that would direct 
pluripotent stem cells towards epidermal lineages is developed. 
The main prerequisite that has to be met when manipulating cell fate of a 




morphogenesis of a given tissue, in order to achieve efficient production of 
desired cell type. For example, a three-stage process for the efficient and 
reproducible differentiation of hESCs to hepatocytes was achieved by 
recapitulating liver development in vivo (Hay et al., 2008). In this approach 
hESCs were first primed towards definitive endoderm with activin A and 
sodium butyrate, then further differentiated to hepatocytes with dimethyl 
sulphoxide and matured hepatocyte growth factor and oncostatin M. 
Therefore, in order to develop an efficient differentiation protocol for 
derivation of skin cell lineages from hESCs, epidermal morphogenesis in 
vivo must be understood. 
 
1.8 EPIDERMAL MORPHOGENESIS 
A number of articles have thoroughly reviewed epidermal morphogenesis 
and homeostasis (Fuchs and Raghavan, 2002, Simpson et al., 2011, 
Blanpain and Fuchs, 2009). 
 
1.8.1 Early ectodermal development and the “default model” 
After gastrulation, the embryo surface emerges as a single layer of 
neuroectoderm, which will ultimately specify the nervous system and skin 
epithelium. This decision is guided by Wnt signalling, which blocks the 
ability of ectoderm to respond to fibroblast growth factors (FGFs) (Figure 5). 
In the absence of FGF signalling the cells express bone morphogenetic 
proteins (BMPs), and become fated to develop into epidermis. Contrarily, 




to receive and translate activating cues by FGFs, which then attenuate 
BMP signalling through inhibitory cues (Chang and Hemmati-Brivanlou, 
1998, Stern, 2005). This “default model” of neural differentiation has been 
widely accepted. Two hallmark studies revealed that depletion of three 
different BMPs (2, 4 and 7), together with the related protein anti-
dorsalising morphogenetic factor (ADMP) or with abrogation of the 
organizer region where ADMP is normally expressed, results in the 
formation of a massive brain (Reversade et al., 2005, Reversade and De 
Robertis, 2005). These results are taken to support the “default model”, 
indicating that inhibition of BMP activities in the early embryo is sufficient 
to cause great expansion of the nervous system at the expense of epidermis. 
The embryonic epidermis that results from this process consists of a single 
layer of multipotent epithelial cells. It is covered by a transient protective 
layer of tightly connected squamous endodermis-like cells, known as a 
periderm, which are shed once the epidermis has stratified and 
differentiated (Akiyama et al., 1999, Polakowska et al., 1994). This single-
layerd epidermis persists from mouse embryonic day 9.5 (E9.5) to E12.5. As 
mesenchymal cells populate the skin, the signals are transmitted that 
instruct the stratification of the epidermis and direct the positioning of 
down growths that denote the initiation of hair follicle morphogenesis 
(Koster and Roop, 2007). 
Simultaneously, the innermost, basal, layer of the stratifying epidermis 
produces numerous extracellular matrix (ECM) proteins and growth factors, 




a growth-supporting platform, but also as a physical border between the 
epidermis and the dermis. 
 
 
Figure 5 Early signalling during embryonic epidermogenesis.  
In the absence of Wnt signalling, ectodermal progenitors respond to FGFs, downregulate 
BMP signalling and progress towards neurogenesis. Wnt signalling blocks the ability of 
early ectodermal progenitor cells to respond to FGFs, allowing them to respond to BMP 
signalling and adopt an epidermal fate forming single-layered embryonic epidermis. The 
cells that fail to respond to Wnts become fated to become epidermal cells through BMP, 
EGF and Notch signalling. The cells that do respond to Wnt signalling also receive 
underlying FGF and BMP inhibitory signals from the mesenchyme. These cumulative 
signals instruct the cells to produce the hair placode. From (Fuchs, 2007). 
!
1.8.2 Stratification 
Epidermal stratification is brought about by specific transcription factors 
(Mack et al., 2005). The initial stages of stratification (E12.5–E15.5) are 
marked by suprabasal cell division, which is aimed at rapid expansion of 
epidermal cells. However, these suprabasal cells soon undergo complete 
differentiation. Stratification is generally completed by E17.5, by which 
point the epidermis consists of an inner layer of highly proliferative basal 
cells and layers of terminally differentiating, suprabasal cells. 
During transit to the skin surface, keratinocytes undergo a dramatic 




basal cells in the mammalian epidermis undergo asymmetric divisions to 
drive stratification during epidermal morphogenesis and identified the 
cytoarchitectural elements regulating this process suggested that this 
process occurs through reorientation of mitotic spindles in the basal layer 
(Lechler and Fuchs, 2005). While basal cells remain attached to an 
underlying matrix and proliferate, some of their daughter keratinocytes 
enter the spinous layer, “stratum spinosum”, through asymmetric mitoses, 
where they exit the cell cycle, grow larger and establish robust intercellular 
connections. These suprabasal cells no longer have cell–matrix adhesions, 
which completely alters their cell polarity and cytoskeletal architecture 
(Watt, 2002). Cells in the granular layer, “stratum granulosum”, flatten and 
assemble a water-impermeable cornified envelope underlying the plasma 
membrane. Finally, corneal layer, “stratum corneum”, keratinocytes release 
lysosomal enzymes to degrade major organelles, become completely 
squamous and are tightly crosslinked together to complete the cutaneous 
barrier (Michel et al., 1988, Candi et al., 2005, Kalinin et al., 2002). 
 
1.8.3 Keratin expression 
In epidermal keratinocytes, intermediate filaments fill the cytoplasm and 
mechanically connect hemidesmosomes at the basement membrane and 
desmosomes at the lateral membrane to the cell nucleus. The intermediate-
filament-associated protein plectin binds #6$4 integrin at hemidesmosomes 
but also associates with nesprin 3, a protein embedded in the outer nuclear 




nesprin 2, regulates nuclear envelope morphology (Luke et al., 2008). 
Therefore, in keratinocytes the desmosome–nesprin complex creates a 
unique mechano-sensory mechanism, which responds to mechanical forces 
at the periphery of the cell by directly influencing nuclear activity during 
epidermal morphogenesis. 
Well-defined changes in keratin gene expression accompany epidermal 
morphogenesis and stratification (Fuchs and Green, 1980). Keratin 8 and its 
binding partner keratin 18 are expressed earliest during embryonic 
development (Oshima et al., 1983). Keratins 8/18 serve as a marker for 
simple epithelia. Keratin 19 can associate with different partners and is 
expressed in embryonic, simple, and stratified epithelia (Stasiak and Lane, 
1987). Keratins 5/14 are markers for the basal proliferative layer of 
epidermis. As cells enter the spinous layer, they switch off the expression of 
genes encoding keratins 5 and 14. Simultaneously, spinous cells switch on 
the expression of genes encoding keratins 1 and 10 to form an even more 
robust intermediate filament network that provides resistance against 
mechanical stresses at the body surface. Cornification involves biochemical 
crosslinking of various keratinocyte proteins such as loricrin and involucrin 
by transglutaminases (TGases), but it eventually terminates with nuclei 
and organelles being broken down by intracellular and secreted proteases, 
including a specialized caspase (Eckhart et al., 2000) Granular cells express 
additional structural proteins that are deposited beneath the plasma 
membrane. These proteins become enzymatically cross-linked, forming an 
indestructible sac, which acts as a water-impermeable barrier (Candi et al., 




from intracellular lamellar granules into the extracellular space between 
dead flattened stratum corneum cells, known as squames. The squames are 
interposed by lipids on the outside and filled with a fibrous mass of keratins 
that is encased by the cornified envelope (Fuchs and Raghavan, 2002, 
Reversade et al., 2005). The cellular junctions in stratum corneum are called 
corneodesmosomes. Those contain the cadherins desmoglein 1 (DSG1) and 
desmocollin 1 (DSC1), which must be cleaved by serine proteases to allow 
proper shedding of the outer epidermis (Caubet et al., 2004). 
Therefore mature epidermis displays tissue-level polarization with 
asymmetric distribution of signalling activity, protein expression and 




Keratinocytes of the basal layer are inherently polarized as their lower 
surface is anchored to the basement membrane by integrins (Figure 6). 
Integrins are heterodimeric transmembrane receptors that bind specific 
ECM components, such as laminin, collagens and fibronectin via their 
extracellular domains (Watt, 2002). Each integrin is a heterdimer of two 
glycoproteins, known as #- and $-subunits, that are non-covalently 
associated. As many as 11 integrin heterodimers have been described in 
epidermal keratinocytes (Margadant et al., 2010). The most abundant 




(predominantly, laminin-332 and -511/521 receptor) and #6$4 (mainly 
laminin-332 receptor) (Watt and Hertle, 1994, Margadant et al., 2010). 
In normal, undamaged epidermis, integrin expression is confined to the 
basal layer and outer root sheath of the hair follicle. #6$4 integrin has a 
special role in organizing large integrin complexes called hemidesmosomes 
(Tsuruta et al., 2003). Hemidesmosomes connect to the BM through #6$4 
integrin and the transmembrane protein bullous pemphigoid antigen 2 
(BPAg2; also known as type XVII collagen), and are tethered to 
intermediate filaments by the linker proteins plectin and bullous 
pemphigoid antigen 1e (BPAg1e; also known as BP230 or dystonin). 
Clusters of $1 integrins are interspersed with hemidesmosomes on the basal 
surface of basal keratinocytes, but the majority of $1ntegrins are found to 
form an "O" ring at the periphery of the cell (Jensen et al., 1999) 
Integrin heterodimers regulate cell growth and differentiation through 
signal transduction (Hynes, 1992, Dedhar and Hannigan, 1996). 
Transmembrane connection is achieved through association of integrin tails 
with actin via adaptor proteins on the intracellular side and recruitment of 
various factors to their cytoplasmic tails. For example, through such signal 
transduction #3$1 integrin plays a crucial role in morphogenesis of the BM 
through influencing the ability of keratinocytes to secrete ECM components 
(McMillan et al., 2003). Total loss of #3 integrin results in neonatal lethality 
and sub-epidermal blistering due to a discontinuous BM between 




integrin results in duplicated areas of the BM and microblisters at the DEJ 
(Margadant et al., 2009).  
Initial in vitro experiments showed that terminal differentiation and cell 
cycle withdrawal of cultured keratinocytes is induced by their release from 
an underlying matrix (Green, 1977, Watt, 1994). Furthermore, in intact 
epidermis, keratinocytes cease proliferating as they leave the basal layer, 
which coincides with loss of contact with the BM and suppression of integrin 
expression. This suggests a vital role for integrins in epidermal homeostasis. 
It has been hypothesized that stratification-associated down-regulation of 
integrins diminishes proliferation in the suprabasal epidermal layers 
(Margadant et al., 2010, Watt, 2002). Under normal circumstances, 
mitogenic signalling from epidermal growth factor receptor (EGFR) via the 
mitogen-activated protein kinase (MAPK) pathway is restricted to basal 
keratinocytes, which have high expression of various integrins (De Potter et 
al., 2001, Aplin and Juliano, 1999). Integrins can bind to receptor tyrosine 
kinases, including EGFR, providing a possible mechanism for how they may 






Figure 6 Constitutively expressed integrins of the basal epidermal layer.  
Basal keratinocytes are attached to the BM (composed of lamina lucida and lamina densa) 
via numerous hemidesmosomes and integrin-based adhesions. Hemidesmosomes connect to 
the BM through #6$4 integrins and the transmembrane protein BPAg2 (also known as type 
XVII collagen), and are tethered to intermediate filaments (IF) by plectin and BPAg1e 
proteins. #3$1 and #2$1 integrins are receptors for laminins-332, -511/521 and collagens, 
respectively. Through association of integrins with ECM proteins basal epidermal layer is 
attached to underlying dermis via anchoing fibrils and collagen. Both #3$1 and #2$1 
integrins provide transmembrane connections by recruiting several cytoplasmic ligands to 
their intacellular domains. 
 
Defects in integrin expression have a profound effect on all aspects of skin 
function. In mice, deletion of $4 integrin prohibits formation of 
hemidesmosomes, resulting in severe blistering (Dowling et al., 1996, van 
der Neut et al., 1996). Loss of $4 integrin also appeared to induce apoptosis 
of basal cells (Dowling et al., 1996), whereas deleting the cytoplasmic tail of 
$4 impairs proliferation (Murgia et al., 1998). On the other hand, deletion of 




and skin inflammation (Niculescu et al., 2011). In humans, defective 
expression of the #6$4 heterodimer has been implicated in JEB and 
associated with congenital gastric outlet obstruction, pyloric atresia (Gil et 
al., 1994, Niessen et al., 1996). Furthermore, in squamous cell carcinoma 
overexpression of #6$4 integrin is seen throughout the tumour mass and 
correlates with poor prognosis (Downer et al., 1993, Van Waes et al., 1995). 
Consistently, in hyperproliferative human conditions, such as psoriasis and 
carcinomas, integrin expression is seen beyond the basal layer (Hertle et al., 
1992, Guo and Giancotti, 2004, Haase et al., 2001). Conversely, deletion of 
$1 integrin in skin produces a hypoproliferative epidermis with more 
differentiating keratinocytes than in normal epidermis (Raghavan et al., 
2000, Brakebusch et al., 2000). However, this also results in extensive 
epidermal blistering. Therefore it remains difficult to dissect the potential 
effects of faulty integrin expression on skin homesostasis and integrity. 
Importantly, a range of human disorders, such as junctional EB, EB simplex 
and bullous pemphigoid, result from integrin-based adhesion being 
compromised by mutation or by autoimmune responses and are 
characterized by varying degrees of epidermal fragility and blistering 
(McGrath et al., 1995, Groves et al., 2010, Gache et al., 1996, Gil et al., 
1994). 
 
1.8.5 Epidermal cell junctions 
Cadherin-based junctions, including adherens junctions and desmosomes, 




composed of the classic cadherins such as E-cadherin and placental cadherin 
(P-cadherin; also known as cadherin 3). Variations in different cadherin 
expression play an important role in epidermal morphogenesis because they 
allow keratinocytes to be sorted into discrete epidermal layers (Gumbiner, 
2005, Runswick et al., 2001). Gap junctions in the epidermis allow direct 
cytoplasmic communication between keratinocytes and are implicated in 
epidermal morphogenesis and disease (Lai-Cheong et al., 2007, Mese et al., 
2007). 
In basal keratinocytes, cellular junctions have a polarized organization and 
contribute to mitotic spindle orientation during stratification. In 
undifferentiated basal keratinocytes actin filaments are highly associated 
with cell–matrix junctions, whereas during differentiation they become 
coupled to intercellular junctions (Perez-Moreno et al., 2003, Vaezi et al., 
2002, Kubler et al., 1991). In vitro, cadherin–catenin complexes at adherens 
junctions are linked into a cortical ring of bundled microfilaments, which 
effectively couples the actin cytoskeletons of neighbouring cells (Vasioukhin 
et al., 2000). It is believed that these actin-linked adhesions bind motor 
proteins such as myosin to generate the tension required for a keratinocyte 
to move over a neighbouring cell (Perez-Moreno et al., 2003, Vaezi et al., 
2002). 
Stratification induces a marked increase in the amount of desmosomal 
cellular junctions. Desmosomes are built from clustered transmembrane 
cadherins called desmogleins (DSGs) and desmocollins (DSCs). These bind 




armadillo protein family. In turn, this binding recruits the cytolinker 
desmoplakin, which binds keratin intermediate filaments (Hatsell and 
Cowin, 2001, Green and Simpson, 2007). Through this chain of interactions, 
desmosomal components directly link intercellular junctions and the 
intermediate filament cytoskeleton. Changes in desmosomal cadherin 
expression modulate intracellular signalling and control epidermal 
differentiation (Merritt et al., 2002, Hardman et al., 2005, Elias et al., 2001, 
Kljuic et al., 2003). It has been suggested that desmosomal cadherins might 
promote the switch from proliferation to differentiation upon stratification 
(Lechler and Fuchs, 2007, Teuliere et al., 2004, Green and Simpson, 2007). 
In the granular layers, tight junctions help to promote an environmental 
barrier for the skin (Niessen, 2007). Tight junctions seal multicellular 
sheets by forming a belt-like adhesion between cells, allowing the passage of 
only small molecules and ions (Morita and Miyachi, 2003). Numerous 
proteins are present in the tight junctions, including claudins, junctional 
adhesion molecules, occludins and tricellulin, as well as scaffolding proteins 
of the zonula occludens family (Niessen, 2007). Tight junctions play a crucial 
role in the skin immune response by allowing antigen sampling by resident 
Langerhans cells (Kubo et al., 2009). 
 
1.9 APPROACHES FOR EPIDERMAL DIFFERENTIATION 
To date there have been numerous attempts to devise an efficient protocol 
for differentiation of hESCs towards keratinocyte cell lineages. Epidermal 




et al., 2000, Coraux et al., 2003a) and human ESCs (Aberdam et al., 2008, 
Gambaro et al., 2006, Ji et al., 2006, Metallo et al., 2010c, Schuldiner et al., 
2000, Troy and Turksen, 2006).  Keratinocyte differentiation in embryoid 
bodies has been spontaneous (Bagutti et al., 2001, Bagutti et al., 1996) or 
induced with type IV collagen (Ji et al., 2006). Alternative approaches 
included co-culture (Troy and Turksen, 2006) and through the cultivation of 
nodules derived from teratomas (Green et al., 2003), as well as direct 
culture as monolayer (Coraux et al., 2003a). However, in all of the above 
protocols the commitment was inefficient, resulting in a highly 
heterogeneous cell population along with remaining undifferentiated ES, 
which could still produce teratomas. Furthermore, these hESC derivatives 
exhibited a lower proliferative capacity compared with primary 
keratinocytes, and immortalization was required to extend the lifespan of 
these cultures (Iuchi et al., 2006).  
The current understanding is that BMP-4 and all-trans-retinoic acid (ATRA) 
act synergistically to achieve hESCs differentiation to keratinocytes with 
BMP-4 acting to block neural differentiation and ATRA directing cells to an 
epithelial fate (presumably through induction of %Np63 isoform expression). 
It has been demonstrated that the exogenous expression of %Np63 isoform 
specifically is required for epidermal commitment of murine keratin 18-
positive ectodermal cells into keratin 14-positive keratinocytes (Aberdam et 
al., 2007). Further investigation revealed that %Np63 isoform is expressed 
soon after BMP-4 treatment, along with the simultaneous expression of 
direct or indirect p63-target genes associated with epidermal morphogenesis 




Retinoids are potent regulators of cell proliferation and differentiation and 
are highly involved in embryonic development. In skin retinoids have 
profound effects. Topical administration of ATRA to photoaged skin reduces 
wrinkling (Kligman et al., 1986, Weiss et al., 1988). This effect is brought by 
thickening and compaction of the stratum corneum and increased 
keratinocyte proliferation. On the other hand, systemic retinoid treatment 
in psoriasis ameliorates the lesions by an opposing mechanism of decreasing 
keratinocyte poroliferation (Williams and Elias, 1981, Orfanos and Runne, 
1978). In culture, ATRA inhibits growth of the rapidly proliferating 
keratinocytes, while stimulating growth of quiescent cells (Varani et al., 
1989). In addition, ATRA may inhibit the in vitro production of ECM 
proteins by keratinocytes, and therefore reduces adhesion. Interestingly, the 
concentration required for matrix production inhibition is much higher than 
that required to stimulate proliferation. This might in turn explain the 
different effects in topical and systemic administration of retinoids. ATRA 
has been shown to inhibit the terminal differentiation of keratinocytes in 
vitro by modulating p63 isoform expression (Bamberger et al., 2002) and is a 
caudalizing factor that directs ESC-derived neuroepithelia to become motor 
neurons (Li et al., 2005, Wichterle et al., 2002). Interestingly a study that 
used ATRA to induce formation of posterior neuroepithelia also reported 
that early ATRA application induced unidentified non-neural cell fates 
(Pankratz et al., 2007). 
ATRA mediates cellular responses by binding to nuclear retinoic acid 
receptors (RARs), which in turn modulate transcription through several 




hESCs, which express RAR#, initiate p63 transcription, predominantly the 
%Np63 isoforms (Schuldiner et al., 2000). On the other hand, mice 
expressing dominant negative forms of RAR# under the K14 promoter show 
reduced p63 expression and severe defects similar to those observed in p63 
knockouts (Chen and Lohnes, 2005, Saitou et al., 1995). Furthermore, RA 
has been shown to induce %Np63 expression in RAR #&-null keratinocytes in 
the presence of elevated RAR# levels (but not RAR&) (Chen and Lohnes, 
2005). That means that RA may regulate p63 transcription, directly or 
indirectly, in hESCs because of differential expression of RAR subtypes. It 
has been shown that ectodermal derivatives of hESCs can acquire epithelial 
fates in response to ATRA in a stage-specific and dose-dependent manner 
(Metallo et al., 2008b). These authors have showed that significant 
keratinocyte induction occurred only when embryoid bodies were cultured 
with 1µM ATRA at the early stages of differentiation. This process is 
marked by significant increases in keratin 18 and p63 transcription and 
relative decreases in pluripotency (e.g. Oct-3/4, SSEA-4, Nanog) and neural 
gene transcription. After early induction with ATRA and BMP-4, these 
keratin 18+/p63+ cells are subcultured in a defined epithelial medium and 
ultimately give rise to keratin 14+/p63+ keratinocytes. 
Functionality of these differentiated keratinocytes was assessed by their 
ability to undergo stratification and cornification at the air–liquid interface 
induced stratification (Metallo et al., 2010a). This was confirmed by 
immunofluorescence microscopy for terminal differentiation markers, 
including keratin 10, involucrin, and filaggrin. However, the overall tissue 




Further characterization of keratinocytes obtained by the method described 
above revealed that although transcriptional patterns were similar to those 
in primary keratinocyte cultures, genes associated with signal transduction 
and ECM were upregulated (Metallo et al., 2010a). Elevated signalling 
along these pathways might ultimately interfere with the terminal 
differentiation program of keratinocytes and explain the results obtained in 
organotypic culture experiments. Finally elevated expression of embryonic 
genes such as CPN6 and HAND2 was also observed, indicating the presence 
of contaminating embryonic cell types. 
A significant advantage of ATRA-induced differentiation is that can be 
efficiently performed in defined medium as opposed to feeder systems 
(Aberdam et al., 2008) and/or undefined medium application (Ahmad et al., 
2007, Coraux et al., 2003a). Chemically defined serum-free media rather 
than media containing serum was chosen to avoid serum that is subject to 
batch variations and potential contamination by various pathogens that 
could be transmitted in animal serum (Merten, 1999, Froud, 1999). 
 
1.10 SUMMARY 
The epidermis is a thin layer of stratified squamous epithelium that rests on 
top of a BM, which separates it and its appendages from the underlying 
mesenchymally-derived dermis. The epidermis performs vital functions in 
protecting the organism from physical and environmental stress as well as 
providing the first defense against pathogens. Despite its remarkable 




turnover and regeneration. This epidermal homeostasis is supported by 
adult stem cells within the skin. 
However, in some genetic skin conditions, such as EB, skin regeneration is 
severely impaired. The absence of one of the critical components within the 
DEJ leads epidermis to detach from the underlying dermis causing constant 
blistering. Currently, there is no curative treatment available for patients 
with EB. It is very likely that the persistent blisters might diminish the 
endogenous stem cell pool and/or disrupt epidermal stem cell niches. 
Therefore, a potential cell regenerative therapy should be aimed at restoring 
the pool of endogenous epidermal progenitors. 
Several stem cell types have been proposed and evaluated, including adult 
BM-MSCs and HSCs. However, pluripotent stem cells hold the most 
promise in regenerative cell therapy due to their unique capacities for 
infinite self-renewal and differentiation potential. Therefore, the overall aim 
of thesis was to investigate various differentiation strategies to obtain 
highly proliferative epidermal progenitors from human embryonic stem 
cells. 
 
1.11 PROJECT AIMS AND HYPOTHESIS 




1.11.1 Hypothesis 1 
The conditions for culture and/or derivation of pluripotent stem cells can be 
improved towards clinical grade for subsequent derivation of epidermal 
progenitors. 
General aims: 
1. To develop conditions for pluripotent stem cell culture and/or 
derivation that would enable potential therapeutic application of 
these cells. 
2. To confirm the pluripotency potential of stem cells cultued and/or 
derived under such conditions. 
Chapters 2 and 3 focus on this hypothesis. Chapter 2 describes the 
adaptation of the KCL-OO2 hESC line to defined feeder-free conditions, and 
Chapter 3 describes the protocols for non-viral derivation of iPSCs. The 
specific hypotheses and aims are described for each set of experiments 
separately. 
 
1.11.2 Hypothesis 2 
Recapitulating embryonic epidermal morphogenesis, in particular the 
inductive effects of mesenchyme, in vitro is key to efficient production of 





1. To test different methods for inducing epidermal differentiation of 
pluripotent stem cells. 
2. To evaluate the efficiency of the protocol based on epidermal marker 
expression. 
Chapters 4-6 relate to this general hypothesis, and specific hypotheses and 








Human ESC line KCL-002 could be successfully adapted to growth in 
feeder-free culture conditions, while still maintaining all the properties of 
an ESC line, such as expression of marker genes and proteins associated 
with hESCs, spontaneous differentiation through embryoid body formation 
and form teratomas, containing all three germ layers in vivo. 
 
AIMS 
1. Adapt KCL-002 hESC line to growth under feeder-free culture 
conditions 
2. Examine levels of expression of the pluripotency-associated marker 
genes Nanog and Sox-2 in the KCL-002 hESC line 
3. Investigate expression of the pluripotency-associated proteins in KCL-
002 hESC line 
4. Confirm the pluripotency of the KCL-002 hESC line in vitro through 




5. Determine the pluripotency of the KCL-002 hESC line in vivo by 






2.1.1 Definition of ESC  
An ESC line is defined by two indispensible criteria: the ability to self-renew 
ad infinitum, and pluripotency, the ability to differentiate into tissue types 
from all three extra embryonic germ layers. True ESCs will contribute to all 
somatic tissues in the fully developed organism, in addition to the germ line 
of the animal. Due to the combination of these two unique abilities, ESCs 
are considered to be the most attractive cell type for the purpose of 
regenerative medicine.  
 
2.1.2 Derivation of hESC lines 
For the derivation hESC lines, embryos between 5 and 7 days post-
fertilisation, termed blastocysts, are used. A blastocyst is a fluid-filled 
cavity, termed blastocoele, which contains a cluster of cells called the inner 
cell mass (ICM) at its apical side and a thin outer trophoblast layer, or 
trophectoderm (TE), enclosing the cavity.  During normal embryogenesis, 
the TE, becomes the placenta which supports the development of the ICM 
into a foetus. So it is the ICM that harbours those unique pluripotent cells 
that have the potential to develop into any tissue of the body. In the early 
1980s, Evans and Kaufman (Evans and Kaufman, 1981) and Martin 
(Martin, 1981) independently identified the promise that lies within the 
isolation and propagation of the ICM. The mouse ICM was successfully 




conditions, generating the first ESC lines. When injected into a developing 
mouse blastocyst, these ESCs were shown to create chimeric mice 
contributing to all cell lineages including the germ lines, thus proving their 
capacity for pluripotent differentiation (Bradley et al., 1984).  
In 1998, the first hESC line was derived and characterised (Thomson et al., 
1998), and since then numerous lines have been established. Human ESC 
lines can be broadly classed into two groups- normal and specific-mutation 
carrying lines, for example, mutations linked to cystic fibrosis (Pickering et 
al., 2005) or Huntington disease (Stephenson and Braude, 2010). The hESC 
lines carrying a mutation for a specific genetic disease can be used to 
investigate the onset and progression of genetic disorders and facilitate drug 
development which could otherwise not be performed in human patients. 
These specific-mutation carrying lines are derived from clinically unsuitable 
embryos following pre-implantation genetic diagnosis (PGD) (Pickering et 
al., 2003). When PGD demonstrates positivity for alleles carrying a risk of a 
certain genetic conditions, embryos are often donated for medical research. 
In addition the blastocysts used for hESC purposes may be donated to 
medical research by couples who undergone in vitro fertilisation (IVF) 
(Reubinoff et al., 2000, Lanzendorf et al., 2001, Amit and Itskovitz-Eldor, 
2002, Cowan et al., 2004). IVF generally produces a large number of 
embryos, which is supernumerary to reproductive desire requirements. 
Poor-quality embryos which would otherwise be discarded, provide an 
alternative source (Mitalipova et al., 2003).  
The derivation of hESCs at King’s College London is under license from the 




license number R0133) and also has local ethical approval (UK National 
Health Service Research Ethics Committee Reference 06/Q0702/90). In 
accordance with HFEA regulations, a sample of each line that is derived is 
deposited in the UK Stem Cell Bank for distribution to academic and 
research centers internationally. Figure 7 shows the laser-assisted process 
of hESC line derivation, as currently used at King’s College London.  
Alternatively hESC lines could be derived without the destruction of 
embryos. This technique involves a single cell biopsy of an 8-cell embryo, 
and the removed cell (a blastomere) can in some instances be cultured to 
produce a stable hESC line (Klimanskaya et al., 2006, Chung et al., 2006). 
The biopsy is not detrimental to the development of the embryo, as the cell 






Figure 7 Laser-assisted derivation of hESCs.  
(a-e) Single blastomere biopsy from a cleavage-stage (day-3 post-fertilization) embryo. (a) 
Cleavage-stage embryo held with a holding pipette (HP) is exposed to a gentle stream of 
acid Tyrode’s solution coming through a Tyrode’s pipette (TP); (b) A blastomere popping 
through a Tyrode’s solution-drilled hole in the zona pellucida (arrow); (c, d) The 
blastomere is carefully aspirated using an aspiration pipette (AP); (e) The biopsied 
blastomere is examined for the presence of a nucleus and DNA is used for mutation 
diagnosis; (f–i) Laser-mediated ICM dissection. The ICM and TE of a well-developed 
blastocyst are separated with a series of laser pulses (double-arrow); (j ,  k) ICM outgrowth 
on mitotically inactivated human foreskin fibroblasts (HFFs), 5–7 days after plating; (j)  
Two distinct cell populations within an outgrowth; hESC-like colony and TE cells could be 
distinguished under higher magnification about 5–7 days post-plating; (k) TE is dissected 
out with a needle. S, needle scratches on tissues culture plastic; (l) Typical 12–15-day old 
hESC colony on mitotically inactivated HFF. Figure taken from (Ilic et al., 2012) 
 
2.1.3 Germ layer differentiation in human embryogenesis  
Pluripotency of hESC lines presumes that in vitro differentiation of these 
cells would recapitulate embryogenesis in the womb and lead to formation of 
all three primitive germ layers, the ectoderm, endoderm and mesoderm. 




in the gastrula stage and from which the organs and tissues of the body 
develop through further differentiation. 
All three embryonic germ layers in humans are well characterised with 
regard to their development during embryogenesis. An appreciation of the 
germ layers is crucial in order to design a system of tissue culture 
techniques that encourage formation of cell types from a particular lineage. 
During the blastocyst stage of human embryonic development, the primitive 
endoderm forms, as an outer layer of the ICM, and will eventually form only 
the extraembryonic support structures such as the yolk sac. Implantation 
and penetration of the blastocyst into the endometrium lining of the uterus 
occurs, followed by primitive ectoderm formation. Cavitation of the inner 
most group of cells in the primitive ectoderm generates a two-layered 
embryonic structure termed the epiblast. It is from this structure, appearing 
around 16 days post-fertilisation that gastrulation and organogenesis occur. 
Dynamic cell migrations and focal gradients of numerous chemical 
mediators orchestrate the appearance of a body plan. 
 
2.1.4 The embryonic stem cell control network 
The concept of ‘stemness’ was first developed following expression profile 
studies comparing gene expression in human embryonic stem cells to both 
mouse ESC and cancer cell lines (Ramalho-Santos et al., 2002, Sato et al., 
2003, Sperger et al., 2003, Richards et al., 2004, Zeng et al., 2004b, Wei et 
al., 2005) to describe a portfolio of commonly expressed genes whose 




considerable similarities in gene expression between different hESC lines, 
each line has also been proposed to have its own expression signature 
(Abeyta et al., 2004, Skottman et al., 2005). Nevertheless, a core subset of 
genes associated with hESC pluripotency has been identified. 
 
2.1.4.1 Octamer-3/4 and Sox-2 
The first pluripotency-associated transcription factor to be identified, Oct-
3/4 (Octamer-3/4) is a homeodomain-containing POU-family transcription 
factor protein, encoded by the Pou5f1 gene. The POU family of transcription 
factors will bind to the octamer nucleotide sequence ATTTGCAT, in the 
promoter regions of numerous genes and functional activity of Oct-3/4 in 
pluripotent cells has been shown (Okamoto et al., 1990, Rosner et al., 1990, 
Scholer et al., 1990). Knockdown models of Oct-3/4 using RNA interference 
were correlated with loss of ESC phenotype and morphology in vitro (Matin 
et al., 2004), and regulation of the levels of the active Oct-3/4 transcription 
factor has been demonstrated to be critical to the degree of differentiation of 
a cell. Only an optimal level of Oct-3/4 expression will maintain ES cells in 
their undifferentiated state (Niwa et al., 2000). Oct-3/4 has a high binding 
affinity for another transcription factor, Sox-2 (sex-determining region Y box 
2). Oct-3/4 and Sox-2 bind heterodimerically to each other, and also 
stimulate transcription in a feedback loop type manner by binding to their 
opposing number’s encoding gene (Ambrosetti et al., 2000, Catena et al., 
2004, Chew et al., 2005) (Okumura-Nakanishi et al., 2005) (Tomioka et al., 
2002). It is possible that Sox-2 acts more to monitor and modulate levels of 




themselves. This theory is supported by Sox-2 inducible-knockdown 
experiments (Masui et al., 2007). 
Alternative splicing of Oct-3/4 pre-mRNA yields two isoforms, the longer 
Oct-3/4A and the shorter Oct- 3/4B isoforms. Studies have suggested that is 
it the Oct-3/4A isoform, that contains an additional N-domain sequence, 
that is responsible for the pluripotency induction in ESCs (Lee et al., 2006).  
 
2.1.4.2 Nanog 
The NANOG gene and translated protein, which was named after a 
legendary immortal Scottish hero, has been called the master pluripotency 
gene (Chambers et al., 2003, Chambers et al., 2007, Hart et al., 2004). The 
protein itself contains a homeodomain to facilitate DNA binding. Nanog 
mRNA can be detected in mouse and human ESC lines, but never in their 
differentiated progeny (Chambers et al., 2003). It is also detected in the 
inner cell mass of a developing embryo (Mitsui et al., 2003). If the levels of 
Nanog protein are increased by genetic manipulation, the need for Oct-3/4 
activity can be negated (Chambers et al., 2003). Nanog appears to head the 
hierarchy of transcription factors that control pluripotency: Nanog-deficient 
ESCs lose pluripotency and nanog-deficient ICMs failed to develop to the 
epiblast stage (Mitsui et al., 2003).  
Interaction of the Oct-3/4:Sox-2 complex with the Nanog promoter has been 
demonstrated, and a study of the promoter sequences bound to by Oct-3/4, 
Sox-2 and Nanog demonstrated considerable overlap in target genes, 
although binding sites themselves differed (Loh et al., 2006). Over 350 genes 




Pou5f1, Sox-2 and Nanog genes themselves, and also many genes found in 
an inactive state in ESCs. This would suggest the three factors serve to 
repress germ layer differentiation by muting expression of these genes 
(Boyer et al., 2005), and also form a positive feed-forward loop to regulate 
their own expression. 
Nanog is also implicated in many other signalling pathways within the cell 
too. For example, Nanog expression can be up-regulated by Oct-3/4-bound $-
catenin (Takao et al., 2007).  
 
2.1.5 Glycolipids and protein expression 
Similarly, the panel of proteins whose expression has become inseparably 
linked with undifferentiated ESCs line has been devised.  
Immunocytochemical data will often report expression of TRA 1-60 and TRA 
1-81 (tumour recognition antigens 1-60 and 1-81) and SSEA-1, -3 and -4 
(stage specific embryonic antigens 1, 3 and) to characterize an ESC line 
(Henderson et al., 2002, Sato et al., 2003). TRA 1-60 and TRA 1-81 refer to 
two separate binding sites on the same molecule. TRA 1-60 and TRA 1-81 
monoclonal antibodies demonstrate high binding affinities for two epitopes 
on a high molecular weight, heavily glycosylated protein. The glycoprotein is 
localised to the cell surface by function of its transmembrane proteinaceous 
domain and is thought to participate in cell adhesion functions. SSEA-3 and 







2.1.6 Other aspects of hESC biology 
2.1.6.1 hESCs and chromosomal instability 
Using data available from whole genome sequencing, the human genome 
mutation rate is estimated to be ~1.1)108 per site per generation (Roach et 
al., 2010). ESCs in culture are also subject to this mutation frequency, 
however due to their capacity for infinite cell division, ESCs have a greatly 
increased probability of acquiring a mutation during culture. In addition, 
there is a strong selection that is aimed at increasing the probability of self-
renewal (Andrews et al., 2005). Indeed, hESC lines often show progressive 
‘adaptation’ to culture, with the result that late-passage cells may be 
maintained more easily (Enver et al., 2005).  
Acquisition of mutations by hESCs obviously impacts on their potential use 
for patient-centred therapies. Some warning signs reminiscent of neoplastic 
cells, such as growth factor independence, and a particular type of 
chromosomal staining associated with cancer cells have been reported in 
hESCs (Baker et al., 2007, Werbowetski-Ogilvie et al., 2009). Studies of 
karyotypic aberrations have shown chromosomal gains on chromosome 17 in 
three independent hESC lines, with occasional gain on chromosome 12 
(Draper et al., 2004) In the case of trisomy in chromosome 12, morphological 
changes in hESC colonies are dramatic and can be easily visualized by eye 
(Seol et al., 2008). NANOG has been suggested as a candidate gene on 
chromosome 12p which, when overexpressed promotes the self-renewal of 
hESCs (Darr et al., 2006, Chambers et al., 2003). A minimal amplicon in 




gene, BCL2L1, has also been identified (Amps et al., 2011). The 
amplification of this region promotes the survival of ESCs in vitro, thereby 
providing a strong growth advantage. 
Correlations between tissue culture techniques and genetic abnormalities 
have been suggested (Yang et al., 2008, Mitalipova et al., 2005). Therefore it 
is imperative that hESCs culture is optimized to sustain chromosomal 
stability and normal karyotype. 
 
2.1.6.2 hESCs and epigenetics 
Epigenetics refers to functionally relevant modifications to the genome that 
do not involve a change in the nucleotide sequence of DNA. Methylation and 
acetylation are perhaps the most studied epigenetic methods, but other 
epigenetic modifications include ATP-dependent chromatin remodelling, 
exchange of histone variants, ubiquitination, phosphorylation and the 
involvement of small RNA molecules (Gan et al., 2007). Histones can 
package genomic DNA in a slightly different manner, according to 
epigenetic modifications, and therefore affect the probability of transcription 
of the genes occurring. 
Studies of epigenetic processes in ESCs revealed that promoter regions 
demarcated with a specific histone 3 methylation modification were 
transcriptionally active, including the promoters of the well-established 
hESC marker genes Nanog, Oct-3/4 and Sox-2 (Ng et al., 2008, Zhao et al., 
2007). When two repressive trimethylation events were mapped across the 
entire hESC genome, genes with these modifications were often found to be 




epigenetic modifications observed on the Nanog, Sox-2 and Oct-3/4 genes 
appeared to switch from activating to repressive events, upon hESCs 
differentiation. A substantial degree of epigenetic stability over long-term 
culture of hESCs has been suggested as the imprinted genes have been 
shown to retain their monoallelic expression (Rugg-Gunn et al., 2005). 
The importance of culture conditions of hESCs is highlighted by the 
importance of low oxygen (5% pOj, 36 mm Hg) for derivation and 
propagation of hESCs (Lengner et al., 2010). Functional gain of the X 
chromosome, resulting from loss of X-chromosome inactivation in culture-
adapted ESCs with two karyotypically normal X chromosomes has been 
reported (Enver et al., 2005). On the contrary, physiological levels of oxygen 
mimic the uterine environment and prevent X chromosome inactivation 
(Lengner et al., 2010). The presence of two active X chromosomes aids in 
maintaining pluripotency and suppressing spontaneous differentiation by 
maintaining hESCs in a more immature state.  
 
2.1.6.3 hESCs, telomerase and telomere length 
Telomerase is an enzyme that adds specific six nucleotide DNA repeats to 
the 3’-end of telomere regions, situated at the end of chromosomes. In 
human cells, there are around two thousand of these repeats in the average 
telomere. During each round of DNA replication, a small piece at the end of 
telomere is lost, owing to the incapacity of normal DNA polymerases to copy 
the very ends of chromosomes (Harley et al., 1990, Blasco et al., 1997). In 
such a scenario, the chromosomes would become progressively shorter with 




chromosomes could be deleted. Telomerase therefore functions to prevent 
this happening, by lengthening telomeres and providing non-essential 
genetic material that can be sacrificed to the process of replication, without 
the loss of any genetic material (Harley et al., 1990). 
Growth arrest in hESCs has been reported to occur when telomeres are at a 
length similar to that seen in senescent cells (Forsyth and McWhir, 2008). 
The starting telomere length of hESC-derived progenitors also exerts effects 
on the proliferative potential of progeny populations. 
When hESCs were transduced with hTert (the active subunit of telomerase) 
immortalisation of progenitor cell populations was achieved (Forsyth and 
McWhir, 2008). In a study using iPSCs derived from old and young patients, 
the iPS colonies were found to contain cells with telomere lengths longer 
than that of the parental cells, indicating that reprogramming stimulates 
telomere elongation (Marion et al., 2009b). 
 
2.1.7 Human ESCs and the epithelial-mesenchymal transition 
Human ESCs have apical-basal, epithelial-type polarity with functional 
tight junctions and microvilli localized to the apical regions, and asymmetric 
distribution of organelles (Krtolica et al., 2007, Van Hoof et al., 2008).  In 
addition expression of epithelial proteins primarily belonging to epithelium-
related cell-cell adhesion complexes, including adherens junctions, tight 
junctions, desmosomes, and gap junctions, has been reported in hESCs 




An epithelial-mesenchyme transition (EMT) is a phenomenon observed at 
several points during embryogenesis, when cells epithelial cells lose their 
polarity and become motile mesenchymal cells, in order to form additional 
parts of the embryo. EMT events have been documented to occur in the 
neural tube, primitive streak and developing heart during human 
embryogenesis (Ahlstrom and Erickson, 2009, Baum et al., 2008, Duband et 
al., 1995). In hESC colonies an early differentiation process has been 
identified, whereby epithelium-type cells inside or on top of colonies seem to 
alter their morphology to mesenchymal-type cells, and migrate to the 
periphery of the colonies (Ullmann et al., 2007). This process is reminiscent 
of EMT and expression of the EMT-associated genes Snail and Slug are both 
up-regulated in the periphery of colonies examined, in correlation with a 
switch in expression from epithelially-associated E-cadherin to 
mesenchymally-associated vimentin (Ullmann et al., 2007). Increased 
immunopositivity for brachyury through early differentiation of hESC 
colonies mirror those of vimentin, again in combination with elevated levels 
of Snail expression (D'Amour et al., 2005). Brachyyury is a transcription 
factors that defines the midline of a bilaterian organism and mesoderm 
formation during gastrulation (Edwards et al., 1996). These data suggest 
that differentiating hESC cultures include features of an EMT, similar to 





2.1.8 In vitro  differentiation of hESCs: embryoid bodies 
formation 
Embryoid bodies are three-dimensional clusters of cells, formed from 
embryonic stem cells cultured in suspension. These clusters which mimic 
many of the hallmarks of early embryonic development acquire molecular 
markers specific to the three embryonic germ layers (Itskovitz-Eldor et al., 
2000). Following cell aggregation, a layer of primitive endoderm forms 
spontaneously on the exterior surface of the embryoid bodies (Maurer et al., 
2008). The cells compromising this primitive endoderm exhibit an epithelial 
morphology, further differentiate into visceral and parietal endoderm, and 
deposit a basement membrane rich in laminin and type IV collagen (Li et 
al., 2001). As the development of embryoid bodies progresses, differentiated 
cell phenotypes of all three germ lineages can be seen. For example, 
evidence of haematopoietic differentiation of embryoid bodies is supported 
by the appearance of yolk sac-like blood islands and spontaneously 
contractile foci of cells within embryoid bodies, which indicates 
cardiomyogenic differentiation (Doetschman et al., 1985). Elongated cell 
projections resembling neurite extensions can be seen radiating out from 
embryoid bodies upon plating onto adherent substrates. 
Therefore, embryoid body formation is commonly used to initiate 
spontaneous differentiation which can then be manipulated and directed 
towards a specific cell lineage. For example, VEGF is known to direct 
differentiation within embryoid bodies to mesenchymal fate which is 
marked by expression of the mesenchymal intermediate filament protein 




2.1.9 In vivo  differentiation of hESCs: teratoma formation 
Evaluation of the capability of a ESC line to differentiate into any tissue 
within an organism, would optimally be performed by carrying out 
blastocyst chimerism, and then allowing the embryo to develop through the 
full gestation time.  Indeed, mouse ESCs are assessed in this manner 
(Buehr et al., 2008, Ueda et al., 2008). Due to obvious ethical reasons, this 
technique cannot be extrapolated to prove pluripotency of hESCs using 
human blastocysts. 
Instead the teratoma assay can be applied. Transplanting undifferentiated 
hESCs into permissive sites of mice and analysing the resultant tumour, or 
teratoma, provides an indication of the spontaneous differentiation 
capabilities of an hESC line. In a teratoma assay, a true hESC line will 
differentiate into tissue types from each of the three extra embryonic germ 
layers, the ectoderm, endoderm and mesoderm. This is usually assessed by 
recognising cell types by morphology, in H&E stained sections of the 
teratomas.  
The teratoma assay is compulsory for characterization of any new hESC line 
(Brivanlou et al., 2003). Cells are transplanted sub-cutaneously, intra-
testicularly or in some cases into the liver lobes of immune-deficient mice 
(Thomson et al., 1998, Cooke et al., 2006, Gertow et al., 2004, Heins et al., 
2004, Reubinoff et al., 2000, Stojkovic et al., 2004). These injection sites are 
chosen for the ease of delivery of the cells into the correct location, and for 
the confinement of the cells in that location once delivered. Delivery of the 
cells into the liver lobes has been reported to generate teratomas containing 




testicular injection, and also to promote more vascularisation within the 
tumour (Lees et al., 2007). Three-dimensional scaffolds and other 
substances may be co-injected with the hESCs, to improve teratoma 
formation (Lees et al., 2007, Przyborski, 2005). 
The teratoma assay is not only proof of in vivo differentiation but is also a 
proof that the cells are not cancerogenic. Culture-adapted transformed 
hESCs have been shown to form more aggressive tumours, called 
teratocarcinomas, the malignant counterparts of teratomas (Werbowetski-
Ogilvie et al., 2009, Blum and Benvenisty, 2009). 
 
2.1.10 Development of hESC Culture Systems  
The establishment of the first hESC lines was achieved by using mouse 
embryonic fibroblasts (MEFs) as feeders and foetal bovine serum (FBS)-
containing culture medium (Thomson et al., 1998, Reubinoff et al., 2000) 
and many laboratories continue to use them routinely for long-term hESC 
culture. Feeder cells such as MEFs have a capacity to support the growth 
and proliferation of hESCs while maintaining them in an undifferentiated 
state. The exact mechanism of how feeder cells support hESCs growth is not 
understood, but it is likely that feeders provide both a suitable attachment 
substrate through cell membrane proteins and essential soluble growth 
factors. MEFs are primary cells derived from day 12.5–14.5 murine foetuses, 
so they are used optimally between passage 3 and passage 6. To prepare 
feeder layer, MEFs are mitomically inactivated either by &-irradiation or 




Despite the effectiveness of feeder-supported culture of hESCs, the 
continued use of feeders and animal- derived components in hESC cultures 
will hinder the development of clinical applications due to: a) the presence of 
immunogenic material (Martin et al., 2005); b) the risk of transmitting 
animal virus or prion material; and c) difficulty with quality control of these 
undefined components. Furthermore, feeder-dependent culture of hESCs 
calls for manual passaging which is both labour-intensive and time-
consuming. This in turn presents challenges in large-scale expansion of 
hESCs and limits the efficiency and reproducibility of differentiation 
protocols. Therefore, an important advancement in the field is the definition 
of culture conditions that support the proliferation and culture of hESCs 
without the need for feeders or animal-derived components. An optimal 
culture system would include an appropriately buffered medium that 
contains all metabolites, cytokines and growth factors required for self-
renewal and survival of undifferentiated hESCs as well as a culture matrix 
that supports cell growth. 
First optimizations in hESCs culture aimed at replacing animal feeder cells 
with various alternative human cells, such as HFFs (Amit et al., 2003, 
Hovatta et al., 2003), fetal placental fibroblasts (Genbacev et al., 2005), 
uterine endometrium cells (Lee et al., 2005), adult marrow stroma cells 
(Cheng et al., 2003), fetal/adult fallopian tube-epithelial cell origin (Richards 
et al., 2002, Richards et al., 2003). Feeder cells are routinely cultured in 
medium containing FBS which raises an issue of contaminating hESCs with 
animal molecules from serum. To avoid this, several groups have reported 




Wang et al., 2005), but this approach still does not eliminate batch-to-batch 
variation introduced by the presence of serum. Consequently, several 
serum- and feeder-free culture conditions have been developed (Xu et al., 
2001, Levenstein et al., 2006, Amit et al., 2004, Vallier et al., 2005, Lu et al., 
2006).  
One of the most successful culture conditions has been reported by Xu et al 
(Xu et al., 2001). This culture system utilized BD Matrigel™ as a culture 
matrix and MEF conditioned medium supplemented with bFGF. Matrigel is 
a complex mixture of mouse sarcoma origin that contains extracellular 
molecules, such as laminin, type IV collagen, heparin sulphate and 
proteoglycan (Kleinman et al., 1986). Under the conditions described, hESCs 
were maintained for over ?130 population doublings and retained all the 
morphological and molecular characteristics of undifferentiated hESCs, as 
well as normal karyotypes. The cells also retained their pluripotent capacity 
and consistently differentiated into many types of cells including neurons, 
hepatocytes, and cardiomyocytes.  
 
2.1.11 Defined media for hESC culture 
As mentioned above, hESCs were traditionally cultured in FBS (Thomson et 
al., 1998, Reubinoff et al., 2000), which was later replaced with human 
serum (Richards et al., 2002). To overcome serum-related variability, 
several groups have optimized serum-free hESCs culture using serum 
replacement (KnockOut™ Serum Replacement, Ko-SR, Invitrogen) (Amit et 




effectiveness Ko-SR is undefined and contains animal components. 
Consequently, two groups have reported the culture of hESCs in chemically 
defined media (Liu et al., 2006b, Vallier et al., 2005, Yao et al., 2006), 
although none of these methods could be considered xeno-free due to the 
presence of bovine serum albumin (BSA) and xeno-based matrices. Other 
successful feeder- and serum-free cultures have been using ECM and a 
combination of transforming growth factor $ (TGF$) and bFGF  (Amit et al., 
2004), or or high levels of bFGF alone (Levenstein et al., 2006). Successful 
propagation of hESCs has been achieved in xeno-free and defined culture 
media with fibronectin/collagen matrix (Lu et al., 2006). “TeSR” is a serum-
free, xeno-free medium that was shown to support derivation and long-term 
feeder-independent culture of hESCs, and was developed by Ludwig and 
colleagues at the WiCell Research Institute (Madison, WI) (Ludwig et al., 
2006b). The formulation of “TeSR” included high levels of bFGF, together 
with TGF$, &-aminobutyric acid, pipecolic acid, and lithium chloride. The 
original publication described the use of cell support matrix composed of 
type IV collagen, fibronectin, laminin, and vitronectin of human origin 
(Ludwig et al., 2006a). Subsequently, STEMCELL Technologies has 
developed mTeSR™1 as standardized media for feeder-independent 
maintenance of hESCs in culture. This culture medium is complete, serum-
free, defined formulation based on the publications by Ludwig et al (Ludwig 
et al., 2006a, Ludwig et al., 2006b). It contains a bovine albumin source that 
supports the long-term, feeder-independent culture of hESCs and has also 
been used for successful feeder-free derivation of iPSCs (Yu et al., 2007, Sun 




qualified Matrix (BD) is used as a substrate. Each batch of this matrix is 
pre-qualified to ensure consistency, reproducibility, and reliability in 
performance. Such culture system for hESCs ensures consistent conditions 
due to the elimination of undefined medium components and removal of the 
inherent variability associated with feeder cells and conditioned media. 
Standardization of culture methods also dramatically increases 
reproducibility of data.  
Therefore, I opted to adapt the KCL-002 hESC line to grow on Matrigel 
substrate in the presence mTeSR™1 medium. To prove that the adaptation 
was successful it was important to show that the cells remained 
phenotypically homogeneous and karyotypically normal, expressed high 
levels of multiple antigens associated with pluripotency as well as genes 
responsible for their pluripotent status. It was also important to show that 
the cells could be differentiated in vitro and formed teratomas containing 




2.2.1 Mouse embryonic fibroblast culture 
Undifferentiated hESCs are traditionally grown on feeder layer of mouse 
embryonic fibroblasts (Thomson et al., 1998).  
MEFs were derived from embryonic day 16 embryos derived from C57/BL6 





Early passage (P1-P2) MEFs were cultured in 175cm* tissue culture flasks 
(Appleton Woods, Birmingham, UK) in an atmosphere of 5% CO? until 70% 
confluence was reached. Flasks were coated with filtered 0.1% (w/v) gelatin 
solution (Sigma, Gillingham, UK) prior to addition of the cells to facilitate 
cell adherence (5min at room temperature). Excess gelatin-containing 
solution was aspirated away. 
MEF culture medium comprised High Glucose Dulbecco’s Modified Eagle 
Medium (DMEM; Invitrogen, Paisley, UK), 10% embryonic stem cell-tested 
foetal calf serum (ES-FCS; Autogen Bioclear, Calne, UK), 0.1mM non-
essential amino acids (NEAA; Invitrogen), 2mM Glutamax (Invitrogen) and 
0.1mM 2-$-mercaptoethanol (Sigma). All medium components were filtered 
through a 0.2µM filter system (Appleton Woods) to ensure sterility. 
 
2.2.2 Preparation on MEFs feeder-layers 
Passage 3 MEFs at 70% confluence were used to make ‘feeder plates’ for the 
maintenance of hESCs. All feeder plates were made using MEFs derived 
from the same batch to ensure consistency in the cellular environment of the 
plates. 
MEFs in tissue culture flasks were washed with tissue-culture grade 
phosphate-buffered saline (PBS; Invitrogen) and incubated with the 
mitomycin C mitotic inactivation reagent (Sigma) at a working 
concentration of 5µg/ml at 37°C for 2.5 hours. Mitomycin C cross links DNA, 
thereby inhibiting chromosome rearrangement necessary for mitosis. 




with PBS and cells released from the culture vessel surface enyzymatically, 
by incubating with TrypLE Express (Invitrogen) at 37°C for 4min. To 
neutralize the enzyme activity, an equal volume of MEF medium was added 
to the cell solution and the cells were collected by centrifugation at 400g for 
5min. Meanwhile, wells of 4-well plates (VWR, East Grinstead, UK) were 
gelatinised as described above, and 500µl MEF medium added per well. 
Collected MEFs were counted using a haemocytometer (Hausser Scientific, 
Horsham, PA, USA) and 3.2x10 /cm* viable inactivated MEFs per well were 
added. Plates were agitated gently to disperse MEFs evenly through the 
well and incubated overnight to allow for efficient cell attachment. Plates 
were used within 3 days of this time point. 
 
2.2.3 Buffalo rat liver cell culture 
Survival and growth of human embryonic stem cells is greatly enhanced by 
culture in media that has been partially ‘conditioned’ by a previous cell 
population, to release chemical mediators and growth factors into the 
medium. Buffalo Rat Liver cells (BRL cells, gift from Prof. Paul Sharpe, 
King’s College London) were used for this purpose. 
BRL cells were cultured in 175cm* tissue culture flasks, in medium 
composed of High Glucose DMEM, 20% ES-FCS, 2mM Glutamax, 0.1mM 
NEAA and 0.1mM 2-$-mercaptoethanol (Invitrogen) (‘BRL medium’). 
Medium components were filter-sterilised prior to use. 
‘BRL conditioned medium’ (BRLCM) was collected from flasks at 70% 




protect the biological activity of active components of the medium. BRL cells 
were passaged enyzymatically using TrypLE Express, and re-seeded into 
new tissue culture flasks at a ratio of 1:10 until 70% confluence was 
achieved again. Culture technique was maintained in this fashion to 
generate large quantities of BRLCM. 
 
2.2.4 Maintenance of hESCs on MEF feeder layers 
For optimum aseptic techniques, work with hESCs was performed wearing 
surgical masks and shoe covers (Kimberley Clark, West Malling, UK) in 
addition to lab coats and gloves. 
The hESC line used in this study (KCL-002) was derived in the Stem Cell 
Biology Laboratory at King’s College London with Guys and St Thomas’ 
Hospital ethical approval under HFEA license R0133, and with a full 
informed patient consent. Colonies of KCL-002 hESCs were maintained in 
an undifferentiated state by a combination of culture on inactivated MEF 
feeder plates and exposure to the bFGF in culture medium (Pickering et al., 
2005, Pickering et al., 2003). hESC medium was composed of a 1:1 ratio of 
BRL medium and BRLCM and 8ng/ml bFGF (Peprotech, London, UK).  
The medium was replaced every other day (500µl) and supplemented on 
alternate days (250µl). Every 7-10 days the colonies were mechanically 
passaged by ‘cutting’ undifferentiated cell colonies into small clumps under 
a dissection hood, using Pasteur pipettes (Sigma) pulled to a fine point in a 




sections were transferred to new wells containing fresh MEF-feeder layers 
and bFGF-containing medium. 
The colonies were maintained at the approximate density of 300-500 cells 
per colony to avoid premature differentiation. 
 
2.2.5 Feeder-free maintenance of hESCs 
For feeder-free culture, KCL-002 cell line was grown on BD Matrigel hESC-
qualified matrix (BD, Oxford, UK) diluted 1:100 in DMEM:Ham F-12 
(Invitrogen). Small (250µl) aliquots of undiluted BD Matrigel were stored at 
-80°C for up to 6 months and thawed slowly on ice when required. For a 6-
well plate, 1ml of diluted Matrigel was used per well. Coated plates were 
then left at 37ºC for 1 hour before aspirating and replacing with mTeSR1 
medium (Stem Cell Technologies, Grenoble, France). If not used 
immediately, plates were sealed with Parafilm (Appleton Woods) to prevent 
dehydration and stored at 4°C for up to 7 days after coating.  
hESCs were passaged when the colonies were large and begin to merge, and 
had centres that were dense and phase-bright compared to their edges. 
Depending on the size and density of seeded aggregates, cultures were 
usually passaged 5-7 days after initial seeding. 
Passaging was performed enzymatically using dispase at a concentration of 
1mg/ml (Invitrogen). Stock solutions of 5mg/ml were prepared with PBS and 
stored at -20°C. Stock was further diluted with DMEM:Ham F-12 to 





If differentiated regions were observed, they were removed by scraping with 
a pipette tip. The culture medium was then aspirated and the plates rinsed 
with DMEM:Ham F-12. Dispase (1ml per well in a 6-well plate) was added 
and incubated at 37°C for up to 5min. Enzymatic activity was confirmed 
under phase-contrast microscope: the colony edges appeared slightly folded 
but most of the colony remained attached to the plate. Dispase was then 
removed and the plates gently rinsed twice with DMEM: Ham F-12 to dilute 
away any remaining dispase. DMEM:Ham F-12 (2ml per well) was then 
added to the plate and colonies scraped off using a cell scraper (Appleton 
woods). The detached cell aggregates were transferred into a 15ml conical 
tube and the wells rinsed with additional 2ml of DMEM:Ham F-12 to collect 
any remaining aggregates. The cell aggregates were centrifuged at 300g for 
5min, the supernatant aspirated and pellet resuspended in mTeSR1 by 
gently pipetting. The split ratio of the initial cultures was 1:4. As the cells 
became more adapted to the new culture conditions, the split ratio was 
increased to 1:10. The aggregates were seeded onto a new plate coated with 
Matrigel. 
 
2.2.6 Cryopreservation and thawing of cryopreserved hESCs 
cultured in feeder-free conditions 
Only high quality hESC colonies (less than 15% of the cells being 
differentiated) were cryopreserved. The colonies were passaged as described 
above and following centrifugation gently re-suspended in mTeSR1 




taking care to leave the clumps larger than would normally be done for 
passaging. Larger clump size would ensure better survival of hESCs during 
cryopreservation and recovery. The suspenson was aliquoted into labeled 
cryovials and stored at -80°C overnight before being transferred into a liquid 
nitrogen vapor tank. To recover hESCs from liquid nitrogen, cryovials were 
quickly thawed in a 37°C waterbath until only a small frozen pellet remains. 
The cryovial was wiped with 70% ethanol to sterilize prior to opening. The 
contents were transferred into a 15ml conical tube using a 2ml pipette to 
minimize breakage of cell clumps. Pre-warmed mTeSR™1 was added 
dropwise to the tube, gently mixing as the medium is added. The cells were 
centrifuged at 300g for 5min. The medium was aspirated and the pellet 
resuspended in 5ml of mTeSR1, taking care to maintain the cells as 
aggregates. The colonies were then seeded onto Matrigel-coated 6-well 
plates. The cells were grown at 37°C, with 5% CO? and 95% humidity. 
 
2.2.7 Immunofluorescent cytochemistry 
To investigate the presence of molecules of interest immunocytochemical 
analysis was performed. The principle of immunostaining is reliant on a 
specific interaction of primary antibody with the target antigen and of the 
secondary antibody with the bound primary antibody. Immunostaining 
assumes both of these reactions occur with high affinity and allows the 
examination of cell preparations cultured in vitro for the expression of 
specific markers. For immunocytochemistry, KCL-002 hESC colonies were 




and before spontaneous differentiation began, cultures were washed once in 
PBS and incubated in 500+l of 4% paraformaldehyde (PFA; Sigma) fixative 
for 30min at 4°C. The wells were then washed with PBS for 5min at room 
temperature. For intracellular or nuclear proteins, cell membranes were 
permeabilised to allow access of the antibody to the relevant antigen. Where 
target proteins were expected to be expressed on the cell surface, 
permeabilsation of the cell membrane was not employed. Table 3 describes 
the details of antibodies used. Permeabilisation was achieved by adding 
0.1% (v/v) Triton™ X-100 (Sigma) to solutions used in all steps. The nature 
of immunostaining relies on a specific reaction between an antibody and its 
cognate antigen epitope. To prevent both primary and secondary antibodies 
forming interactions with proteins in a non-specific manner, samples were 
incubated with a blocking solution for 1 hour at room temperature. The 
blocking solution consisted of PBS, 10% normal goat serum (NGS; 
Invitrogen), 1% BSA (Sigma) for all antibodies apart from anti-Sox2 
antibody. Anti-Sox2 antibody was raised in goat therefore, 5% (w/v) milk 
powder (Marvel, St. Albans, UK) in PBS was used to block unspecific 
binding for this antibody. The cells were incubated with primary antibodies 
diluted to a working concentration (outlined in Table 3) for 1 hour, washed 
twice in PBS, and incubated with Alexa Fluor-conjugated secondary 
antibodies (Invitrogen) at 1:500 dilution for 30min. Both primary and 
secondary antibodies were diluted in 1% BSA in PBS. Alexa Fluor-
conjugated secondary antibodies used throughout the course of this study 
are detailed in Table 46"Electrons in fluorophores such as the Alexa Fluor 




excitation wavelength). The gained energy is released in the form of light of 
another wavelength (the emission wavelength), when the electrons return to 
the lowest possible energy level. Light emitted after excitation can be 
exploited when such dyes are conjugated to antibodies, to visualise 
immunopositivity for an antigen in cells and processed cellular samples. 
One drop of ProLong® Gold antifade reagent (Invitrogen) containing 4',6-
diamidino-2-phenylindole (DAPI) was added to simultaneously mount and 
counterstain the nuclei. ProLong Gold preserves the fluorescent signal and 
DAPI binds to regions of double-stranded DNA rich in A and T bases and is, 
therefore, used to visualize the nuclei. DAPI nuclear staining elucidates a 
blue colour at a 350:460nm excitation: emission spectra. To allow for 
visualization of immunofluorescent staining glass coverslips (13 mm 
diameter; Scientific Laboratory Services, Wilford, UK) were put on top of the 
cells in the stained wells. The samples were visualised with fluorescence 
microscope (Nikon, London, UK).  Images are taken with CCD camera, and 
processed with Photoshop CS8 (Adobe). 
Control procedures with the omission of either the primary or secondary 








Table 4 Secondary antibodies used throughout this study. 
!
Antibody Supplier Host Species 
reactivity 
Isotype Concentration Antigen 
Localization 
Anti-




















Mouse Human IgG3 1:50 dilution Extracellular 
Anti-Sox2        
(Y-17) 
Santa Cruz Goat Human, 
Mouse, Rat 









IgG1 5µg/ml Intracellular 









Goat anti-Mouse IgG Alexa Fluor 
488 
488nm 520nm Green 
Goat anti-rabbit IgG Alexa Fluor 
488 
488nm 520nm Green 
Goat anti-mouse IgG Alexa Fluor 
568 
575nm 600nm Orange-red 
Goat anti-rabbit IgG Alexa Fluor 
568 
575nm 600nm Orange-red 
Donkey anti-goat IgG Alexa Fluor 
594 
594nm 660nm Red 
Goat anti-mouse IgM Alexa Fluor 
488 




2.2.8 Quantification of immunofluorescence data  
Quantification of immunofluorescence data was carried out by counting cells 
showing a positive fluorescence signal for Nanog and Oct3/4 in 3 
independent fields containing 100 cells. Data are presented as percentage of 
cell numbers in relation to the total number of DAPI-positive cells. 
Quantification was carried out in 3 independent experiments. Values are 
presented as mean ± Standard Error of the Mean (SEM). Inferential error 
bar was used in this analysis in order to more accurately interpret the data. 
SEM= SD/,n and represents a measure of how variable the mean will be, if 
the study is repeated many times.  
 
2.2.9 Quantitative polymerase chain reaction 
To study the expression levels of gene of interest quantitative real-time 
polymerase chain reaction (quantitative PCR) technique was used. When a 
gene is transcribed from genomic DNA sequences, a chain of nucleotides 
encoding a specific amino acid sequence is generated, termed messenger 
ribonucleic acid (mRNA). Presence of mRNAs corresponding to a particular 
gene in a sample is used to infer the transcriptionally active status of that 
gene. mRNA molecules are extremely unstable and particularly vulnerable 
to degradation by RNase enzymes, due to the open structure of the hydroxyl 
bonds in the ribose sugars. mRNA molecules are only ever intended to be 
transient information-relaying molecules. Continuous presence of mRNAs 
and resulting continuous translation into protein of the genetic code it holds 




owing to the presence of stronger hydrocarbon bonds in the deoxyribose 
sugar.  Therefore, a conversion of isolated RNAs into DNA-like molecules 
termed complementary DNAs (cDNAs) provides a more stable and malleable 
platform from which to study the expression levels of genes of interest. 
 
2.2.9.1 Total RNA preparation 
KCL-002 hESC colonies were harvested with dispase and centrifuged in 
1.5ml microfuges at 8,000rpm for 30min. Total RNA extraction was then 
performed using the RNeasy kit (Qiagen, Crawley, UK). Cell membranes 
were lysed by mixing samples with 350µL activated Buffer RLT and 
homogenized by vortexing. Activation of buffer RLT involves addition of the 
reducing agent $-mercaptoethanol, which irreversibly denatures RNases 
released by the cell during lysis, to protect the quality of purified RNA. 
Equal volumes of 70% ethanol were added and samples were applied to an 
RNeasy spin column set in a collection tube and flow-through discarded 
after centrifugation at 10,000rpm for 15s. Use of ethanol separates the 
sample into aqueous and organic phases. RNA will remain in the aqueous 
phase, and then become attached to the membrane of the columns. 
Digestion and removal of any contaminating genomic DNA was performed 
by a 350µl wash of buffer RW1, incubation with DNase I for 15min at room 
temperature and washing with RW1. Two wash steps were then performed 
with 500µl of RPE buffer for 15s and 2min both at 10,000rpm, and a 
penultimate spin in a new collection tube with no added buffer on the 
column at 13,000rpm for 2min. Metabolites, macromolecular components 




membrane out. Addition of 20µl RNase-free water and a final centrifugation 
step for 1min at 10,000rpm eluted the purified RNA. Resultant total RNA 
was either used immediately for cDNA preparation or stored at -80°C. 
Purity of RNA was assessed spectrophometrically by examining the ratio of 
absorbance of light by sample at 260nm and 280nm. For this purpose a 
Nanodrop ND1000 UV-Vis Spectrophotometer (Labtech Int Ltd, Ringmer, 
UK) was used. Nucleotide absorbance is maximal at 260nm, whereas 
proteins will absorb light maximally at 280nm. Total RNA samples derived 
had an RNA purity ratio of between 1.8-2.0, which is widely considered good 
quality.  
 
2.2.9.2 Complementary DNA preparation 
Delicate RNA molecules can be converted into their more durable 
counterparts, DNA molecules, by the process of reverse transcription. DNA 
molecules generated are termed cDNAs. Levels of cDNA expression in 
samples were used to infer gene expression. Specialised primers directed 
against the poly(A) tail found at the end of mRNA molecules can be used as 
a selection tool to ensure only mRNA molecules are reverse transcribed: 4µg 
Oligo d(T)18 (Molecular Biology Unit, King’s College London, UK), 0.5mM 
PCR nucleotides (Promega, Southampton, UK) and between 2-6µl total RNA 
were combined in sterile PCR tubes. Volume was brought to 14µl with 
analytical grade water and the sample was incubated at 70°C for 3min to 
denature RNA secondary structures and then quickly placed on ice to allow 
annealing of primers to RNA. After that 4µl of 5X AMV buffer, and 40 units 




AMV reverse transcriptase (Promega) or 1µl dH2O were added to 
experimental or control samples respectively to make the final 20µl volume. 
Addition of distilled HjO in the place of reverse transcriptase served as a 
control for the presence of contaminating genomic DNA within the samples. 
Using a Dyad Peltier Thermal Cycler machine (Bio-Rad, Hemel Hempstead, 
UK), the samples were then taken through the following series of 
incubations: 37°C for 10min, 42°C for 30min, 52°C for 20min and finally 
80°C for 10min. For quantitative PCR analysis, 20ng of cDNA samples were 
used. 
 
2.2.9.3 Primer design 
Oligonucleotides may be designed to anneal preferentially to sequence 
within genes or exons of interest. Primer pairs used in this chapter are 
detailed in Table 5. The Primer3 website (http://frodo.wi.mit.edu/) was used 
to facilitate this process. The optimal annealing and extension temperature 
of the DNA Polymerase contained in the SYBR® Green PCR Master Mix 
(Roche, Burgess Hill, UK) is 60°C, hence primers had to be chosen that were 
compatible with reagents to be used. Primers were designed with a 
maximum product size of 250 base pairs (bp).  Specificity of the primer pairs 
for relevant genes was verified by performing nucleotide alignment searches 
using the Basic Local Alignment Search Tool (BLAST). All primers pairs 





2.2.9.4 Choice of internal control 
Primers were also designed against internal control gene (or ‘housekeeping 
gene’). Levels of expression of these genes are assumed to remain constant, 
in situations where genes of interest vary in their levels of expression, for 
example following differentiation of pluripotent cells. The number of copies 
of housekeeping genes present in a sample after amplification is therefore 
used to normalize gene expression levels for sample size. For this purpose 
GAPDH gene was chosen. 
 
2.2.9.5 Standard curve derivation 
For each gene to be assayed, positive control cDNA samples at 
concentrations of 25ng/µL were used to generate standard curves. Seven 
serial three-fold dilutions were made from the positive control cDNA 
samples, and labelled dilutions A to H. Template dilutions were combined in 
0.1mL tubes with quantitative PCR reagents as follows: 
11.5µl Positive control template dilution 
4µl 2X SYBR® Green PCR Master Mix  
1.0µl relevant primers at 25ng/µl of both forward and reverse primers 
Distilled H2O was added in place of template in additional tubes as a 
sentinel for possible contamination of reagents (‘no template controls’), all 
dilutions of template were assayed at least in duplicate. 
The Rotor-Gene 3000 Quantitative multiplexing system (Qiagen) and Rotor-
Gene 6 (Version 6.0) software were used to expose samples to 3-step PCR 




(i) Initial denaturation: 95-C, 10min 
(ii) Denature: 95-C, 10s 
(iii) Anneal: 60-C, 15s 
(iv) Extension: 72-C, 20s 
(v) Temperature ramp: 72-C-95-C, 
.1-C /5s. 
Incubations (ii-iv) were repeated 40 times.  
When the size of an amplicon is larger, more heat energy is required to 
denature the hydrocarbon bonds holding the double-stranded DNA in its 
helix format. The temperature ramp at the end of quantitative PCR reaction 
represents the temperature at which most products in a reaction became 
denatured, and is termed the melt curve. Plots on a melt curve peaking at 
the same temperature are considered to be amplicons of similar size.  Rotor-
Gene 6 (Version 6.0) software was used to derive standard curves by 
assigning dilution factors to diluents A-H of the positive control cDNA 
samples and correlating each with the quantitative PCR cycle at which 
SYBR Green-mediated fluorescence reached a threshold value (CT). 
Standard curves were accepted when R* and efficiency values were /0.90 
and 0.6, respectively. R* is a measure of the degree of linearity between the 
concentration of positive control cDNA template and the CT value. When a 
standard curve is derived for a gene, the number of quantitative PCR cycles 
at which analysed samples produce a CT can be used to infer copy number 
of the gene of interest, by way of the equation for a straight line of a graph, 





2.2.9.7 Quantitative real-time PCR 
11.50µl of cDNA samples were combined with 1.0µl relevant primers at 
25ng/µl of both forward and reverse primers, 4µl 2X SYBR® Green PCR 
Master Mix and brought to a votal volume of 20µl with distilled H?0. SYBR 
Green within quantitative PCR mastermix binds to double stranded DNA. 
The DNA-SYBR Green complex absorbs light at 488nm and emits it at 
522nm. As amplicons are synthesised throughout the quantitative PCR 
reactions, more SYBR Green becomes bound to DNA, and hence more 
fluorescence is observed. The threshold cycle is used to determine the copy 
number of the amplicon per sample. The Rotor-Gene™ 3000 Quantitative 
multiplexing system and accompanying software were used to run 
quantitative PCRs using cycle profiles under which the standard curves for 
each gene were obtained. Samples were run at least in duplicate (technical 
replicates), and all runs included ‘no template controls’ as described above. 
Housekeeping gene primers were also used in samples where no reverse 
transcriptase was added during the cDNA preparation process, as a final 
check for contamination by genomic DNA. 
The copy number of amplicons produced by each primer set in each sample 
was extrapolated by importing previously acquired standard curves for the 
relevant genes. Quantitative PCRs for housekeeping genes were performed 
in parallel as normalisers, and copy numbers of all genes of interest were 





2.2.9.8 Statistical analysis 
The mean value for each data set was used to describe the central location of 
the data. Standard deviations (SD) were used as a measure of the dispersion 
of data around the mean. Analysed data was assumed to be normally 
distributed (Gaussian distribution). Box-and-whisker (box) plots were used 
to identify outlying data points (>3 SD from the mean), which were 
eliminated from the statistical analysis. Unpaired two-tailed Student’s t-test 
was used to analyze data for statistical significance. Graphs and analysis 
were generated with GraphPad Prism (Version 5) Software. Differences in 
the means between two data sets were deemed statistically significant if the 
generated p value was less than 0.05.  
 










































Table 5 Details of primers used in quantitative PCR reactions in Chapter 2.  
Tm = melting temperature. * These cDNA samples were used to derive standard curves for 





2.2.10 Directed differentiation of hESCs by embryoid body 
formation 
Embryoid bodies are three-dimensional clusters of cells, formed from 
embryonic stem cells. Embryoid body cultures are used to initiate and 
encourage differentiation of hESCs into a wide variety of somatic cell types 
of all three germ layers. 
Undifferentiated hESC colonies were enzymatically passaged as described 
above, and transferred into 60mm diameter Ultra Low Adherence Petri 
dishes (Appleton Woods) containing 6ml of mTeSR1 medium. Embryoid 
bodies are sensitive to mechanical disruption and are prone to shattering 
during the early stages of their formation. To minimise the rate of embryoid 
body loss in this way, colonies were passaged into significantly bigger pieces 
than for propagation purposes. No media changes were performed during 
embryoid body differentiation. 
Differentiating embryoid bodies were harvested after 7 days of suspension 
culture and dissociated into single-cell suspension by passing through a 23-
guage needle. The resultant cell suspension was seeded into gel-coated 
tissue culture plates in basic early mesoderm induction medium composed of 
mTeSR™1 supplemented with 10ng/ml recombinant human VEGF (R&D 
Systems, Abingdon, UK). VEGF was reconstituted at 100µg/ml in sterile 
PBS containing 0.1% BSA and stored at -20°C. The medium was changed 






2.2.11 Teratoma assay 
KCL-002 hESC colonies were harvested using dispase, washed in PBS and 
resuspended in 100µl PBS volumes. Injections were performed using 1ml 
syringes and attached 27 gauge needle (both Terumo). 2x10Q 
undifferentiated hESCs were injected sub-cutaneously into NOD-SCID 
(Non-Obese Diabetic Severe Combined Immunodeficiency) mice. A total of 2 
mice received hESC transplantations.  
Mice were cared for in accordance with Home Office license guidelines and 
palpated regularly to monitor growth of teratomas. The susceptibility of 
their immune systems also dictated that the mice were housed in filter 
cages to prevent influx of foreign antigens. Animals were sacrificed using 
Schedule 2 methods at a time judged to be a humane end point. This point 
represented a time when discomfort of the animal had not become extreme, 
yet significant tumour growth had been achieved. All animal maintenance 
and sacrificing was carried out in compliance with Home Office guidelines. 
 
2.2.11.1 Teratoma harvesting and processing for 
immunohistochemistry 
After 9 weeks, tumours were harvested from sacrificed mice, washed in PBS 
to remove debris and submerged fully in 4% PFA at 4°C for 24 hours. 
Tumours were then washed in PBS and submerged in decalcifying solution 
composed of 4% (w/v) EDTA (VWR) in PBS for 4 days at room temperature. 
This allows calcium deposits in regions of bone or bone-like formation in 




PBS, tissue samples were placed in plastic cassettes (Sigma) and 
dehydrated by immersion in 75%, 90%, 95% and finally in 100% ethanol, 
using an automated tissue processor. Dehydration is necessary to permit the 
infiltration of paraffin wax into the tissue section. Once embedded in wax, 
samples were hardened by cooling to room temperature. A microtome was 
then employed to cut sections of 6µm thickness. 
Sections were then floated on the surface of water heated to 45°C to smooth 
out creases, before being lifted onto positively charged glass slides (VWR) 
and baked at 60°C to firmly attach the sections. Wax-embedded sections and 
paraffin blocks were stored at room temperature until further processing. 
 
2.2.12 Immunohistochemical analysis of teratoma sections 
2.2.12.1 De-waxing prior to immunohistochemical analysis 
Wax contained within the sections would repel the aqueous solutions used 
throughout the immunohistochemistry protocol; therefore, de-waxing steps 
are required prior to immunostaining. To de-wax parafin-embedded 
sections, slides were taken through two incubations in Xylene (5min at room 
temperature) and then through graded ethanol immersions, beginning with 
100%, followed by 90%, 70% and finally ending with 50% ethanol (3min at 






2.2.12.2 Antigen retrieval 
Preserving tissues involves long exposures to formalin solution, to ensure 
thorough infiltration of the fixative solution. Although effective in 
preserving tissue morphology, prolonged formalin-based fixation leads to 
formation of methylene bridges which cross-link proteins and therefore 
mask the antigens present within the tissue. Antigen retrieval methods 
serve to break the methylene bridges and expose the antigenic sites in order 
to allow the primary antibodies to bind. Antigen retrieval was achieved by 
submerging slides in boiling Sodium Citrate Buffer solution (10mM Sodium 
Citrate, 0.05% Tween 20, pH 6.0; Sigma) and microwaving at 850W. When 
the solution came to the boil, the power was reduced to 650W and slides 
were heated for a further 20min taking care that the solution did not 
overboil and evaporate. The slides were then cooled on the bench top for a 
further 20min. This allows the slides to cool enough so they may be handled, 
and allows the antigenic site to re-form after being exposed to high 
temperature. The slides were then rinsed in gently running tap water and 
incubated in water for 10min. All sections were demarcated using a wax pen 
(VWR). Introducing wax boundaries around each section serves as a barrier 
to the spread of liquids within the wax circle.  
 
2.2.12.3 Permeabilization 
All incubations were carried out in a humidified chamber to avoid drying of 
the tissue. Drying at any stage will lead to non-specific binding and 




and wet tissue paper in the bottom was used for this purpose. 
Permeabilisation to allow access of the antibody to the relevant intracellular 
antigen was achieved with addition of 0.1% (v/v) Triton X-100 (Sigma) to 
Tris-buffered saline (TBS). TBS working solution (1X TBS) was made by 
diluting 10x TBS stock solution (200mM Tris base (VWR), 1.5M sodium 
chloride (Sigma), deionized water; pH 7.4) with deionized water.  
 
2.2.12.4 Horse-radish peroxidase-mediated immunostaining 
For detection of antigens of interest, horse-radish peroxidase (HRP)-
mediated immunostaining was used. Firstly, endogenous peroxidase block 
(3% (v/v) hydrogen peroxidase (Sigma) in deionised water) was applied for 
30min at room temperature to quench endogenous peroxidase activity, 
which may otherwise result in high levels of non-specific background 
staining. Hydrogen peroxide acts as a substrate for any endogenous 
peroxidase present, leading to its irreversible inactivation. The slides were 
then washed in 0.1% (v/v) Triton X-100 in TBS for 5min at room 
temperature. To prevent both primary and secondary antibodies forming 
interactions with proteins in a non-specific manner, samples were incubated 
with a blocking solution (10% NGS, 1% BSA in TBS) for 30min at room 
temperature. The slides were then incubated with pre-diluted primary 
antibodies for 90min at room temperature. Primary antibodies used to test 
for the presence of three germ layers are shown in Table 6. The slides were 
then washed twice in 1x TBS. In order to amplify immuno-expression 
signals, avidin-biotin enhancement of immunostaining was carried out. 




high binding affinity of avidin for biotin was exploited in this technique. 
Therefore, secondary antibody incubation was carried out with an 
appropriately targeted biotinylated antibody for 30min at room temperature 
(1:250; Dako, Ely, UK). After two washes in 1x TBS, slides were incubated 
with Streptavidin / Biotinylated HRP complex (Vector Labs, Peterborough, 
UK) for 30min at room temperature and washed in 1x TBS for 5min. By 
additionally labelling the HRP conjugated to avidin with biotin, the 
formation of large complexes of HRP-avidin is encouraged, as a function of 
the tetravalent nature of avidin. Samples were then exposed to a solution 
containing diaminobenzidine (DAB), composed according to manufacturer’s 
instructions (Vector Labs kit). DAB is a substrate for HRP, and reaction of 
DAB with HRP associated with the avidin/biotin complex on immobilized 
secondary antibodies generated an insoluble brown coloured precipitate, or 
black precipitate if nickel chloride was added to the DAB solution. After 
10min incubation with DAB solution, the slides were washed under running 
tap water for 5min. Control procedures with the omission of either the 
primary or secondary antibody were performed to check the specificity of the 
antigen: antibody interactions. 
Antibody Supplier Dilution Localisation of target proteins  
GFAP Abcam 1:500 Ectoderm germ layer 
Desmin Sigma 1:1500 Mesoderm germ layer 
Alpha-foetoprotein Sigma 1:400 Endoderm germ layer 
Keratin 14 Covance 1:1000 Basal epidermal layer 
Keratin 5 Covance 1:1000 Basal epidermal layer 
Keratin 18 Chemicon 1:50 Single-layer embryonic epidermis 
Collagen type II Sigma 1:80 Cartilage 
Involucrin (SY5) Sigma 1:100 Terminally differentiated epidermal cells 







To visualise cell nuclei, counterstaining was performed using haematoxylin 
(Mayer’s haemalum; Sigma) for approx 90s, after which the slides were 
washed again under a running tap for 5min. To ensure the appropriate level 
of nuclear staining the slides were dipped for 5s in 0.5% HCL in 70% 
methylated spirit and quickly returned to water, washed for 5min and then 
examined microscopically. If nuclear staining was too weak, the slides were 
returned to Mayer’s haemalum solution for a further 3min. If nuclear 
staining was too strong, the slides were dipped again in acid solution. Tissue 
sections were mounted by covering with 22x50mm coverslips (VWR), using 
Di-N-Butyle Phthalate in Xylene mountant (DPX; VWR). DPX is a viscous 
anhydrous solution containing Xylene, which protects stained samples. 
However, because this solution is not compatible with aqueous solutions, 
samples were first dehydrated by immersions in 100% ethanol followed by 
Xylene. The slides were allowed to dry for 30min and the sections were 
visualized with Zeiss Axiophot fluorescence microscope (Zeiss).  Images were 
taken with a CCD camera (DS-U2, Nikon), and processed with Photoshop 
CS5 (Adobe). 
 
2.2.12.6 Haematoxylin & Eosin Y staining of teratoma sections 
The haematoxylin component stains basophilic structures, such as those 
with high nucleic acid content, with a blue-purple colour by binding to lysine 




cytoplasm of a cell, in an electrostatic nature. After dewaxing (section 
2.2.11.1), slides were immersed in a solution of Mayer’s haemalum (Sigma) 
for 3min at room temperature and washed with deionised water. To ensure 
the appropriate level of nuclear staining the slides were dipped for 5s in 
0.5% HCL in 70% methylated spirit and quickly returned to deionised 
water, washed for 5min, and then examined microscopically. If nuclear 
staining was too weak, the slides were returned to Mayer’s haemalum 
solution for a further 3min. If nuclear staining was too strong, the slides 
were dipped again in acid solution. Eosin staining was subsequently 
performed by immersion in 0.5% eosin Y (VWR) staining solution for 3min 
at room temperature, sections washed in deionised water. The sections were 
mounted by covering with 22x50mm coverslips (VWR), using DPX in Xylene 
mountant as described in section 2.2.11.4. 
 
2.2.12. 7 Periodic acid-Schiff  (PAS) and Alcian Blue Histological 
stains 
PAS histological stain can be used to demonstrate the presence of 
carbohydrates in tissue sections. The periodic acid oxidises the tissue 
carbohydrates containing 1-2 glycols, such as polysaccharides, 
mucopolysaccharides, glycoproteins and glycolipids. The oxidising reaction  
produces aldehyde groups, which can then condense with Schiff's reagent 
forming a bright red colouration and demonstrating the tissue component to 




Alcian Blue, when used at pH 0.2, can be used to detect the presence of 
highly sulphated proteoglycans, such as those found in the extra cellular 
matrix of cartilage, as well as some types of mucopolysaccharides and 
sialylated glycocalyx of cells. The tissue parts that specifically stain by this 
dye become blue to bluish-green after staining.  
A combined method utilising the properties of both the PAS and alcian blue 
methods was used to demonstrate the full complement of tissue 
proteoglycans in teratoma sections. The rationale of the technique is that by 
first staining all the acidic mucins with Alcian blue, those remaining acidic 
mucins which are also PAS positive will be chemically blocked and will not 
react further during the technique.  Those neutral mucins which are solely 
PAS positive will subsequently be demonstrated in a contrasting manner.  
Where mixtures occur, the resultant colour will depend upon the dominant 
moiety. 
Teratoma sections were deparaffinized as described in section 2.12.1. The 
slides were then rinsed with distilled water and immersed in alcian blue 
solution (pH 0.2; 1.0% (w/v) in 0.1N hydrochloric acid (VWR)) for 15min. The 
slides were then washed in running tap water 2min and treated with 1% 
aqueous solution of periodic acid (PAS kit; Sigma) for 5min at room 
temperature. The sections were then washed in distilled water to remove 
any traces of the periodic acid, and the Schiff's reagent (PAS kit; Sigma) was 
applied for 15min at room temperature. The slides were then washed 
thoroughly under  running tap water, and the nuclei were counterstained, 






2.3.1 Morphology of the KCL-002 hESC line cultured on 
inactivated MEF feeders 
Undifferentiated hESCs have a very characteristic morphology that can be 
easily evaluated under phase-contrast microscope: colonies appear to be 
tightly packed with a defined border; individual cells have phase bright 
edges, a high nuclear/cytoplasmic ratio, and prominent nucleoli. On MEF 
feeders the KCL-002 hESC line has a typical morphology of undifferentiated 
hESCs and grows as uniform domed colonies (Figure 8). The cells are tightly 
packed within the colony, and maintain a defined border at the periphery of 
the colony. Colonies can grow on top or among the feeders, pushing away 
then outward as they proliferate. Differentiation is often observed as visible 
structure or organization, or it exhibits a darker shade, within an hESC 
colony. Differentiation often begins in the central part of an hESC colony. 
The morphology described should be preserved following adaptation to 
feeder-free culture. 
 
2.3.2 Morphology of the KCL-002 hESC line adapted to growth in 
feeder-free conditions 
During the adaptation period morphological characteristcs of KCL-002 
hESC colonies were closely monitored. In the first 3 days after seeding 
undifferentiated KCL-002 hESCs grown on Matrigel in the presence of 
mTeSR1 appeared transparent and not very densely packed with cells 




rapidly after this time point and typical hESC colony morphology was 
observed. The colonies continue to grow as compact, multicellular colonies, 
as shown in Figure 9.  
The borders of colonies grown under feeder-free conditions were distinct and 
more pronounced compared to feeder-dependent cultures. The loss of border 
integrity indicated a differentiation process. Therefore, the KCL-002 hESC 
line has maintained the typical morphology expected of pluripotent stem 
cells. The next step was to confirm the expression of marker proteins. 
 
Figure 8 Morphological appearance of KCL-002 hESC colonies grown on 
inactivated MEF-feeder layer.  
Uniform colonies growing on top (A) and amongst (B) MEF feeders. A: The colonies are 
separated from feeders by a defined border (yellow arrow); B: Visible differentiation can be 
seen in the central part of a colony (red arrow). The undifferentiated cells are tightly 
packed with a high nuclear/cytoplasm ratio (insert). Scale bar=100+m. 
 
Figure 9 ! Morphology of KCL-002 hESC colonies under feeder-free conditions 
grown on Matrigel with mTeSR™1.  
A: hESC colony 2 days after passaging; B: Large hESC colony ready to be passaged. 





2.3.3 Expression of pluripotency-associated markers 
In order to confirm that the KCl-002 hESC line still maintained 
pluripotency, immunocytochemistry was performed on undifferentiated 
KCL-002 hESCs for 2 nuclear transcription factors Sox2 and Oct3/4 and 2 
extracellular molecules Tra 1-60 and SSEA-4. Bright immunofluorescent 
signal and correct localization of investigated antigens suggested that KCL-
002 hESCs were strongly positive for all 4 markers (Figure 10). When 
quantification of immunofluorescency data was carried out in three 
independent fields (n=3) selected at random, 92.667±2.728 and 91.000±2.646 
of hESCs were found to be positive for Oct3/4 and Sox2, respectively (Figure 
11). This suggests that pluripotency-associated markers are highly 
expressed in the KCL-002 adapted to feeder-free conditions. 
The immunofluorescent analysis was consequently repeated every 10 
passages for quality control, which confirmed that the KCL-002 hESC line 
remained highly positive for the expression of marker molecules throughout 
the course of this study. In order to further confirm its pluripotent status, 
quantitative PCR for two transcription factors was carried out. 
 
2.3.4 Pluripotency gene expression of the KCL-002 hESCs in 
feeder-free conditions 
Following the adaptation to feeder-free culture, the expression of two 
pluripotency genes, Nanog and Sox-2, was examined in the KCL-002 hESC 




gene (Figure 12). The analysis was carried out after 5 passages under 
feeder-free conditions. Data is presented as ratio of the copy number of the 
relevant gene of interest to the copy numbers of the normalising gene (‘Gene 
expression ratio’). Human dermal fibroblasts (HDFs) served as a negative 
control. Statistical analysis revealed there was a significant difference in the 
expression of Nanog and Sox-2 in KCL-002 hESCs (KCL-002 Nanog 8.008 ± 
3.528, Sox-2 2.350 ± 0.794) as compared to HDF controls (Nanog not 
detectable, Sox2 0.001 ± 0.001 ); p values were 0.0075 for Nanog and 0.0097 
for Sox-2, (Mann-Whitney U test). n=5 for each cell type and gene 
expression. 
Having confirmed the pluripotency status at mRNA level, it was important 
that the KCL-002 hESC line grown under feeder free conditions was indeed 
able to undergo spontaneous multilineage differentiation. 
 
2.3.5 Directed differentiation of KCL-002 hESCs through 
embryoid body formation assays 
Directed differentiation capacity of KCL-002 hESCs under feeder-free 
conditions was confirmed through embryoid bodies formation assay. When 
cultured in suspension, KCL-002 hESCs readily formed embryoid bodies 
which continued to grow within the time course of the experiment. Phase 
contrast photomicrographs of representative embryoid bodies are shown 
(Figure 13). When the embryoid bodies were dissociated into single-cell 
suspension in cultured in medium supplemented with VEGF for 1 week, 




In addition, some cells positive for brachyury transcription factor were also 
detected (Figure 13C), further confirming the presence of early 
mesenchymal cell lineages. This indicates that the KCL-002 hESC line 
could be directed towards differentiation into a desired cell lineage (i.e. 
mesoderm) in vitro. Spontaneous differentiation was then assessed by 




Figure 10 Expression of pluripotency-associated markers in the KCL-002 hESC line adapted to feeder-free culture.  
Panel A shows the staining for the molecule of interest: four different markers were examined, from top to bottom: Oct3/4, Sox2, SSEA-4 and Tra 1-60. Panel 
B- DAPI nuclear staining. Panel C- merged images to show the correct localization of each molecule: nuclear localization of Oct3/4 and Sox2 transcription 







Figure 11 Quantification of pluripotency markers expression in the KCL-002 
hESCs adapted to growth under feeder-free conditions.  
The figure shows percentage of Oct3/4- (green) and Sox2- (red) positive cells as calculated 




Figure 12 Expression of the pluripotency-associated genes Nanog and Sox-2 in 
the KCL-002 hESC line after adaptation to feeder free conditions.  
Expression of the same genes was not detected in human dermal fibroblast (HDF) negative 
controls. Values are mean ± SD and represent the ratio of gene of interest: GAPDH 
transcript copy numbers. Statistical analysis demonstrated that there were significant 
differences in the expression of both Nanog and Sox-2 compared to HDF controls. n=5 **p < 







Figure 13 Evaluation of directed differentiation of the KCL-002 hESC line in 
vitro through embryoid bodies formation.  
A: KCL-002 hESCs readily form embryoid bodies in suspension culture and at day 7 large 
aggregates are seen. B: Embryoid bodies were dissociated into single-cell suspension and 
cultured in basic mesenchymal induction medium for a further 7 days. The resulting cell 
population is positive for early mesenchymal marker vimentin (green). C: In addition, some 
cells were also positive for brachyury. D: No primary antibody negative control Scale 
bars=50!m. 
 
2.3.6 Teratoma assay 
The capacity of KCL-002 hESCs under feeder-free conditions to undergo 
spontaneous differentiation was confirmed through the teratoma assay. 
After 9 weeks, two tumours could be palpated in two NOD/SCID mice 
(Figure 14A). Histological examination of the tumours revealed presence of 
large multi-lobed cysts (Figure 14B), which had expanded from the original 
site of subcutaneous injection. Upon histological processing and examination 




(Figure 15). Amongst these tissues, neuroepithelium, a derivative of the 
ectodermal germ layer was identified by the presence of neuroepithelial 
rosettes (Figure 15A). The formation of stratified epithelium was also 
observed (Figure 15B). Simple columnar and ciliated epithelium were also 
identified, both derivatives of the endodermal germ layer (Figure 15C). 
Smooth muscle (Figure 15D) and cartilage (Figure 16B-D) from the 
mesodermal germ layer were also identified. 
PAS/Alcian blue staining demonstrated the full complement of tissue 
proteoglycans within teratoma (Figure 16). revealed the presence of 
"glandular epithelioid" structures containing neutral mucin (Figure 16A). 
These structures lie within a dense fibrous stroma that contains levels of 
acidic mucins that are lower than that found in the looser connective tissue 
surrounding the area, as indicated by a more intense blue staining. 
Cartilage was also identified by PAS/Alcian blue staining which showing 
abundance of glycogen in chondrocytes (red) and acidic mucins (blue) in the 
ground substance. Interestingly, a structure adjacent to cartilage highly 
resembled a transverse-section of a bronchus. Immunohistochemistry 
directed against type II collagen, the main component of cartilage, has also 
confirmed the presence of cartilage in the teratoma (Figure 16D). 
In subsequent immunohistological analysis, markers of all three germ 
layers were detected (Figure 17). Glial fibrillary acidic protein (GFAP) is a 
member of the class III intermediate filament protein family. It is heavily, 
and specifically, expressed in astrocytes and certain other astroglia in the 
central nervous system, in satellite cells in peripheral ganglia, and in non 




GFAP positivity confirms the presence of ectodermal lineages in harvested 
teratomas. Desmin is a type III intermediate filament found near the Z line 
in sarcomeres of skeletal muscle tissue, smooth muscle tissue, and cardiac 
muscle tissue (Capetanaki et al., 1984). Therefore, positive desmin staining 
indicates the presence of mesodermal tissue. Alpha-foetoprotein ("-
foetoprotein) is a major plasma protein produced by the yolk sac and the 
liver during foetal development (Tomasi, 1977), and, therefore, serves as a 
reliable endodermal marker. 
In order to assess the ability of the KCL-002 hESC line to undergo 
epidermal differentiation, a further immunohistochemical analysis was 
carried out against epidermal-associated proteins (Figure 18). The analysis 
revealed abundance of simple single-epithelium keratin 18 (Figure 18A and 
E), as well as basal keratins 5 and 14 (Figure 18B-D). Furthermore, 
minimal involucrin expression was also detected (Figure 18F), indicating 
terminal differentiation of hESC-derived keratinocytes in the resultant 
teratoma.  
Collectively these results confirm that the KCL-002 hESCs line grown 
under feeder-free conditions is capable of differentiating into all three germ 





Figure 14 The appearance and histology of teratomas.  
A: The appearance of subcutaneous tumour in NOD/SCID mouse; B: Histological analysis 
at low maginification reveals presence of large multi-lobed cysts. Simple columnar 
epithelium (green arrow), adipose tissue (yellow arrow) and presumptative neuroepithelial 
rosettes (red arrow) can be easily identified. Scale bar= 100µm. 
$
Figure 15 H&E staining of teratoma sections.  
A: Presumptive neuroepithelial rosettes; B: Stratified epithelium; C: Simple 






Figure 16 Histological staining of teratomas with PAS and Alcian Blue. 
Acidic mucins stained blue, neutral mucins- magenta, mixtures of above- purple, nuclei-
deep blue. 
A: Low magnification image showing neutral mucin in glandular epitheliod structures 
(magenta) within dense fibrous tissue containing acidic mucins (light blue) and loose 
connective tissue (blue); B: Low magnification image showing cartilage formation within 
teratoma C: Higher magnification image showing the structure resembling a brochus. 
Yellow arrowhead indicates neutral mucin in epithelium, red- cartilage, black-  
glycogen/neutral mucins in ground substance of surrounding loose connective tissues; D: 




Figure 17 Spontaneous differentiation of the KCL-002 hESC line in vivo  
through teratoma assay.  
Ectoderm formation was confirmed by Glial fibrillary acidic protein (GFAP) positivity. 
Mesoderm formation was validated by Desmin positivity, and "-fetoprotein confirms the 





Figure 18 Immunohistochemical analysis of teratomas for epidermal-
associated proteins. 
A: Low magnification image showing keratin 18 positivity; B: Low magnification image 
showing keratin 5 positivity; C and D: Higher magnification images for keratin 5 and 14 
staining, respectively; E: Higher magnification image showing keratin 18 positivity; F: 
Minimal involucrin positivity was also detected. Scal bars=100!m. 
!
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2.3.7 Technical discussion 
To conclusively claim the true nature of immunofluorescent staining, it is 
crucial to demonstrate that the antibodies used are specific, selective, and 




there are over 180 antibody companies that produce over 350,000 
commercially available antibodies against a huge collection of target 
proteins for the research and clinical markets 
(www.antibodyresource.com/onlinecomp.html). However, despite the 
manufacturer claims regarding the specificity of an antibody, it is not 
always safe to assume that a commercial antibody would only bind the 
desired target protein and not a range of other proteins (Couchman, 2009). 
Therefore, the responsibility of validating the antibody should lie within the 
researcher using it. Several approaches and algorithms for antibody 
validation have been published (Bordeaux et al., 2010, Rhodes and 
Trimmer, 2008, Saper and Sawchenko, 2003) 
The key to proving antibody specificity is often the correct use of negative 
controls. As such, no primary antibody negative control during 
immunofluorescent analysis would provide valuable information about the 
antibody’s specificity. However, a better negative control is a cell line or 
tissue that is known not to express the protein of interest. For example, 
fibroblast lines would serve as an effective negative control for epidermal 
targets, and would, therefore, be useful for validation of anti-keratin 14 
antibody used in this study. In the cases when true negative lines are not 
available, lysates of cell lines where the target protein has been knocked 
down using RNAi (RNA interference) technology would provide the best 
negative controls. These are known as small interfering RNA (siRNA) or 
small harpin RNA (shRNA) knockdown controls. Similarly for a positive 
control, lysates from cell lines that have been transfected to overexpress 




Western blotting is widely used to determine an antibody’s specificity and is 
an appropriate first validation step. For this purpose, a variety of cell line 
lysates or tissue homogenates can be used so that both positive and negative 
cell lines are analyzed. The first indication that the antibody is specific for 
the selected target would be observing a single band at the known molecular 
weight for the target. For example, the expected molecular weight of the 
keratin 14 antibody used in this study is 55 kDa. It is worth noting, 
however, that the presence of multiple bands or bands at a wrong molecular 
weight might simply represent the same target at different post-
translational modifications forms. While western blotting is a useful tool for 
antibody validation, an antibody demonstrating no binding on western blot 
may still be specific for its intended target when in its native conformation 
and an immunoprecipitation experiment can be the next step in determining 
the specificity of the antibody if the goal is for use with immunocytochemical 
analysis. An alternative approach for validating an antibody for 
immunofluorescent analysis is to titer the antibody on a tissue microarray 
(TMA) comprised of formalin-fixed, paraffin-embedded cell line pellets 
corresponding to the same cell lines used to first validate by western 
blotting. The usefulness of TMA as an antibody validation tool was 
demonstrated for HER2 testing, diagnostic of breast cancer (Kay et al., 
2004). On TMA a good antibody should have the following characteristics: 1) 
it will stain only the cell pellets expressing the target, 2) the level of 
staining will decrease with increasing dilutions of the antibody, and 3) it 
will demonstrate an expression pattern that is consistent with biological 





In order to produce safe clinical-grade hESC lines for therapeutic purposes, 
propagation and maintenance of hESCs must be performed under good 
manufacturing practice (GMP) quality standards. In addition, all the risks 
of infections transmitted by animal pathogens as well as immunological 
reactions should be eliminated. Moreover, in order to produce sufficient 
numbers of differentiated cells for clinical application, culture conditions of 
hESCs should allow up-scaling and cost-effectiveness. 
This study begun using the KCL-002 hESC line, derived and maintained 
under feeder-dependent conditions in the Stem Cell Biology laboratory at 
King’s College London.  
Therefore, prior to any differentiation work, two prerequisite goals had to be 
met. 
The adaption the KCL-002 hESC line to feeder-free conditions was essential 
in order to overcome the following hurdles: a) the presence of immunogenic 
material; b) the risk of transmitting animal virus or prions; and c) difficulty 
with quality control of these undefined components. In addition, adaptation 
to enzymatical passaging in feeder-free cultures allows to significantly scale-
up hESC production and enables more effective testing and application of 
differentiation protocols. 
Secondly, once adapted to growth under feeder-free conditions, the 
pluripotent nature of the KCL-002 cell line had to be validated.  
For feeder-free cultures several possibilities exist. Those include laminin 
(Genbacev et al., 2005, Xu et al., 2001, Beattie et al., 2005), fibronectin 




(Stojkovic et al., 2005). These matrices are considered to be more defined, 
however perhaps due to high batch-to-batch variability long-term culture of 
hESCs on these substrates has not been reported. Arguably the most 
successful commercially available matrix for long term hESCs culture is 
Matrigel (Sato et al., 2004, Xu et al., 2005, Xu et al., 2001). BD Matrigel™ 
BM Matrix is a solubilized basement membrane preparation extracted from 
the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, a tumor rich in 
extracellular matrix proteins to include laminin (a major component), type 
IV collagen, heparan sulphate proteoglycans, and entactin/nidogen 
(Kleinman et al., 1982, Kleinman et al., 1986). Each batch of BD Matrigel 
has been qualified and optimized for use with mTeSR1 medium to ensure 
consistency and reproducibility. A comprehensive multi-centre study carried 
out by the International Stem Cell Initiative Consortium has assessed 
different defined culture systems for their ability to support hESC growth 
and concluded that a combination of mTeSR1 with Matrigel as coating 
substrate was the most effective in maintaining growth and characteristics 
of undifferentiated hESCs (Akopian et al., 2010). Therefore, this defined 
culture system was chosen for feeder-free adaptation of the KCL-002 hESC 
line. 
The KCL-002 hESC line adapted well to growth in feeder-free conditions on 
Matrigel as a substrate in the presence of mTeSR1 medium. The cell line 
has also been adapted to enzymatic passaging using dispase, which has 
allowed a significant scale up in production. The results of this chapter 
confirm that KCL-002 hESC line grown under these conditions maintained 




pluripotency genes Nanog and Sox2 was verified by quantitative PCR and 
the presence of pluripotency-associated markers Oct-3/4, Sox2, Tra 1-60 and 
SSEA-4 was confirmed by immunocytochemistry. The KCL-002 hESC line 
was capable of spontaneous differentiation in vitro through embryoid bodies 
formation and primitive mesenchyme was visualized by staining with the 
mesodermal marker protein vimentin. Furthermore, when injected into 
NOD-SCID mice, KCL-002 hESCs produced teratomas confirming 
differentiation potential in vivo. 
The results of this chapter demonstrate that the KCL-002 hESC line has 
been successfully adapted to growth in feeder-free conditions and fully 
characterized thus allowing to proceed with differentiation studies. 
However, it is worth mentioning that while Matrigel is highly effective in 
supporting hESCs proliferation and maintaining their pluripotent status, 
this basement membrane preparation is derived from EHS mouse 
carcinoma and therefore the culture system described here cannot be 
considered xeno-free (Kleinman and Martin, 2005, Kleinman et al., 1986). 
Hence, future work should be directed at optimizing the culture to avoid the 











The proteins of actively proliferating hESCs in combination with epigenetic-
modifying small molecules might have the capacity to induce 
reprogramming of adult human dermal fibroblasts (HDFs). 
 
AIMS 
1. Examine whether the transfer of proteins extracted from the KCL-002 
hESC line into HDFs could achieve somatic cell reprogramming in 
combination with epigenetic-modifying compounds. 







3.1.1 Integration-free methods for generation of iPSCs 
The discovery that various somatic cell types could be successfully 
reprogrammed into pluripotent stem cells offers exciting possibilities of 
patient-specific iPSC lines, as well as avoiding ethical issues associated with 
hESC application. The original iPSC induction system used retroviral 
vectors (Takahashi and Yamanaka, 2006), which integrate transgenes into 
the host genome. Integrating viral-based methods are highly efficient in 
producing iPSCs and are acceptable when the remaining reprogramming 
factors do not significantly interrupt designed assays. However, the 
transgene integration and alteration of the endogenous genomic 
organization raises a safety issue when considering medical applications. 
The insertion of tumourigenic genes, such as c-Myc, and activation of proto-
oncogenes by long terminal repeats increase the risk of tumour formation 
(Okita et al., 2007, Hacein-Bey-Abina et al., 2003).  
Therefore, different non-integrating approaches have been devised for 
somatic cell reprogramming and are summarized in Table 7. These can be 
divided into four main categories based on vector type for delivery of the 
reprogramming factors: 1) DNA-based; 2) excisable; 3) RNA-based; and 4) 
protein-based.  
Reprogramming was achieved using non-integrating DNA-based vectors, 




2009, Si-Tayeb et al., 2010, Stadtfeld et al., 2008b), showing that iPSCs can 
be induced by the transient expression of reprogramming factors. However, 
iPSC generation by non-integrating adenoviruses and plasmids was very 
inefficient and estimated to be less than 0.0002%, over 1000-fold lower than 
that of viral transduction (Takahashi and Yamanaka, 2006). Furthermore, 
in a large number of iPSC clones, transgenes had been integrated into the 
host genome (Okita et al., 2008). Generation of iPSCs by transfection with 
non-integrating episomal vectors has also been reported (Yu et al., 2009).  
Excisable vectors such as piggyBac transposon (Woltjen et al., 2009, Kaji et 
al., 2009), Cre-recombinase excisable viruses (Soldner et al., 2009) and loxP-
flanked lentiviral vectors (Somers et al., 2010) have been used to 
reprogramme somatic cells. While the transgenes can be excised by 
inducible gene expression once reprogramming is established (Soldner et al., 
2009, Woltjen et al., 2009), residual sequences and chromosomal disruptions 
may still result in harmful alterations that could pose clinical risks.  
Several RNA-based methods have also been tested. One of the recent 
improvements to non-integrating methods is the application of Sendai virus 
(Fusaki et al., 2009). Sendai virus is a minus strand RNA virus, which 
replicates its genome in the cytoplasm of infected cells, and thus can stably 
express reprogramming factors and achieve high reprogramming efficiency. 
However, the established iPSCs were shown to carry the virus genome even 
after long-term culture. Recently, direct delivery of synthetic mRNA has 
been shown to generate iPSCs with high efficiency (Warren et al., 2010). 




sensitive to reagents and labour-intensive. Fast reprogramming to 
pluripotency using microRNAs has also been reported (Miyoshi et al., 2011).  
One of the most exciting developments in the field is protein-based 
induction of pluripotency (Kim et al., 2009, Zhou et al., 2009). This 
methodology has distinct advantages over other non-integrating approaches: 
it avoids the risks of occasional genomic integration associated with DNA-
based vectors and is much less labour intensive than current RNA-based 
methods. Therefore, if proven efficient, protein-based reprogramming could 






Efficiency Advantages Disadvantages References 

























(Okita et al., 
2008, Si-









Requires 3 individual 
plasmids carrying 7 
factors 
Includes SV40 oncogene 



























!0.1 Reasonably efficient 
 
Labour-intensive 
screening of excised 
lines 























































No risk of 
integration 
Less efficient than other 










Sendai virus Human 
fibroblasts 
!1 High efficiency 





Difficult to remove 











!0.001 No DNA-related 
complications 
Low efficiency (Kim et al., 
2009, Zhou 










!0.001 No DNA-related 
complications 
Low efficiency (Cho et al., 
2010) 




3.1.2 Protein-based reprogramming methods 
Protein-based reprogramming methods can be subdivided into: 1) tagged 
recombinant proteins and 2) whole protein extracts from ESCs. 
 
3.1.2.1 Recombinant proteins for reprogramming 
A major hurdle for intracellular delivery of macromolecules such as proteins 
is their limited ability to cross the cellular membrane (Belting et al., 2005). 
The human immunodeficiency virus transactivator of transcription (HIV-
TAT) protein can overcome this hurdle with a short basic segment residing 
at amino acid 48-60 that allows this protein to penetrate the cell membrane 
and activate HIV-specific genes (Frankel and Pabo, 1988, Frankel et al., 
1988). It has been previously demonstrated that various proteins can be 
delivered into cells by conjugating them with a short peptide that mediates 
protein transduction, such as HIV-TAT and poly-arginine (Inoue et al., 
2006, Michiue et al., 2005, Wadia and Dowdy, 2002). These naturally 
occurring peptides that are capable of overcoming the cell membrane barrier 
contain a high proportion of basic amino acids (e.g., arginine or lysine) and 
are known as cell penetrating proteins (CPP) (El-Sayed et al., 2009, Ziegler 
et al., 2005). This strategy has been exploited to create CPP-reprogramming 
proteins and generate iPSCs from murine embryonic fibroblasts (Zhou et al., 
2009). The method involved a prolonged four-cycle treatment of murine 
fibroblasts with a high concentration (8mg/ml) of reprogramming factors 




observed after 30-35 days of culture. Subsequently, iPSCs from human 
fibroblasts were generated by four reprogramming proteins (Oct-3/4, Sox-2, 
Klf4, and c-Myc) fused with a CPP (Kim et al., 2009). In contrast to the 
protocol described by Zhou et al. (2009) the reprogramming proteins used 
were expressed in mammalian cells as opposed to refolded proteins after 
expression in E. coli. This difference may explain the lower efficiency of the 
protocol described by Zhou et. al. (2009), as bacterial expression systems 
often result in proteins that do not fold properly and are, therefore, 
biologically inactive. Furthermore, lack of mammalian enzymes responsible 
for post-translational modifications, such as glycosylation, may also result 
in inactive proteins. It is worth noting that the authors tested several 
treatment conditions until reprogramming was observed (Kim et al., 2009). 
In an initial series of experiments, 5#107 human neonatal fibroblasts were 
treated with combined total extracts of four HEK293 cell lines, each stably 
expressing one of the four human reprogramming factors (Oct4, Sox2, Klf4, 
and c-Myc) fused with a CPP for 16 hours, however no reprogramming was 
observed. Subsequently, repeated protein treatment was tested and several 
iPSC-like colonies were detected, but none of these colonies showed alkaline 
phophotase activity, suggesting incomplete reprogramming. Therefore, the 
authors repeated this procedure for a total of 6 cycles, and the number of 
iPSC-like colonies significantly increased and, as a result, two iPSC lines 
were established and characterized (Kim et al., 2009). Recently, the same 
group has reported that protein-derived iPSCs could produce fully 
functional dopamine neurons that could treat a rat model of Parkinson 




3.1.2.2 Whole ES protein extracts for reprogramming 
Cellular protein extracts rather than recombinant proteins have been shown 
to direct pluripotent stem cells differentiation into specific lineages 
(Hakelien et al., 2002, Qin et al., 2005), or dedifferentiation into the 
pluripotent state (Taranger et al., 2005). However, repeated transfer of 
extracts from embryonic carcinoma or ESC did not produce fully 
reprogrammed iPSCs in terms of the transcriptional state, in vivo 3 germ 
layer differentiation capacity, and developmental potential (Taranger et al., 
2005, Rajasingh et al., 2008). Subsequently, a single transfer of ESC protein 
extracts, rather than repeated transfer or prolonged exposure, was shown to 
effectively mediate reprogramming of murine adult fibroblasts that were 
biologically and functionally ESCs in vitro and possessed in vivo 
differentiation and developmental potentials (Cho et al., 2010). The authors 
estimated the total amount of Oct-3/4 protein available for reprogramming 
in their method was 9.25ng (Cho et al., 2010), which is a substantially lower 
concentration than that used in reprogramming mediated by CPPs (Zhou et 
al., 2009). This implies that other effector molecules, which could be the 
downstream targets of the defined transcriptional factors, may be 
responsible for ES extract protein-mediated reprogramming. Extensive 
analysis implied that cytoplasmic proteins were equally important for 
induction of reprogramming as nuclear proteins (Cho et al., 2010). It has 
also been suggested that a certain group of ESC–derived proteins between 





3.1.3 Epigenetic modifiers to enhance iPSC generation 
A global survey of DNA methylation in iPSCs revealed that pluripotent 
stem cells have much higher DNA methylation than somatic cell types (Doi 
et al., 2009, Deng et al., 2009). The upregulation of DNA methyltransferase 
(DNMT) 3b and 3l occurs during the reprogramming process, and might be 
responsible for de novo methylation during the production of iPSCs. 
Therefore, it is not surprising that epigenetic modifying drugs, such as such 
as 50-azacytidine and RG108, or DNMT inhibitors, can improve iPSC 
generation (Shi et al., 2008). Other epigenetic modifications, such as histone 
methylation and acetylation, are also involved in iPSC reprogramming. 
BIX01294 is a selective inhibitor of G9a histone methyl transferase (G9a 
HMTase) (Kubicek et al., 2007). G9a HMTase regulates gene expression of 
Oct-3/4, and BIX01294 was shown to enhance the reprogramming efficiency 
of neural progenitor cells (Shi et al., 2008). Addition of VPA, a HDAC 
inhibitor, improves reprogramming efficiency in both mouse and human 
fibroblasts (Huangfu et al., 2008b, Huangfu et al., 2008a). Other HDAC 
inhibitors, suberoylanilide hydroxamic acid, trichostatin A and sodium 
butyrate, can also greatly increase iPSC generation (Huangfu et al., 2008a, 
Ware et al., 2009, Mali et al., 2010).  
 
3.1.4 Inhibition of p53 pathway to increase reprogramming 
efficiency 
The expression of pluripotency marker genes is often found in immature 




3/4 and Nanog (Ezeh et al., 2005). In fact, both immature tumour cells and 
iPSCs are quite similar in their origin and derived from somatic cell types, 
which acquire differentiation potential to transform into different cell types. 
The p53 pathway reduces cancer initiation by inducing apoptosis or cell 
cycle arrest in response to a variety of stress signals, including over-
expressed oncogenes such as c-Myc, one of the major transcription factors 
for reprogramming (Nakagawa et al., 2008). Another important 
reprogramming factor, Klf4, can either activate or antagonize p53, in a 
context-dependant manner (Rowland et al., 2005). Several studies have 
examined the effect of p53 inhibition on the reprogramming efficiency (Hong 
et al., 2009, Kanatsu-Shinohara et al., 2004, Kawamura et al., 2009, Zhao et 
al., 2008). Germ cells were shown to undergo spontaneous reprogramming 
in the absence of p53 (Kanatsu-Shinohara et al., 2004) and p53 siRNA 
expression increased iPSC formation (Zhao et al., 2008). Accordingly, 
reprogramming somatic cells to iPSCs was shown to be associated with 
activation of the p53 pathway, which serves as a barrier to reprogramming 
(Kawamura et al., 2009). The transduction of p53-null MEFs with the four 
reprogramming factors revealed marked enhancement of iPSC generation 
(Hong et al., 2009). Furthermore, improved reprogramming efficiency was 
also reported when wild-type adult HDFs were transduced with a dominant-
negative form of p53 or its short hairpin RNA (Hong et al., 2009).  
These collective data imply that the efficiency of somatic cell 
reprogramming is reduced through oncogene-mediated activation of the p53 




provide a useful tool for enhancing reprogramming efficiency. However, 
permanent p53 suppression may lead to genomic instability and thereby 
increase the probability of malignant transformation; therefore, continuous 
suppression should be avoided (Marion et al., 2009a). Rather, transient 
inhibition using chemical antagonists, such as pifithrin (PFT-"), that avoid 
genetic disruption could be employed (Komarov et al., 1999). Cyclic PFT-" 
(cPFT-") was found to be one log more potent than PFT-" for p53 
inactivation (Pietrancosta et al., 2005), and therefore, was used in my 
studies. 
For my set of experiments, it was hypothesized that protein extracts of 
actively proliferating KCL-002 hESCs, in combination with epigenetic-
modifying small molecules and p53 inhibitors, can induce generation of 
iPSCs from human somatic cells, namely HDFs. 
 
3.2 METHODS 
3.2.1 hESC proteins extraction 
Prior to protein extraction, the KCL-002 hESC line was cultured under 
feeder-free conditions as described in section 2.2.5. Proteins were extracted 
using Cayman's protein extraction kit according to manufacturer's 
instructions (Cayman, USA; distributed by Cambridge Bioscience Ltd., 
Cambridge, UK). Undifferentiated hESCs were collected with dispase 
(Sigma) and centrifuged at 300g for 5min. The resulting cell pellet was 




cell counting, 1x107 cells were transferred into a pre-chilled 15ml tube and 
centrifuged at 300g for 5min at 4°C. After that, the supernatant was 
discarded and the cell pellet was resuspended in 5ml ice-cold PBS solution 
containing phosphatase inhibitors and centrifuged again at 300g for 5min at 
4°C. The phosphatase inhibitors limit events controlled by 
dephosphorylation, including, but not limited to, transcription factor 
activation, movement of proteins in and out of the nucleus, proteolysis, and 
new protein expression. Once the supernatant was discarded, 500!l ice-cold 
1x Hypotonic buffer was added to the cell pellet, mixed gently by pipetting, 
and transferred to a pre-chilled 1.5ml microcentrifuge tube. The cells were 
then placed on ice for 15min to allow the cells to swell and increase 
membrane fragility. After that, 100!l of 10% Nonidet P-40 (nonionic, non-
denaturating detergent) reagent was added and mixed gently by pipetting. 
Addition of detergent breaks the cell membrane allowing access to 
cytoplasmic proteins fraction while maintaining the integrity of the nuclear 
membrane. Pulse spin centrifugation for 30s at 4°C was performed in a 
microcentrifuge. The resulting supernatant contained the cytoplasmic 
fraction of hESC proteins. A small (1!l) amount was kept for quantification 
and the rest was transferred to a new 1.5ml microcentrifuge tube and stored 
at -80°C until transfer into HDFs. The pellet was resuspended in 50!l ice-
cold 1x Complete Nuclear Extraction buffer containing 10mM dithiothereitol 
as well as protease and phosphatase inhibitors, vortexed for 15s at the 
highest setting, then gently rocked on ice for 15min using a shaking 
platform, vortexed for a further 30s at the highest setting and then gently 




4°C, the resulting supernatant contained the nuclear hESC proteins 
fraction. A small (1!l) amount was kept for quantification and the rest was 
stored at -80°C until transfer to HDFs. 
 
3.2.2 Protein quantification 
Protein concentration was measured by the Bicinchoninic Acid (BCA) 
protein assay kit (Thermo scientific). This assay combines the well-known 
reduction of Cu2+ to Cu1+ by protein in an alkaline medium with the highly 
sensitive and selective colorimetric detection of the cuprous cation (Cu1+) by 
BCA (Smith et al., 1985). The first step is the chelation of copper with 
protein in an alkaline environment to form a light blue complex. In this 
reaction, known as the biuret reaction, peptides containing three or more 
amino acid residues form a coloured chelate complex with cupric ions in an 
alkaline environment containing sodium potassium tartrate. 
In the second step of the colour development reaction, BCA reacts with the 
reduced (cuprous) cation that was formed in step one. The intense purple-
coloured reaction product results from the chelation of two molecules of BCA 
with one cuprous ion. The BCA/copper complex is water-soluble and exhibits 
a strong linear absorbance at 562nm with increasing protein concentrations. 
The purple colour can be measured at any wavelength between 550nm and 
570nm with minimal (less than 10%) loss of signal. The BCA reagent is 
approximately 100 times more sensitive (lower limit of detection) than the 




Accordingly, protein concentrations generally are determined and reported 
with reference to standards of a common protein such as BSA. A series of 
dilutions of known concentration were prepared using the same diluents as 
for the respective sample. Final BSA concentrations (!g/mL) in standard 
were as follows: 2000, 1500, 1000, 750, 500, 250, 125 and 25. Since the 
cytoplasmic proteins fraction contains a small amount of detergent, which 
can interfere with accurate protein quantification, 1x Hypotonic buffer 
without Nonidet P-40 was used as the blank and for diluting the 
cytoplasmic fraction 1:25 prior to protein quantification. For nuclear 
samples, 1x Extraction buffer was used as the blank and for diluting 
samples. 
A total volume of 25!l of diluted cytoplasmic and nuclear fractions was 
added to a microplate well in duplicate. The total volume of the BCA 
working reagent required was calculated using the following formula: (4 
standards + 2 samples) # (2 replicates) # (200!l) = 2.4ml. The BCA working 
reagent was prepared by mixing BCA Reagent A with BCA Reagent B at a 
50:1 ratio. BCA Reagent A consists of sodium carbonate, sodium 
bicarbonate, bicinchoninic acid and sodium tartrate in 0.1M sodium 
hydroxide; BCA Reagent B contains 4% cupric sulphate. After 200!l of the 
BCA working reagent was added to each well, the microplate was rocked 
thoroughly on a plate shaker for 30s. The plate was covered and incubated 
at 37°C for 30min. Once the plate was cooled to room temperature, the 
absorbance was measured at 562nm on an ELISA plate reader. The average 




from the 562nm measurements of all individual standards and cytoplasmic 
and nuclear fraction replicates, and a standard curve was prepared by 
plotting the average blank-corrected 562nm measurement for each BSA 
standard vs. its concentration in !g/ml. The standard curve was then used 
to determine the protein concentration of cytoplasmic and nuclear fraction 
samples. A concentration of 35mg/ml of both cytoplasmic and nuclear 
proteins was used for protein-based reprogramming of HDFs. 
 
3.2.3 hESC protein extracts transfer 
A simplified scheme for protein-based reprogramming of HDFs is outlined in 
Figure 19. Following the protein transfer HDFs were cultured with or 
without supplementation with the small-molecule compounds. In addition, 
when small molecules were added to the culture medium, three working 
concentration of cPFT-! were tested. Therefore, a total of 4 experimental 
groups were investigated. 
HDFs were washed in PBS and harvested with 0.1mM trypsin/1mM EDTA 
solution. For each condition tested, a total of 8x108 HDFs were collected by 
centrifugation at 500g for 10min at 4°C, and 108 cells were resuspended in 
separate 1.5ml tubes containing 977µl cold Ca2+- and Mg2+-free Hank’s 
balanced salt solution (HBSS; Invitrogen) in 1.5ml tubes (8 technical 
replicates). The tubes were placed in a water bath at 37°C for 2min, and 
23µl of streptolysin O (SLO; Sigma-Aldrich) (100µg/ml stock diluted 1:10 in 




The pore-forming toxin SLO is frequently used to reversibly permeabilize 
adherent and nonadherent cells, allowing delivery of molecules of up to 
100kDa mass to the cytoplasm (Walev et al., 2001). Samples were incubated 
horizontally in a water bath for 50min at 37°C with occasional agitation and 
placed on ice for 5min, and the cells were then collected by centrifugation at 
600g for 3min at 4°C. After permeabilization, cells were suspended at 2000 
cells/µl in 200µl of hESC-derived extract containing an ATP-generating 
system (1mM each nucleotide triphosphate, 10mM phosphocreatine, and 
25µg/ml creatine kinase; all Sigma) and incubated for 1 hour at 37°C in a 
water bath with occasional agitation. To reseal plasma membranes, the cell 
suspension was diluted with 1ml mTESR medium containing 2mM CaCl2, 
and incubated for 2 hours at 37°C. After that time, the cell suspension was 
placed in 15ml tubes and washed in 10ml PBS and centrifuged at 600g for 
10min at 4°C. Cells were then resuspended in mTESR medium and seeded 
on Matrigel (BD) coated 6 well culture plates (Appleton Woods) at a density 
of 108 cells per well. The medium was changed daily with or without small-
molecule compounds. As discussed previously, O? tension is an important 
aspect for hESCs maintenance and differentiation (Ezashi et al., 2005), and 
generation of iPSCs performed in hypoxic conditions (5% O?) shows up to 
four-fold increase in the reprogramming efficiency in both mouse and 
human fibroblasts (Yoshida et al., 2009). Therefore, following protein 
transfer, HDFs were cultured under hypoxic conditions. 
The experiment was repeated twice with HDFs thawed and recovered from 






Figure 19 A schematic representation of the protein-based reprogramming 
protocol.  
HDFs are reversibly permeabilized by SLO treatment and incubated with hESC proteins 
extract for 1 hour. At the end of the incubation time, the cell membrane is resealed by 
CaCl2, and the cells are cultured in mTESR medium with or without small-molecule 
compounds (blue arrow). Modified from (Walev et al., 2001) 
 
3.2.4 Preparation of small molecules to enhance protein-based 
reprogramming 
In general, small-molecule compounds were dissolved to 1/1000 
concentration, stored at -20°C, and added fresh to the mTESR media to the 
working concentration desired before every media change. Three working 
concentrations of cPFT-" (Tocris, Bristol, UK) were tested: 10µM, 1µM and 
100nM. According to previously published optimal conditions (Huangfu et 
al., 2008a), following protein transfer, HDFs were treated with 1mM VPA 
(Stemgent, supplied by Miltenyi, Bergisch Gladbach, Germany) for 10 days. 
BIX01294 (Stemgent) was used at a 1µM working concentration, which has 
previously been shown to effectively improve reprogramming (Shi et al., 
2008). RG108 (Stemgent) was used at a 5µM working concentration. Sodium 




20°C in glass vials and a working concentration of 0.25mM was used (Mali 







cPFT-"  p53-pathway 
inhibitor 
10µM,/1µM/100nM Kawamura et al., 
2009 
VPA HDAC inhibitor 1mM Huangfu et al., 2008a 
BIX01294 G9a HMTase 
inhibitor 
1µM Shi et al., 2008 
RG108 DNMT inhibitor 5µM Shi et al., 2008 
Sodium butyrate HDAC inhibitor 0.25mM Mali et al., 2010 
Table 8 Summary of compounds used in to enhance iPSC generation. 
 
3.2.5 Immunocytochemistry 
When small clumps of cells appeared in cultures of HDFs that had received 
hESCs proteins, they were transferred to a Matrigel-coated tissue culture 4 
well plate and cultured for a further 14 days in mTESR medium. The iPS-
like colonies were first partly subcultured onto a new Matrigel-coated tissue 
culture 4 well plate, and then fixed in 4% PFA and stained for pluripotency-
associated markers, as described in section 2.2.7. The following antibodies 
were tested: mouse anti-SSEA-4 and rabbit anti-Nanog (Abcam). 
 
3.3 RESULTS 
The concentration of hESC-derived proteins was 2000µg/µl and 7200µg/µl 
for nuclear and cytoplasmic fractions, respectively, as measured by BSA 




when epigenetic-modifiers were used (Figure 20A and B); no clumps were 
observed when supplementation with small-molecule compounds was 
omitted. The number of clumps varied depending on the concentration of 
cPFT-" used: 0-2 in 10!M, 4-6 in 1!M and 1-3 in 100nM. This suggested 
that the optimal concentration of cPFT-" was 1µM. All clumps were 
manually picked and transferred onto new Matrigel coated dishes in 
mTESR in an attempt to obtain iPSC colonies. Out of total 16 clumps 
recovered, only 2 grew into colonies with an iPS-like morphology, as 
evaluated under phase-contrast microscopy: colonies appeared to be tightly 
packed with a defined border; individual cells were uniform with phase 
bright edges, a high nuclear/cytoplasmic ratio, and prominent nucleoli 
(Figure 20C). Both colonies were subcultured onto a new Matrigel coated 
dishes before being fixed and processed for immunocytochemistry. Due to a 
low yield of putative iPS-like colonies only two pluripotency-associated 
markers could be tested for by immunocytochemistry, namely SSEA-4 and 
Nanog. The colonies stained positive for SSEA-4 (Figure 20D). However, 
Nanog expression was not detected detected (Figure 20E). Following 
subculture, excessive apoptosis was observed and the colonies could not be 






Figure 20 Morphological appearance and expression of pluripotency markers 
of cells following transfer of hESC-derived proteins.  
A, B: Small clumps of cells appear after approximately 7 days of culture following hESC-
proteins transfer (red arrow). Some cells with typical fibroblast morphology can also be seen 
(yellow arrow); C: Colonies resembling iPSCs appear after subsequent 14 days of culture; 
D: These colonies only stain positive for the pluripotency marker SSEA-4; E: However, the 







Protein-based reprogramming of adult somatic cells offers prospects of a 
completely nucleic acid-free methodology, which, therefore, avoids any risks 
of genomic integration and associated mutagenesis. It is also relatively 
simpler technically than current RNA-based methods. Therefore, in this set 
of experiments I sought to investigate whether HDFs could be successfully 
reprogrammed using whole protein extracts from the KCL-OO2 hESC line. 
Such protein-derived iPSCs could potentially be used for subsequent 
derivation of epidermal cell lineages. Furthermore, patient specific iPSCs 
could be generated for tailored therapy of RDEB when revertant mosaicism 
is detected (Almaani et al., 2010, Pasmooij et al., 2010, van den Akker et al., 
2011). Unfortunately, despite a high concentration of hESC proteins and 
application of epigenetic-modifying factors, protein-based reprogramming of 
HDFs did not yield any true iPSC colonies. Considering, the low efficiency of 
previously reported protein-based generation of iPSCs from mouse 
fibroblasts (Cho et al., 2010), it is very likely that comprehensive 
optimization would be required to yield positive results with human 
fibroblasts, which would have extended well beyond the time frame of this 
PhD study. 
 
Following the transfer of hESC-derived protein extracts into HDFs and 
application of small-molecule compounds to enhance reprogramming, only 2 
iPS-like colonies were observed after careful culture. These colonies were 




individual cells had phase bright edges, a high nuclear/cytoplasmic ratio, 
and prominent nucleoli. Despite their morphological similarities to 
pluripotent stem cells, these colonies tested negative for the expression of 
pluripotency-associated transcription factors Oct-3/4 and Nanog, although 
SSEA-4-positivity was observed. This observation indicated that full 
reprogramming to iPSC state was not achieved.  
Previously, it was shown that the ectopic expression of defined factors 
frequently results in partially reprogrammed “intermediate” cell 
populations (Chan et al., 2009, Mikkelsen et al., 2008) suggesting that 
transfer of proteins into some cells might be insufficient for reprogramming 
up to pluripotency or protein-based reprogramming approach might be also 
a stochastic rather than deterministic process (Hanna et al., 2009). When 
the relationship between cell number and reprogramming efficiency was 
examined using the secondary induction system, the authors claimed that 
reprogramming is a continuous stochastic process dependent on such events 
as the initial cell condition, microenvironment, variation in gene expression 
and epigenetic modification (Hanna et al., 2009). The authors of that study 
argued that all target cells would eventually give rise to iPSCs after 
extended cultivation. For this reason, the colonies obtained in this set of 
experiments were further subcultured in an attempt to assess where full 
pluripotency status can eventually be achieved. However, the cells 
underwent apoptosis and expansion could not be attained. 
In the original study, on which this set of experiments was based, 5-10 




2010). This is comparable to the amount of clumps observed when 
epigenetic-modifying small molecules and 1µM cPFT-" were added to 
culture medium. Consequently, the authors have reported that only 2 iPSC 
lines were established (Cho et al., 2010).  
An important consideration is that marked differences in protein expression 
between different ESC lines can lead to significant differences in 
reprogramming efficiency. Cho et al. (2010) achieved successful 
reprogramming when the C57 ESC line was used for protein extraction. 
However, when a different ESC line was used as protein donor no 
reprogramming was observed. Therefore, it is plausible that the specific 
protein expression in the KCL-002 hESC line was insufficient for 
reprogramming of HDFs. 
Overall, the establishment of human iPS-like colonies using protein-based 
methods takes about 8 weeks (Kim et al., 2009), approximately double that 
seen with viral transduction (Park et al., 2008b, Takahashi et al., 2007, Yu 
et al., 2007). Furthermore, at present, the efficiency of iPS generation using 
protein-based methods is only about 0.001%, which is significantly lower 
compared to virus-based protocols (cca 0.01%) (Park et al., 2008b, Takahashi 
et al., 2007, Yu et al., 2007). Furthermore, the reprogramming efficiency of 
human fibroblasts is approximately 10-fold lower than that of mouse 
fibroblasts when retroviral vectors, the most efficient tool for iPSCs 
generation, are used (Takahashi et al., 2007, Takahashi and Yamanaka, 
2006). Considering that the protein-based method has a very low efficiency 




that the generation of human iPSCs also might not be successful using the 
same method. It is unclear whether an iPSC generation method with such a 
low efficiency would offer any therapeutic value for patients with RDEB. In 
order to gain some clinical potential for protein-based reprogramming of 
human fibroblasts, extensive revisions and modifications would presumably 
be required, which could not be accommodated within the time frame of this 







Undifferentiated hESCs exposed to a complex, tissue-specific 
microenvironments such as de-epidermized dermis of skin, in combination 
with appropriate tissue culture conditions, might be induced to undergo 
efficient epidermal differentiation.  
 
AIMS: 
1. Devise organotypic culture conditions which would enable hESCs to 
differentiate towards keratinocyte lineages and form epidermis, 
specifically stratified keratinizing epithelium.  






4.1.1 Decellularized matrices for tissue engineering and 
regenerative medicine 
Functional replacement of whole organs and complex tissues in regenerative 
medicine and tissue engineering relies on the use of natural readily 
available ECM, obtained by the decellularisation of allogeneic or xenogeneic 
whole organs or tissues. These decellularized matrices serve as an inductive 
three-dimensional biological template around which a functional tissue can 
be rebuilt by either recruiting endogenous cells or assembling exogenously 
provided replacement cells with the appropriate spatial distribution and 
functional maturation of these cells (Chen et al., 1999, Dahl et al., 2003, 
Badylak, 2007). Successful proof of principle of the potential therapeutic 
approaches has been shown for such organs and complex tissues as liver 
(Uygun et al., 2010, Soto-Gutierrez et al., 2011), heart (Ott et al., 2008), 
lung (Ott et al., 2010, Petersen et al., 2010, Daly et al., 2012), oesophagus 
(Badylak et al., 2011), and skeletal muscle (Mase et al., 2010). One of the 
most successful applications of this type of therapeutic strategy was 
achieved when a decellularized human trachea in a bioreactor was 
reconstituted with cultured autologous respiratory epithelial cells and 
autologous chondrocytes of bone marrow-derived mesenchymal stromal cell 
origin, and the resultant graft was used to replace a terminally diseased left 
main bronchus (Macchiarini et al., 2008). Since then the procedure has been 
further improved by shortening the time required for decellularisation of the 
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trachea and by use of the recipient’s body as a bioreactor (Laurance, 2010). 
Subsequently, this approach was used in nine paediatric and adult patients 
with benign and malignant diseases. It is important to note, however, that 
in three patients a partial collapse of the scaffolds was observed, and a 
number of improvements in decellularisation, recellularisation, 
biomechanical stabilisation, and implantation approaches for tracheal grafts 
are now under investigation (Curcio et al., 2010, Baiguera et al., 2012). 
 
4.1.2 Organotypic cultures as in vitro  model of the 
reconstruction of skin  
In organotypic cultures, keratinocytes are cultured at an air-liquid interface 
on a dermal equivalent such as de-epidermized or devitalized dermis (DED)   
(Régnier and Darmon, 1991, Gibbs et al., 1997, Ponec et al., 1997).  
The critical point of harvesting the ECM from an organ or tissue is a 
complete removal of cells from their integrin-bound anchors and 
intercellular adhesion complexes while maintaining the structure, 
composition, and ligand background of the native matrix. The first method 
of recombining epidermal and dermal elements for keratinocyte culture 
came from culturing human skin explants on flaps on dead pig skin 
(Freeman et al., 1976). Subsequently, a more physiological system, namely 
DED, was developed (Prunieras et al., 1979). DED is a dead acellular 
dermal component of the skin that is still covered by mostly intact lamina 
densa of BM (Régnier M. et al., 1981), however, some antigens such as 180-
!&#$
$
kDa bullous pemphigoid were found to be missing indicating some 
constitutive differences from the in vivo state (Woodley et al., 1982). 
The cultivation of epidermal keratinocytes on DED has been shown in vitro 
to express all the morphologic markers of epithelial differentiation 
(Prunieras et al., 1983).  Moreover, a positive influence from fibroblasts on 
keratinocyte proliferation has been known for a long time (Rheinwald and 
Green, 1975), and, accordingly, pre-seeding DED with both fibroblasts and 
keratinocytes exhibit very good epidermal morphology and production of 
ECM components in vitro (el-Ghalbzouri et al., 2002, Marinkovich et al., 
1993, Smola et al., 1998). Co-culture of keratinocytes or keratinocyte 
progenitors with dermal fibroblasts was shown to replicate the physiological 
conditions in situ and encourage keratinocyte terminal differentiation and 
increased synthesis of ECM and other BM components. Furthermore, such 
co-culture systems enable extensive morphogenesis and subsequent 
formation of epidermis-like structures (Ralston et al., 1999, Krejci et al., 
1991). The positive effects of fibroblasts on keratinocyte differentiation are 
consistent with the inductive role of the dermis during embryonic 
development (Sengel, 1976). 
Therefore, organotypic cultures represent in vitro models of 
epidermogenesis that have been widely used to study cellular interactions, 
gene expression and wound healing (Parenteau et al., 1991, Fuchs, 1993, 
Smola et al., 1993, Garlick and Taichman, 1994, Boyce, 1996). In addition, 
such cultures provide a unique tool for pharmacological and toxicology 
studies in vitro (Gay et al., 1992, Ponec and Kempenaar, 1995). 
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4.1.3 Organotypic cultures for skin grafting 
DED has been extensively studied as a potential therapeutic dermal 
equivalent to improve keratinocyte grafting in wounds (Heck et al., 1985, 
Krejci et al., 1991, Cuono et al., 1986, McKay et al., 1994, Ghosh et al., 
1997). Keratinocytes from a small skin biopsy can be expanded to generate 
large, multilayered epithelial sheet grafts within 3–4 weeks in culture 
(Green et al., 1979), but on application to full thickness wounds, these grafts 
are unstable and fragile due to a flat DEJ and perhaps lack of mechanical 
support, tend to blister, and can lead to subsequent scarring (Woodley et al., 
1990). This suggests that the lack of dermal component renders poor take 
rates of epidermal cover (Cuono et al., 1986, Navsaria et al., 1994). 
Consequently, DED has been used successfully for the resurfacing of full-
thickness wounds (Krejci et al., 1991, Gustafson and Kratz, 1999) and also 
cultured in combination with fibroblasts and/or keratinocytes (Régnier et 
al., 1984, McKay et al., 1994, Ghosh et al., 1997). Accordingly, organotypic 
cultures are frequently used in skin tissue engineering, where there is a 
requirement for both epidermal and dermal cellular components within 
different sections of the same matrix scaffold (Parenteau et al., 1992, Horch 
et al., 2005, Huang et al., 2003). In addition, unseeded human DED has 
been successfully used for ventral hernia repair (Brewer et al., 2011). 
4.1.4 Organotypic culture to induce epidermal differentiation of 
hESCs 
Organotypic culture systems offer an attractive approach to direct cellular 
differentiation in vitro, and various modifications of this technique are 
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available (Parenteau et al., 1992, Horch et al., 2005, Margulis et al., 2005, 
Supp and Boyce, 2005). Previously, the utility of whole acellular lung for the 
development of engineered lung tissue from murine ESCs was demonstrated 
(Cortiella et al., 2010). It was found that acellular lung allowed for better 
retention of cells with more differentiation of mouse ESCs into epithelial 
and endothelial lineages than commercially available matrices. The authors 
observed some organization of differentiating ESCs into three-dimensional 
structures reminiscent of complex tissues, as well as expression of immature 
lung epithelial cell and pneumocyte markers (Cortiella et al., 2010). In 
another study, rat renal ECM was successfully seeded with mouse ESCs 
infused through the renal artery and the ureter, and proliferation and cell-
specific differentiation of the stem cells within the glomerular, vascular, and 
tubular compartments was observed (Ross et al., 2009). These studies 
proved proof-of-concept that an appropriate three-dimensional tissue 
scaffold can successfully direct ESCs towards a required cell lineage. 
Previous mouse studies utilized DED to induce epidermal differentiation 
from murine hESCs though embryoid body formation (Bagutti et al., 2001). 
The aim of that study was to investigate the reasons for failure of $1-null 
mouse ESCS to undergo epidermal differentiation in vitro, while 
maintaining an ability to produce keratinocytes through subcutaneous 
teratoma formation in syngeneic mice or within the epidermis of chimeric 
wild-type/$1-null mice (Bagutti et al., 1996). Prior to seeding onto the BM of 
the DED, wild-type and $1-null murine ESCs were allowed to differentiate 
into embryoid bodies (Bagutti et al., 2001). After 16-26 days in culture, a 
small number (4.6±2 per section) of cysts resembling stratified squamous 
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epithelia were detected on the DEDs populated with wild-type murine 
ESCs, but not with $1-null cells. Interestingly, the authors have shown that 
co-culture with epidermal keratinocytes had no effect on the ability of ESCs 
to undergo epidermal differentiation. However, consistent with the 
inductive role of the dermis during embryonic development (Sengel, 1976) 
and positive effects on normal human keratinocyte proliferation, the 
incorporation of human dermal fibroblasts significantly increased (from 
4.6±2 to 15.6±6 per section) the number of epidermal cysts formed by wild-
type ESCs . Furthermore, small clumps of keratin 14-positive cells were also 
observed in $1-null ESC cultures. Because there was no direct contact 
between the two cell types, growth factors secreted by fibroblasts were 
suggested to be responsible for the enhanced differentiation. Consequently, 
it has been proposed that the inability of $1-null ESCs to undergo epidermal 
differentiation in vitro is due to a reduced sensitivity to such soluble factors. 
With respect to assessing the ability of organotypic cultures to direct 
epidermal differentiation of hESCs only a very limited number of studies 
has been conducted (Hewitt et al., 2009). Hewitt et al. (2009) cultured a 
mixture of hESC-derived keratin 18-positive epithelial precursors and 
mesenchymal cells at an air-liquid interface. Employing this method 
requires that the cultures are fed from underneath and are exposed to the 
oxygenated air (Prunieras et al., 1983). Using this approach, the authors 
successfully detected expression of several keratins and BM proteins 
(Hewitt et al., 2009). However, neither keratin 14 nor p63 expression was 
detected, suggesting that these progenitors have not acquired the basal 
epidermal phenotype. In another study, dermal constructs using rat tail 
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collagen I demonstrated the ability of hESC-derived keratinocytes to 
terminally differentiate and undergo stratification and cornification 
(Metallo et al., 2010b). However, the profile and strength of terminal 
differentiation markers differed to that of in vivo samples. The study 
showed that the cells continued to proliferate and maintained p63 
expression in the basal layers after 3 weeks at an air-liquid interface; 
however, the basal compartment was much less defined compared to human 
skin or primary foreskin keratinocyte-containing tissues.  
To date, no studies utilizing DED as an inducer of epidermal differentiation 
of hESCs have been reported. Since the three-dimensional tissue 
architecture in organotypic co-cultures enables human keratinocytes to 
recapitulate their tissue-specific differentiation program in vitro, it is 
plausible that when undifferentiated hESCs are subjected to such 
conditions, which mimic the natural microenvironment and provide 
inductive cues from the underlying mesenchymal component, efficient 
epidermal differentiation could be promoted. 
 
4.2 METHODS 
4.2.1 Human Embryonic Stem Cell Culture 
Undifferentiated KCL-002 hESCs were cultured under defined feeder-free 
conditions on Matrigel in mTESR1 medium (Stem Cell Technologies) as 




4.2.2 DED preparation  
The Euro Skin Bank in Holland (www.euroskinbank.org) provided the 
glycerol-preserved cadaveric skin that was used for DED preparation. The 
preserved skin was provided in a sealed and labelled clear plastic bottle and 
was removed from its original packaging and washed six times with PBS. It 
was then placed in a 500ml sterilized bottle containing 300ml of PBS and 
antibiotic mix (600 units/mL penicillin-G, 600mg/mL streptomycin sulphate, 
and 250mg/mL gentamycin sulphate; all from Sigma) and stored in an 
incubator at 37°C for 10 days. This process allows for the separation of the 
dermis from the epidermis (Ghosh et al., 1997). After day 10, the storage 
container was removed from the incubator and the skin was removed using 
sterile forceps. The epidermis was peeled away easily at this point and any 
remaining epidermis and cells was washed away as the skin was washed 
with PBS three times. The DED was then equilibrated in a mixture of 
DMEM (Invitrogen) and 10% foetal calf serum (FCS) at 37°C in 10% CO2 for 
2 hours. The large piece of skin was then cut with a sterile disposable 
surgical knife into 1.5x1.5cm squares ready for use. 
 
4.2.3 Experimental groups 
Four experimental conditions were tested; these are shown in Figure 21. 
DED was inoculated with hESCs alone, or in combination with normal 
human keratinocytes (NHKs). The third experimental group involved 
addition of laminin-332 alpha3 sequence to DEDs to aid cell adhesion. 
ATRA was added to the differentiation medium in the fourth experimental 
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groups. All experimental groups were done with or without addition of 
HDFs to the reticular side of the DED. 
 
4.2.4 Seeding DEDs with cells 
The 1.5cm% DED pieces were placed in six-well cell culture plates and then 
1cm-diameter stainless steel rings were placed on top of each DED.  
For the fibroblast-containing experimental groups, HDFs were seeded as 
follows. HDFs were collected from the flask using 0.05% trypsin in 0.02% 
EDTA (Invitrogen), counted using a haemocytometer, and centrifuged at 
400g for 5min. The cells were resuspended in DMEM with 10% FBS and 
were seeded into the rings on the reticular dermal surface of the DED at a 
density of 2x108 cells per DED in 1ml volume. Medium was also added to 
the area surrounding the DEDs. Following 24 hours incubation, the rings 
were removed and DEDs were inverted to orient the papillary dermal 
surfaces on top before the rings were replaced on the DEDs as before. 
To seed hESCs, undifferentiated colonies were enzymatically passaged 
using dispase, centrifuged at 300g for 5mins and resuspended in mTESR1 in 
a single-cell suspension. The cells were counted and 2x108 cells per DED 
were added to the papillary side. When co-culture of hESCs with NHKs was 
employed, 1x108 of each cell type was seeded per DED. NHKs were grown in 
Defined Keratinocyte Serum-Free Medium (DKSFM; Invitrogen) and 
collected by incubation with TrypLE™ Express (Invitrogen) for 5min at 
37°C. For experimental groups containing laminin-332 "3 sequence, human 
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recombinant laminin peptide sequence PPFLMLLKGSTR was added to the 
reticular side of DEDs at a concentration 70µl/ml. The laminin peptide was 
purchased from GenScript Corporation (Piscataway, USA). Peptide 
sequence was synthesized by manual solid phase peptide synthesis on 2-
chlorotrityl chloride resin using standard procedures (Chen and White, 
2000). Briefly, the pentafluorophenyl esters of 9-fluorenyl methoxy carbonyl 
(Fmoc) amino acids were used in the process along with 1-
hydroxybenzotriazole. The peptides were cleaved from the resin with a 
trifluoroacetic acid/thioanisole/ethanedithiol/ anisole (9:0.5:0.3:0.2) mixture 
and precipitated with cold diethyl ether. The purity and composition of the 
peptide was determined using high-performance liquid chromatography and 
amino acid analysis, respectively. The purified peptide was identified using 
matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) 
mass spectrometry and the purity of peptide was found to be >99%. 
Once seeded onto DED, hESCs were allowed to attach and adapt in 
mTESR1 for 2 days. 
 
4.2.5 Differentiation protocol 
After 2 days, the cultures were raised to the air-liquid interface by placing 
DEDs on stainless steel grids. The medium containing 25ng/ml BMP-4 
(R&D Systems) was added to all experimental groups. In addition, one 
experimental group also had 1µM ATRA (Sigma) applied to the 
differentiation medium. The medium was changed every 2 days for 1 week 
(days 3-9 inclusively). At day 10, the medium in all experimental groups was 
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changed to DKSFM in order to propagate the potential epidermal 
progenitors. DKSFM was changed every 2 days for a further 2 weeks (days 
10-24 inclusively). Each experimental group was done in duplicate 
(technical replicates). The experiment was independently repeated three 
times with different batches of DEDs (n=3 biological replicates). The 
differentiation protocol is outlined in Figure 21. 
DED with HDFs only, and hESCs seeded on Matrigel directly onto a six-well 
cell culture plate, were used as negative controls. DED with HDFs and 
NHKs were used as a positive control. 
At the end of the differentiation protocol, the samples were recovered and 
washed with PBS. For histological and immunohistochemical evaluation 
each DED sample was fixed in 10% formalin (at 4˚C overnight), washed in 
PBS and dehydrated by immersion in 50%, 70%, 90% and finally in 100% 
ethanol, using an automated tissue processor.  After that, the samples were 
embedded in paraffin, allowed to cool at room temperature and cut at 5!m 
using a Reichert-Jung 2035 microtome. Sections were picked up on 2% 3-





Figure 21 Protocol outline and experimental groups used in DED-induced 
epidermal differentiation study.  
Four experimental groups were tested: 1) DED inoculated with hESCs and differentiation 
medium containing BMP-4 only; 2) Co-culture of hESCs with NHKs on DED (red); 3) 
Laminin-332 peptide added to the papillary surface of DED (orange); 4) ATRA added to 
differentiation medium (purple). Each experimental group was done with or without 
seeding HDFs on the reticular surface of DED (green). 
 
4.2.6 Haematoxylin & Eosin Y staining of DED sections 
After dewaxing (section 2.2.11.1), slides were immersed in a solution of 
Mayer’s haemalum (Sigma) for 3min at room temperature and washed with 
deionised water. To ensure the appropriate level of nuclear staining, the 
slides were dipped for 5s in 0.5% HCl in 70% methylated spirit and quickly 
returned to deionised water, washed for 5min and then examined 
microscopically. If nuclear staining was too weak, the slides were returned 
to Mayer’s haemalum solution for a further 3min. If nuclear staining was 
too strong, the slides were dipped again in acid solution. Eosin staining was 
subsequently performed by immersion in 0.5% eosin Y (VWR) staining 
solution for 3min at room temperature, sections washed in deionised water. 
DED sections were mounted by covering with 22x50mm coverslips (VWR), 
using DPX in Xylene mountant (VWR) as described in section 2.2.11.4. The 
slides were allowed to dry for 30min and the sections were visualized with 
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Zeiss Axiophot fluorescence microscope (Zeiss).  Images are taken with a 
CCD camera (DS-U2, Nikon), and processed with Photoshop CS5 (Adobe). 
 
4.2.7 Fluorescence-mediated immunohistochemistry of DED 
samples 
4.2.7.1 De-waxing and antigen retrieval 
De-waxing of paraffin embedded sections and subsequent antigen retrieval 
were performed as described in sections 2.2.11.1 and 2.2.11.2, respectively. 
 
4.2.7.2 Permeabilization 
For intracellular antigen staining, permeabilization was performed in 0.6% 
H?O? (Sigma) and 0.1% Triton X-100 (Sigma) in water for 10min at room 
temperature. After that, the slides were washed in PBS with gentle 
agitation (2 times for 5min each). The use of Triton X-100 helps to reduce 
surface tension, allowing reagents to cover the whole tissue section with 
ease; it is also believed to dissolve Fc receptors, therefore reducing non-
specific binding. The secondary antibody may cross react with endogenous 
immunoglobulins in the tissue; this was minimized by pre-treating the 
tissue with a blocking solution containing 0.1% v/v Tween® 20 (Sigma), w/v 
1% BSA (Sigma) and 10% v/v normal serum from the species in which the 
secondary antibody was raised. In this study, all secondary antibodies 
employed were raised in goat (see section 2.2.7 Table 2 for details), therefore 
NGS (Invitrogen) was used. The use of normal serum before the application 
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of the primary also eliminates Fc receptor binding of both the primary and 
secondary antibody (Daneshtalab et al., 2010). BSA is included to reduce 
non-specific binding caused by hydrophobic interactions (Boenisch, 2006). 
Tween 20 is a detergent and surface tension reducer which is frequently 
used in blocking solutions (Helenius et al., 1979). The slides were then 
incubated with pre-diluted primary antibodies for 90min at room 
temperature. The primary antibodies used are shown in Table 9. The slides 
were then washed in PBS with gentle agitation (2 times for 5min each) and 
incubated with goat anti-mouse or anti-rabbit Alexa Fluor- conjugated 
secondary antibodies (1:300 dilution) for 30min at room temperature in the 
dark. All antibody dilutions were done in blocking solution and a minimum 
of 80µl of pre-diluted antibodies per section was used. The slides were then 
washed twice in PBS and a final wash was performed in distilled H2O for 
5min. To mount and counter stain the nuclei, one drop of ProLong® Gold 
antifade reagent (Invitrogen) with DAPI was added to each section and then 
glass coverslips (13-mm diameter) were put on top of the slides. The slides 
were allowed to dry for 30min and the sections were viewed using a with 
Zeiss Axiophot fluorescence microscope (Zeiss).  Images were taken with a 
CCD camera (DS-U2, Nikon), and processed with Photoshop CS5 (Adobe). 
Control procedures, with the omission of either the primary or secondary 





Antibody Supplier Host Conc. Protein group 
Anti-Keratin 14 Covance Rabbit 1µg/ml Basal keratinocyte 
Anti-Keratin 5 Covance Rabbit 1µg/ml Basal keratinocyte 
Anti-Keratin 10 Abcam Mouse 10µg/ml Terminal differentiation marker 
Anti-Involucrin (SY5) Sigma Mouse 1:100 Terminal differentiation marker 
Anti-Collagen IV Sigma Mouse 1:500 ECM protein 
Anti-Collagen VII Sigma Mouse 1:1000 ECM protein 
Table 9 Primary antibodies used in Chapter 4. 
 
4.2.9 Scoring system for immunohistochemical staining 
Relative quantification of immunohistochemical data was done by careful 
observation of the sections under the fluorescent microscope. The scoring of 
immunohistochemical staining was done for 4 different factors. Firstly, the 
staining was evaluated with respect to the appearance of cells in the DED 
sample. The structures observed could be divided into 4 categories: 1) 
cellular cysts only, 2) epidermis-like cellular structure inside the DED, 3) a 
short cellular structure on the surface of the DED, but not directly attached 
to it, and 4) a long cellular structure attached to the papillary surface of the 
DED. Representative images for each of the structure types are shown in 
Figure 22. To estimate the total number of each type of epidermis-like 
structures observed under each condition, 10 sections of 5!m thickness of 
each DED sample were evaluated.   
In addition, the extent of expression of type VII collagen, type IV collagen 
and basal keratins 5 and 14 was calculated separately per 5 high-power 
fields (400X) using a score - to 3+ as follows:  
Score - + ++ +++ 






4.3.1 hESCs undergo epidermal differentiation in organotypic 
DED cultures 
Histological and immunohistochemical examination of the samples revealed 
that, when seeded on DED, hESCs filled all pits and holes that are produced 
in the process of epidermis removal and preparation of DED. In addition, 
short structures and cysts resembling epithelium were detected. The 
epithelium-like structures observed could be broadly divided into 4 
categories: 1) cystic structures found on the surface and inside the DED 
(Figure 22, A1 and A2), 2) short cellular structures inside the DED (Figure 
22, B1 and B2), 3) short patches of cells detached from the papillary surface 
of DED (Figure 22, C1 and C2), and 4) long structures attached to the 
papillary surface of the DED (Figure 22, D1 and D2). “Long” epidermis-like 
structures were >750!m in length, and comprised around 25% of the 
papillary DED surface. The majority of cells stained positively for basal 
keratins 5 and 14 (Figure 23), however no terminal differentiation markers 
such as keratin 10 and involucrin were detected. Types IV and VII collagen 
were seen deposited around these presumptive epidermal structures (Figure 
23); although, a discrete BM was not observed. It is important to note, 
however, that neither terminal differentiation markers nor a continuous 
discrete BM were observed in the positive control sample containing NHKs 
and HDFs.  
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Figure 24A and B show the appropriate negative controls for histological 




Figure 22 Histological examination of DED samples revealed the presence of 
4 different epidermis-like structures formed by hESCs.  
A1 and 2: Cystic structures; B1 and 2: Epidermal-like structure inside DED; C1 and 2: 
Short patches of cells detached from the papillary surface of DED; D1 and 2: A long 





Figure 23 Expression of basal keratins 5 and 14 and ECM proteins in hESC-
derived structures in DED samples.  
A: A1- The cells within cystic structures stain positive for keratin 5 marker expression 
(red), and A2- Type IV collagen (green) was seen deposited around the cysts; B: Short 
cellular structures  inside DED stain positive for B1- keratin 14 (red) with type IV collagen 
(green) surrounding the structure, and B2- keratin 5 (red) with type VII collagen (green) 
deposition; C: Epithelium-like patches of cells detached from the papillary surface of DED 
display positivity for C1- keratin 14 (red) and type IV collagen (green) surrounding the 
structure, and C2- keratin 5 (red) with type VII collagen (green) deposition; D: Long 
(>700!m) epithelium-like structure attached to the papillary surface of DED stained 
positive for D1- basal keratin 14 positivity (red) and D2- basal keratin 5 (red) as well as 





Figure 24 Negative controls for figures 23 and 24. 
A: Negative control for histological examination (figure 23) showing DED with HDFs only; 
B: Negative control for immunohistochemical analysis (figure 24) showing no primary 
antibody control. Scale bar=100!m. 
 
4.3.2 Culture conditions involving ATRA and laminin-332 
peptide induce epidermal differentiation of hESCs most 
efficiently 
The scoring of immunohistochemistry data is shown in Table 10, 11 and 12. 
From this analysis, two conditions tested appear to induce epidermal 
differentiation of hESCs most efficiently, namely addition of ATRA to 
differentiation medium or application of laminin-332 "3 sequence to the 
DED surface. Under both of these conditions, long epidermis-like cellular 
structures  (>750!m in length) were observed (Table 10) that were similar to 
the structures obtained with positive control experiments involving DED 
populated with NHKs on the papillary surface and HDFs on the reticular 
surface (Table 12). Furthermore, the expression of types IV and VII collagen 
and basal epidermal keratins 5 and 14 closely resembled that detected in 
the positive control sample (Table 11). These epidermis-like structures 
covered approximately 25% of each section, and were not observed under 
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any other experimental conditions. When BMP-4 alone was used to induce 
epidermal differentiation of hESCs, a total of 24 cystic structures were 
observed in 10x5!m sections examined (Table 10). However, no long 
epidermis-like structures were detected. Similarly, when undifferentiated 
hESCs were co-cultured with NHKs in the presence of BMP-4, 18 cystic 
structures were detected, as well as 6 short structures. Under all 
experimental conditions tested, the number of more defined epidermal 
structures as well as expression of epidermal markers increased when the 





 Total number of epidermis-like structure per 1mm 
 Cystic Inside Short Long Cystic Inside Short Long 
Condition -HDFs +HDFs 
BMP-4 only 24 1 0 0 12 6 0 0 
BMP-4+ATRA 18 5 2 0 11 4 9 1 
BMP-4+NHKs 18 1 6 0 20 2 1 0 
BMP-4+Lam 17 3 0 0 8 0 5 1 
Table 10 Quantification of various epidermis-like structures observed under 
different experimental conditions. 
Evaluation of the number of epidermis-like structures reveals that addition of ATRA to 
differentiation medium or application of laminin-332 "3 sequence to DED surface 
significantly improves epidermal differentiation from hESCs. 
 
 -HDFs +HDFs 
 ColIV ColVII Krt14/5 ColIV ColVII Krt14/5 
BMP-4 only - + ++ + + + 
BMP-4+ATRA ++ + ++ +++ +++ +++ 
BMP-4+NHKs - +++ +++ ++ ++ - 
BMP-4+Lam - ++ ++ +++ +++ +++ 
Table 11 Scoring of immunohistochemical data for epidermal marker 
expression  
Scoring suggests that addition of ATRA or laminin-332 peptide improves epidermal 
differentiation efficiency of hESCs on DED. 
$
 Epidermis-like structures Epidermal markers 
 Cystic Inside Short Long ColIV ColVII Krt14/5 
Positive control 0 0 11 1 +++ +++ +++ 
Negative control 0 0 0 0 ++ + - 
Table 12 The total number of epidermis-like structures and expression of 
epidermal markers in positive and negative control experiments. 
 
4.3.3 Technical discussion 
One potential source of experimental artifacts in the DED experiment 
described in this chapter is keratinocytes and/or fibroblasts from donor skin 
which could have survived the process of de-epidermalization and started to 
proliferate under experimental conditions. 
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To rule out the possibility of contamination with donor keratinocytes and/or 
fibroblasts and confirm the hESC origin of the epidermal cells quantitative 
fluorescent PCR for multiple microsatellite markers of genomic DNA can be 
applied.  
PCR-based techniques allow the origin of the cells to be identified and 
quantified and have an advantage over cytogenetic Y chromosome probing 
by FISH as they are not limited exclusively to sex-mismatched 
transplantations. Microsatellites are highly variable tandemly repeated 
sequences commonly used for mapping, linkage analysis and to trace 
inheritance patterns. The repeating unit is generally 1 to 4 nucleotides long 
and variation in the number of repeats affects the overall length of the 
microsatellite. Specific primer pairs corresponding to microsatellite markers 
can be used to generate a profile of PCR amplifiers diagnostic for each 
genotype. When being used as a diagnostic tool as in preimplantation 
genetic haplotyping, the specific number of repeats in a given microsatellite 
is not important, but rather the difference in the number of repeats between 
alleles, allowing the origin of the allele to be tracked.  
Previously, microsatellite analysis of the KCL-002 hESC line and HDFs 
used in this study has been carried out according to the published 
quantitative fluorescence PCR protocol (Mann et al., 2004). In the procedure 
the chromosome markers are co-amplified in one multiplex PCR assay. PCR 
products are analysed on 310 and 3100 capillary-based genetic analysers 
(Applied Biosystems, Foster City, CA, USA). Genotyper version 2.5 can be 
used for sizing and labelling alleles. The results of this analysis are shown 
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in Table 13. Therefore, to confirm the absence of contamination from donor 
skin cells, microsatellite analysis of the DED samples can be performed and 
the results compared to those obtained with two cell lines. Detecting the 
repeat numbers which correspond only to those in the KCL-002 hESC line 
and HDFs repeat numbers would confirm the origin of epidermal cells; 
whereas a new repeat number in the DED samples would indicate 
contamination by donor cells.  
 
 KCL-002 HDFs 
MARKER ALLELE 1 ALLELE 2 ALLELE 1 ALLELE 2 
D13S252 299 303 275 295 
D13S305 450 450 429 450 
D13S325 286 302 281 298 
D13S628 457 457 457  
D13S634 401 406 403 411 
D18S386 340 359 356 375 
D18S390 368 372 360 371 
D18S391 214 218 218 228 
D18S535 478 482 474  
D18S819 400 412 400 412 
D18S978 211 220 215 220 
D21S11 241 256 245  
D21S1409 212 229 187 195 
D21S1411 305 317 300 313 
D21S1435 185 185 189 193 
D21S1437 331 335 315 319 
Table 13 Microsatellite results for 16 markers from the KCL002 hESC line 
and HDFs.  




The results described here suggest that when undifferentiated hESCs are 
exposed to a complex, tissue-specific microenvironments such as DED of 
skin, in combination with appropriate differentiation-inducing conditions, 
the cells can be directed to undergo epidermal differentiation and form 
epithelium-like structures. However, these structures did not show signs of 
stratification and did not cover the whole surface of the DED.  
 
4.4.1 Organotypic culture of hESCs in combination with 
appropriate differentiation-inducing conditions supports the 
formation of epithelium-like structures 
When seeded on DED, hESCs occupied all the pits produced in the process 
of DED preparation. This observation is in agreement with results obtained 
when NHKs are cultured on DED (Régnier et al., 1986). No single keratin 
14-positive cells were observed and differentiated cells were seen to cluster 
in groups or patches. Such cell-sorting behaviour has also been described for 
interspersed populations of dermal fibroblasts and keratinocytes (Wang et 
al., 2000). This suggests that proximity and inter-communication with 
neighbouring cells is critical for epidermal differentiation. Four types of 
epithelium-like structures were detected at the end point of the 
differentiation protocol that stained positive for basal keratins 5 and 14 
expression, although a continuous epidermal layer was not observed. 
Furthermore, stratification was not detected in experimental groups, as well 
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as in the positive control sample. Such observations could be explained by 
the fact that the DEDs studied lacked a complete BM. 
Removal of epidermis with PBS has been shown previously to preserve the 
BM of skin (McKay et al., 1994, Régnier et al., 1984). However, in our study, 
no discrete BM was observed and ECM proteins accumulated exclusively 
around hESC-derived structures, suggesting that they were secreted by the 
differentiating cell population. It has been reported previously that 
epidermal cells grown on a collagen sponge formed clumps of keratinocytes 
found in the interior of the sponge instead of a well-organized epidermis 
(Doillon et al., 1988). Similarly, in another study, a well-organized 
epidermis was not detected in the C-GAG composites due to a lack of BM 
(Ojeh et al., 2001). Therefore, it is very likely that the absence of a fully 
formed BM in DED preparations hinders the successful development of a 
fully-formed stratified epidermis covering the whole surface of DED. 
Instead, hESCs invaded the interior of the DED, where they formed 
epithelium-like structures. The formation of hESC-derived cysts has been 
previously shown when murine embryoid bodies were seeded on DED 
(Bagutti et al., 2001). Although in our model embryoid bodies formation was 
not employed and cells were seeded in a single cell suspension, the tendency 
of ESCs for spontaneous embryoid body formation when the culture 
conditions are changed from a two-dimensional monolayer to three-$
dimensional structure is well known (Keller, 1995, Hopfl et al., 2004, Dang 




4.4.2 Co-culture with NHKs has no effect on epidermal 
differentiation of hESCs, while co-culture with HDFs enhances 
the formation of epidermis-like structures 
The results obtained in this set of experiments are consistent with 
previously reported data that co-culture of hESCs with NHKs does not 
improve the ability of hESCs to undergo epidermal differentiation (Bagutti 
et al., 2001). Conversely, in all experimental groups, more defined epidermal 
structures and higher expression of epidermal markers were observed when 
the reticular side of the DED was inoculated with HDFs. Previous reports 
also demonstrated that the addition of fibroblasts to organotypic cultures 
led to the formation of a similar morphology to normal skin (Krejci et al., 
1991, Ghosh et al., 1997). This may not be surprising considering the 
importance of mesenchyme in embryonic epidermogenesis (Sengel, 1976) 
and the known supportive role of fibroblasts on keratinocyte proliferation 
(Rheinwald and Green, 1975). Since HDFs remained at the reticular side of 
the DED and therefore had no direct contact with hESCs, it is highly likely 
that any differentiation-improving effects were due to the paracrine action 
of growth factors secreted by fibroblasts. This observation is also in 
agreement with previous studies on murine ESCs (Bagutti et al., 2001). 
 
4.4.3 ATRA and laminin-332 alpha3 sequence improve the 
formation of epithelium-like structures from hESCs 
Under two experimental conditions tested (namely supplementation of the 
differentiation medium with ATRA and addition of laminin-332 "3 sequence 
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to the papillary surface of DED), the formation of epithelium-like structures 
and marker expression was most efficient, based on scoring of histology and 
immunohistochemistry data. 
Supplementation of the differentiation medium with ATRA significantly 
improved the formation of epithelium-like structures from hESCs and 
numerous long cellular structures were observed on the papillary surface of 
the DED, although only one of them was fully attached to it. Stage-specific 
application of ATRA has been previously shown to greatly enhance the 
epidermal differentiation of hESCs (Metallo et al., 2008b), possibly through 
induction of &Np63 expression (Chen and Lohnes, 2005). The known effects 
of ATRA on keratinocyte proliferation and differentiation are described in 
more detail in section 1.9. 
The addition of laminin-332 peptide to the papillary surface of the DED led 
to formation of long (>750!m) epithelium-like structures fully attached to 
the DED. In fact, those structures were equivalent to those obtained in the 
positive control, when DED was inoculated with NHKs and HDFs. Laminin-
332, one of the major constituents of skin BM, forms cross-shaped 
heterotrimers consisting of "3-, $3-, and '2-chains which regulate the stable 
adhesion of the epidermis to the underlying dermis (Rousselle et al., 1991, 
Colognato and Yurchenco, 2000) and which influence keratinocyte 
behaviour through interactions with cell surface integrins "3$1 and "6$4 
(Rousselle and Aumailley, 1994, Niessen et al., 1994). Furthermore, 
laminin-332 participates in cellular functions such as adhesion, migration, 
differentiation, growth, and survival (Nguyen et al., 2000). The laminin "3 
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chain contains a C-terminal globular (LG) domain that consists of five 
globular modules LG1–LG5 (Timpl et al., 2000) with the LG3 domain 
playing an essential role in mediating the unique activity of laminin-332. 
Earlier studies demonstrated that the motif PPFLMLLKGSTR within the 
LG3 domain of recombinant human laminin-332 "3 chains is an active site 
for integrin "3$1 binding (Kim et al., 2005). Previously, the laminin-332 "3 
sequence has been shown to promote cellular adhesion (Damodaran et al., 
2009) and exert positive effects on neurite growth within a collagen scaffold 
(Yao et al., 2010). It is, therefore, plausible that the hESCs were encouraged 
to attach and proliferate on the reticular side of DED and formed 
epithelium-like structures when induced to differentiate. 
 
4.4.4 Conclusions and future work 
Despite producing some epithelium-like structures, hESCs seeded on DED 
and subjected to treatment with BMP-4 and ATRA did not produce a 
continuous stratified epidermal layer. This suggests that the differentiation 
conditions employed failed to completely recapitulate embryonic epidermal 
morphogenesis. It is very likely that hESCs have to be primed to adopt an 
ectodermal fate prior to organotypic culture. Previously, murine ESC-
derived keratin 18-positive epithelial precursors were co-cultured with 
fibroblasts at the air-liquid interface and small areas of well-organized 
reconstituted skin were observed (Coraux et al., 2003a). However, 
reconstituted skin comprised only 20% of the area, while most of the 
construct was occupied by zones of uncharacterized non-organized 
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differentiated cells. The authors suggested that this finding was due to 
heterogeneity of the starting hESC-derived epithelial cell population. 
Indeed, the in vitro differentiation protocol utilized in this study only 
yielded 9.8% of keratin 14 positive cells (Coraux et al., 2003a). Therefore, it 
is plausible that if the efficiency of the in vitro differentiation protocol is 
improved and a keratin 14-positive population of higher purity is obtained, 
then a complete epidermis could be produced when this population is seeded 
on DED. 
One of the most efficient epidermal differentiation protocols demonstrated 
thus far was obtained through ATRA treatment of hESCs (Metallo et al., 
2008b). These authors reported that after 5 weeks of differentiation 87% of 
cells expressed keratin 14. These cells were shown to undergo terminal 
differentiation and stratification when cultured on dermal constructs using 
rat tail collagen I. However, the profile and strength of terminal 
differentiation markers differed to that of in vivo samples. Furthermore, 
residual simple epithelial keratin 18 expression, as well as the expression of 
corneal epithelial markers keratins 3 and 12, was also detected. These 
observations could reflect the sub-optimal nature of the dermal construct 
utilized in this study. Studies of human keratinocytes have shown that 
while elevation to the air-liquid interface in vitro stimulates differentiation 
of the cultivated epidermis, the degree of differentiation is far greater when 
an appropriate dermal construct is used (Prunieras et al., 1983). DED 
composites were shown to accurately replicate keratinocyte behaviour in 
models of wound healing, hyperproliferation, and psoriasis (Leigh et al., 
1995, Asselineau et al., 1986). Consequently, DED composites were accepted 
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to be the organotypic gold standard model (McKay et al., 1994, Prunieras et 
al., 1983). For that reason, if an efficient production of epidermal 
progenitors is achieved in vitro, it would be favourable to subject these 
progenitors to an environment that closely mimics human skin, such as 
DED. Therefore, the work described in the following chapters of this thesis 
was aimed at developing a more efficient differentiation protocol that could 














The sequential contribution of mesenchymal inducers such as stromal 
feeders and type IV collagen can replicate in vitro the effects of embryonic 
mesodermal stimulation and encourage epidermal differentiation from 
hESCs. To test this hypothesis, we used the medium enriched in growth 
factors secreted by the PA6 stromal cell line in combination with type IV 
collagen as substrate since this combination might display mesenchymal 
inducing activity in vivo. 
 
AIMS:  
1. Adapt and optimize and evaluate the efficiency of the existing direct co-
culture differentiation protocol for the KCL-002 hESC line. 
2. Evaluate the efficiency of epidermal differentiation promoted by growth 
factors secreted by the PA6 stromal line by monitoring of epidermal 
marker expression. 
3. Examine whether PA6 growth factors can exert similar effects on 




The rationale behind the hypothesis outlined in this chapter relies on the 
assumption that using mesenchymal inducers such as stromal feeders and 
type IV collagen to direct hESCs differentiation in vitro has the potential to 
mimic the effects of embryonic mesodermal stimulation and encourage 
epidermogenesis. 
 
5.1.1 PA6 cells and Stromal-Derived Inducing Activity (SDIA) 
The instructive effect of mesenchymal factors on epidermal commitment 
correlates well with the induction role of mesodermal cells on ectodermal 
fate during embryonic skin development and post-natally (Sengel, 1976). 
Stromal cell lines such as PA6, derived from mouse bone marrow, have been 
shown to exhibit what has been termed stromal-derived inducing activity 
(SDIA) (Kawasaki et al., 2000). It has been well documented that this 
activity can induce ectodermal differentiation of hESCs, which in the 
absence of other stimuli proceeds towards neural cell fate, and can serve as 
an efficient protocol for obtaining mesencephalic dopaminergic neurons 
(required for cell therapy of Parkinsonism) (Buytaert-Hoefen et al., 2004, 
Kawasaki et al., 2000, Kawasaki et al., 2002, Yan et al., 2005, Zeng et al., 
2004a). Despite numerous studies, the nature of SDIA, however, remains 
unclear. Initial observations indicated that PFA-fixed PA6 cells can induce 
neural differentiation from hESCs, thus suggesting that SDIA accumulates 
on the surface of PA6 cells (Kawasaki et al., 2000). For example, PA6 cells 
express the Notch ligand Jag1 and Notch signalling has been reported to 
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direct ESCs differentiation towards neuroectoderm (Lowell et al., 2006). 
Therefore, it is likely that Jagged1 is a key component of SDIA, and that 
Notch activation in ESCs by PA6-expressed Jag1 favours their 
differentiation towards the neuroectodermal lineage.$
On the other hand, several studies have shown that soluble factors secreted 
by PA6 cells also play a role in inducing neural differentiation from hESCs 
(Schwartz et al., 2005, Yamazoe et al., 2005). Genome expression analysis 
study has attempted to identify factors secreted by PA6 cells that might be 
effective in inducing neural differentiation from hESCs (Vazin et al., 2009). 
In this study, four factors were found to be responsible for PA6 cell-derived 
inducing activity: Stromal cell-derived factor 1, Pleiotrophin, Insulin-like 
growth factor 2, and Ephrin B1. The authors concluded that the 
combination of these four factors, termed SPIE, was primarily involved in 
promoting SDIA, whereas the cell surface activity of PA6 cells enhanced cell 
survival and overall neurogenesis. 
However, a different study carried out by the same group has shown that 
medium conditioned by PA6 stromal cells (PA6 conditioned medium; PA6 
CM) was not as efficient at inducing dopaminergic neurons differentiation 
from hESCs compared to live PA6 cells, although it did promote their 
survival with sustained Oct-3/4 expression (Vazin et al., 2008). 
Interestingly, the same study revealed that SDIA promoted by PA6 cells is 
drastically decreased by both fixation and irradiation but is less affected by 
mitomycin C treatment; conversely, the neural-inducing effect is not altered 
by fixation but is decreased by mitotic inactivation. These collective results 
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suggest that it is very likely that SDIA is in fact mediated by the 
combination of cell surface activity and soluble factors secreted by PA6 cells. 
 
5.1.2 BMP-4 as an antagonist of neural fate 
It has been shown that SDIA-treated ESCs tend to adopt the default neural 
fate unless they receive a considerable level of BMP signalling (Kawasaki et 
al., 2000). In their original study Kawasaki et al. (2000) showed that >90% 
SDIA-treated ESCs differentiate efficiently into neural precursors and 
neurons unless exogenous BMP-4 is added.  
BMPs are members of the transforming growth factor-ß superfamily. In 
Xenopus, BMP-4 plays a pivotal role in establishing the dorsal-ventral axis 
of early embryos: in the ventral part of the egg BMP-4 induces the 
epidermal commitment, while its absence within the dorsal part leads to a 
“default neural” differentiation (Wilson and Hemmati-Brivanlou, 1995). In 
vertebrate embryogenesis, the primordial nervous system arises from 
uncommitted ectoderm during gastrulation. Spemann and Mangold (1942) 
demonstrated that the dorsal lip of the amphibian blastopore, which gives 
rise mainly to axial mesoderm, emanates inductive factors that direct 
neural differentiation in ectoderm. Molecular studies in Xenopus have 
identified neural inducer molecules and revealed their mode of action (Sasai 
and De Robertis, 1997). Neural inducers such as noggin and chordin (Lamb 
et al., 1993, Sasai et al., 1995) induce neural differentiation in isolated 
Xenopus ectoderm (animal caps) and promote dorsalization of mesoderm 
when acting on mesodermal precursors (Sasai and De Robertis, 1997). These 
!)'$
$
neural inducers do not have their own receptors on target cells, instead they 
act by binding to and inactivating BMP, which suppresses neural 
differentiation and ventralizes mesoderm (Wilson and Hemmati-Brivanlou, 
1995, Piccolo et al., 1996). These results suggest that both neural induction 
and mesoderm dorzalization are controlled by a common morphogenic 
signalling, that is, a BMP activity gradient (Sasai, 2000). Similarly, in 
vertebrates, including humans, neural/epidermal binary decision is executed 
in a BMP-dependent manner, where BMP-4 has a critical role in epidermal 
commitment and displays an inhibitory effect on neural induction 
(Hemmati-Brivanlou and Melton, 1997). 
These effects of BMP-4 are achieved through the Smad-mediated apoptosis 
of neural precursors (Gambaro et al., 2006). The original paper on SDIA 
promoted by PA6 co-culture showed that BMP-4 treatment of ESCs 
significantly increased expression of the non-neural ectoderm marker, E-
cadherin, from 16% to 75% (Kawasaki et al., 2000). Furthermore, after 11 
days of culture the expression of keratin 14 increased from 0% to 34%. The 
authors also demonstrated that addition of serum during days 3-5 of the 
induction period further promoted epidermogenesis and generated large 
colonies with a strong keratin 14 signal (47%). Importantly, mesodermal 
induction did not occur in these conditions. 
Therefore, the possibility arises that combining optimal PA6 stromal cells 
co-culture and BMP-4 treatment might efficiently direct hESCs towards 
epidermal fate and produce keratinocyte precursors. 
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5.1.3 Keratins as markers to monitor the efficiency of epidermal 
differentiation of hESCs in vitro  
In 2008, Aberdam et al. developed a method to produce a homogenous 
ectodermal precursor cell population (Aberdam et al., 2008). Their approach 
involved seeding undifferentiated hESCs on formaldehyde-fixed PA6 
stromal feeder cells in the absence of serum for 4 days and exposed to 0.5nM 
BMP-4 treatment for 3 days, followed by an additional 7 days of culturing in 
the presence of 10% foetal calf serum. Under these conditions, a large 
number of keratin 18-positive ectodermal progenitor cells were produced 
(60%), along with keratin 5/keratin 14-positive keratinocytes (20%). A 
related protocol involved subculturing the ectodermal progenitors obtained 
at day 7 on mouse embryonic fibroblast feeders in medium supplemented 
with 5µg/ml insulin, 0.5µg/ml hydrocortisone, 50µg/ml ascorbate, and 
10ng/ml recombinant human epidermal growth factor for another week. 
This procedure yielded a homogeneous population of ectodermal cells, 100% 
positive for keratin 18. These cells could be further expanded on type IV 
collagen and cultured for 15 passages, while maintaining homogeneity for 
keratin 18 staining. This work generated for the first time a stable, somatic 
ectodermal cell population 100% positive for keratin 18. The authors 
proposed that such ectodermal cell population could be particularly useful 
for designing in vitro models to recapitulate early embryonic 
epidermogenesis and lineage specification, as well as a potential source for 




Despite its homogeneity, the cell population obtained was 100% positive for 
the expression of keratin 18, a marker of simple single-layer epithelia 
(Romano et al., 1986). Keratin 18 and its pairing partner keratin 8 are the 
earliest keratins to be expressed in the preimplantation embryo (Jackson et 
al., 1980, Oshima et al., 1986). As the epidermis begins to differentiate, 
expression of simple epithelial keratins is lost from presumptive 
keratinocytes and restricted to periderm (Dale et al., 1985) and then lost 
altogether from skin as the periderm is lost following stratification. Post-
natally, keratins 8/18 expression remains in a variety of tissues where 
simple epithelial lining is present, such as colon, kidney, pancreas, salivary 
glands, liver and placenta (Moll et al., 1982). Aberrant keratin 8/18 
expression in adult skin can be seen in malignancies such as squamous cell 
carcinoma (Markey et al., 1991, Wu and Rheinwald, 1981) 
On the contrary, the authors reported only 20% positivity for the expression 
of basal keratin 14 (Aberdam et al., 2008). Further maturation to keratin 
14-positive cells from the keratin 18-positive ectodermal precursors, 
however, was achieved by transduction with a lentivirus expressing &Np63 
(Aberdam et al., 2008). Spontaneous keratin 14 expression was also 
observed when the ectodermal precursor population was seeded onto a 
HaCaT (human keratinocyte cell line)-derived ECM (Aberdam et al., 2008). 
Therefore, the first objective of this set of my experiments was to adapt and 
replicate the direct co-culture with PA6 cells for hESC line KCL-002 and 
promote further differentiation to keratin 14-positive epidermal precursors 
without the use of viral constructs. Optimization of the protocol was 
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required because both the spontaneous and lineage-specific differentiation 
potential varies among different hESC lines due to a variety of factors such 
as the derivation method, embryo quality and culture conditions (Allegrucci 
and Young, 2007, Skottman et al., 2005). For this purpose, different direct 
co-culture methods were evaluated by morphological criteria. In order to 
promote epidermal differentiation towards keratin 14-positive cells, 
ectodermal progenitors obtained at day 14 were selected for their rapid 
adhesion to type IV collagen (Dong et al., 2007) and subcultured in DKSFM 
(Invitrogen) for a further week. It was then hypothesized that PA6 CM in 
combination with BMP-4 can efficiently direct hESCs towards epidermal 
cell lineages. This hypothesis relies on the assumption that growth factors 
secreted by PA6 CM could promote the same level of SDIA as intact PA6 
cells and, in combination with BMP-4 and type IV collagen, could 
sufficiently induce epidermal differentiation of hESCs. To test this 
hypothesis the effects of a) pooled PA6 CM and b) indirect co-culture method 
using permeable support Transwell® Systems (Corning) were examined. 
 
5.1.4 Indirect co-culture studies 
Haematopoietic (Tian et al., 2004), osteogenic (Tong et al., 2007) and 
chondrogenic (Vats et al., 2006) differentiation of hESCs and pancreatic 
differentiation in mouse ESCs (Uroic et al., 2010) have been successfully 
achieved with permeable support Transwell Systems. These permeable 
supports allow cells to be grown in a polarized state in vitro and permit the 
uptake and secretion of molecules on both basal and apical cell surfaces, 
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thereby replicating metabolic activities in a more natural fashion. In 
indirect co-culture the two cell types are grown in different compartments of 
a Transwell System separated by a microporous 0.4!m membrane (Figure 
25,. Polyester membrane is microscopically transparent, thus allowing 
assessment of cell viability under a phase-contrast microscope. The 
advantage of an indirect co-culture method over PA6 CM alone is that the 
permeable support of a Transwell insert can continuously provide 
undifferentiated hESCs with higher amounts of newly-synthesized factors. 
In addition, even though the pore size would not allow any direct contact 
between the two cell types, some contribution of adhesion molecules, 
integrins, and other cell-surface proteins on the stromal PA6 cells may still 
stimulate important activation pathways. 
The overall goal of this set of experiments was to evaluate and compare the 
efficiency of epidermal differentiation of hESCs induced by SCID exerted by 
PA6 cells using two different methods, the first one relying on PA6 CM 
alone (Figure 26B) and the second utilizing an indirect co-culture method 






Figure 25 Indirect co-culture of hESCs and PA6 stromal cells in the 
Transwell System.  
A: Schematic representation of indirect co-culture using the Transwell System. hESCs are 
seeded in the lower compartment at the bottom of the well. PA6 cells are seeded onto the 
Transwell insert in the upper compartment. Microporous 0.4!m membrane separates the 
two compartments; B: Six-well plate with Transwell inserts; C: Electron photomicrograph 
showing the structure of a 0.4!m polyester pore. B and C are taken from Corning Inc Life 




5.2.1 PA6 cell culture: maintenance and propagation 
PA6 cells (Riken Cell Bank, Ibaraki, Japan) were grown in cell culture 
flasks (Appleton Woods) at a density of 2x108 cells per 75cm% flask and 
cultured in DMEM (Invitrogen) supplemented with 10% FBS (PA6 culture 
medium). Approximately every 5 days, subconfluent (cca 80% confluency) 
cultures were passaged as follows. The medium was aspirated and the 
flasks were rinsed with Ca%B and Mg%B-free PBS (Invitrogen). TrypLE™ 
Express (Invitrogen) was added to the flasks and incubated for 5min at 
37°C. After that, PA6 culture medium was added and the cell aggregates 
were broken down by gentle pipetting. The cell suspension was then 
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transfered into a 15ml conical tube and centrifuged at 400g for 5min. The 
medium was aspirated and the pellet resuspended in PA6 culture medium 
according to the desired split ratio. Cells were grown in a 37°C incubator at 
5% CO? until confluent. 
 
5.2.2 Preparation of PA6 CM 
For PA6 CM preparation, subconfluent (cca 80%) cultures of PA6 cells were 
used. These cultures were obtained by plating 2x108 cells per 75cm% flask 
and growing them for 5 days in PA6 culture medium. CM was prepared by 
incubating subconfluent PA6 cells in 85% DMEM:Ham’s F-12 medium (1:1) 
(Invitrogen) and 15% Ko-SR (Invitrogen) for 24 hours. Pooled PA6 CM were 
filtered to remove cell debris and stored at -20°C for a maximum of 2 days 
before use. 
  
5.2.3 Preparation of PA6 feeder layers 
PA6 cells were seeded at 3x107 cells per well in collagen type I-coated 24-
well plates and allowed to attach overnight.  
Fixation with 4% PFA was done as follows. Plates were rinsed with PBS and 
500µl of 4% PFA per well was added for 10min at room temperature. Plates 
were then rinsed twice with PBS before seeding hESCs. Mitomycin C 
treatment: 500µl of mitomycin C (Sigma) diluted in DMEM:Ham F-12 (1:1) 
(Invitrogen) to a concentration of 10µg/ml was used per well. The plates 
were incubated for 3 hours at 37°C and rinsed thoroughly with PBS (three 
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times) before seeding hESCs. In the case of live co-culture, hESCs were 
seeded directly onto PA6 feeders. Undifferentiated hESC colonies were 
passaged enzymatically, as described previously (section 2.2.5) and seeded 
at a density of 10x10( cells per cm% for all experiments. 
 
5.2.4 Direct co-culture differentiation 
The timeline of the direct co-culture differentiation is outlined in Figure 
26A. Undifferentiated hESC colonies were passaged enzymatically using 
dispase and seeded at a density of 15x10( cells per well in 24-well plates. 
The colonies were cultured in 84% DMEM:Ham’s F-12 medium (1:1) 
(Invitrogen), 15% Ko-SR (Invitrogen), 1% nonessential amino acids 
(Invitrogen), 0.1mM $-mercaptoethanol (Invitrogen) for 3 days. At day 4, 
0.5nM human recombinant BMP-4 (R&D Systems) was added to the culture 
medium for a further 3 days. At day 7, BMP-4 was removed, and cells were 
cultured for one week in differentiation medium composed of 60% DMEM, 
30% Ham’s F-12 medium, and 10% FBS, supplemented with 5µg/ml insulin, 
0.5µg/ml hydrocortisone, 50µg/ml ascorbate, and 10ng/ml recombinant 
human epidermal growth factor. The putative ectodermal precursors 
obtained at this stage were selected for their rapid adherence to type IV 
collagen (described below) and further expanded in DKSFM (Invitrogen). 
The differentiation protocol was independently repeated 3 times with hESCs 






Figure 26 Schematic representation of differentiation protocols described in 
this chapter, relying on SDIA of the PA6 cell line.  
A: Direct co-culture method; B: PA6 CM method; C: Indirect co-culture method 
MMC- mitomycin C; CM- PA6 conditioned medium; CIV- type IV collagen; DKSFM- 
Defined Keratinocyte Serum Free Medium 
 
5.2.5 Rapid Adhesion Enrichment method 
Type IV collagen from human placenta (BD) was reconstituted to a stock 
concentration of 1.0mg/ml in 10mM acetic acid. The reconstituted solution 
was allowed to dissolve for 3-5 hours at 4°C, swirling occasionally. For 
coating, type IV collagen solution was added to culture dishes to a final 
concentration of 5µg/cm2. The plates were incubated for 1 hour at room 
temperature and washed thoroughly with distilled H?O to remove any 
remaining acetic acid before plating the cells. The cells were allowed to 
attach for 15min at 37°C before being washed until there were no moving 
cells seen under the phase contrast microscope. After fresh DKSFM was 
added to the culture plates, the remaining cells were returned to the 
incubator and allowed to grow until further analysis. 
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5.2.6 PA6 CM-induced differentiation 
The protocol of differentiation using PA6 CM is shown in Figure 26B. 
Undifferentiated hESCs were passaged enzymatically and seeded onto type 
IV collagen-coated plates at the density described above. The cells were 
grown in PA6 CM alone for 3 days with daily media changes because of 
possible degradation of secreted factors. At day 4, 0.5nM human 
recombinant BMP-4 was added to the culture medium. At day 7, BMP-4 was 
removed, and cells were cultured for one week in the differentiation 
medium, as described in direct co-culture method. At the end of this stage, 
ectodermal progenitors were expanded as described in the “Rapid adhesion 
enrichment” method section 4.2.5 and allowed to grow for a further week 
before being fixed in methanol or 4% PFA for immunofluorescence analysis. 
The differentiation protocol was independently repeated 3 times with hESCs 
at different passage number (n=3 biological replicates). 
 
5.2.7 Indirect co-culture differentiation using Transwell® 
Systems 
The indirect co-culture protocol outline is shown in Figure 26C. PA6 cells 
were collected by trypsinization and seeded onto polyester 0.4µm Transwell 
insets (Corning, supplied by Appleton Woods) in 6-well plates with insert 
membrane growth area of 4.67cm2  (Figure 25). PA6 cells were seeded at a 
density of 2,000/cm2 in 1.5ml of PA6 culture medium and allowed to adhere 
overnight. Two days prior to adding the PA6-containing Transwell inserts, 
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hESCs were enzymatically passaged onto type IV collagen-coated 6-well 
plates and cultured in hESC medium. After the addition of the inserts, the 
medium was changed to DMEM:Ham’s F-12 (1:1) (Invitrogen), 15% KSR 
(Invitrogen) medium. After 3 days, 0.5nM BMP-4 was added and media 
changes were performed daily for a further 3 days. At day 7, Transwell 
inserts were discarded and differentiating cells were cultured for a further 
week in differentiation medium, as described previously. At that point, the 
putative epithelial sheets were subcultured on type IV collagen (as 
described in “Rapid adhesion enrichment” method section 4.2.5) and 
maintained for a further week prior to immunocytochemical analysis and 
flow cytometry and RNA extraction. 
The differentiation protocol was independently repeated 3 times with hESCs 
at different passage number (n=3 biological replicates). 
 
5.2.8 Immunocytochemistry 
In order to examine the expression of epidermal-associated proteins, cells at 
different time points of differentiation were fixed and processed for 
immunocytochemistry. At each time point 3 wells of a 24 well plate were 
randomly chosen for immunocytochemical analysis (3 technical replicates). 
Fixation was performed with ice-cold methanol at 4°C for 10min, which 
allows for simultaneous permeabilization of the cell membrane. For "6-
integrin staining, permeabilization of the cell membrane was not employed 
and the cells were fixed with 4% PFA for 10min at room temperature. The 
protocol was then as described in section 2.2.7. Primary antibodies used in 
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this chapter are detailed in Table 14. Secondary antibodies are described in 
section 2.2.7. Figure 34 shows representative images for no primary 
antibody negative controls for antibodies used in this chapter. 
Table 14 Primary antibodies used in Chapter 5. 
 
5.2.9 Quantification of immunofluorescence data  
Quantification of immunofluorescence data was carried out by counting cells 
showing a positive fluorescence signal for keratin 14 in 3 independent fields 
chosen at random containing 100 cells at two time points, day 14 and 21. 
Data are presented as percentage of cell numbers in relation to the total 
number of DAPI-positive cells. Quantification was carried out in 3 
independent experiments. Values are presented as mean ± Standard Error 
of the Mean (SEM). An inferential error bar was used in this analysis in 
order to more accurately interpret the data. SEM= SD/)n and represents a 
measure of how variable the mean will be, if the study is repeated many 
times. An unpaired two-tailed Student’s t-test was used to analyze data for 
statistical significance for keratin 14 protein expression between two 
differentiation protocols at two time points. Graphs and analysis were 
Antibody Supplier Host Species 
reactivity 





Covance Rabbit Human, 
Mouse 
IgG 1µg/ml Intracellular 
Anti-
Keratin 5 
Covance Rabbit Human, 
Mouse 








Abcam Mouse Human IgG2b 1µg/ml Transmembrane 






IgG 1µg/ml Intranuclear 
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generated with GraphPad Prism (Version 5) Software. A p value < 0.05 was 
considered to be statistically significant. 
5.2.10 Indirect Flow cytometry for keratin 14 staining 
The cells were harvested by trypsinization using TrypLE Express 
(Invitrogen) and centrifugation at 300g for 5min. The cell suspension was 
adjusted to a concentration of 0.5-1x108 cells/ml in ice-cold Flow Cytometry 
(FC) buffer (1% BSA/PBS) and 100µl of cell suspension was added to each 
sample tube. Polystyrene round-bottom 12x75 mm Falcon tubes (BD) were 
used for cell staining. A minimum of 107 cells/per sample was analyzed. To 
fix the cells 100µl of 4% (v/v) PFA in PBS was added to each sample tube 
and kept for 10min at 4°C. The cells were then washed with 2ml FC buffer 
at 500g for 5min. The supernatant was then poured off leaving 
approximately 100µl volume containing the cell pellet. For intracellular 
keratin staining, each sample was permeabilized with 500µl ice-cold 0.1% 
Triton-X 100/PBS and kept on ice for 20 min. The samples were then 
washed with 2ml FC buffer at 500g for 5min. The cells become more 
buoyant after permeabilization and much care had be exercised to maintain 
the volume of cells. The supernatant was poured off and 1µg of pre-diluted 
primary rabbit anti-keratin 14 antibody (Covance, PRB-155P) in 20µl FC 
buffer was added to each sample. The antibody dilutions were made using 
3% BSA/PBS. The tubes were vortexed and incubated for 45min at room 
temperature. The samples were then washed with 2ml FC buffer at 500g for 
5min. The supernatant was poured off and 1µg of pre-diluted Alexa-Fluor 
488 labelled secondary antibody (Invitrogen) in 100µl FC buffer was added 
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to each sample. The tubes were vortexed and incubated for 45min at room 
temperature in the dark and then washed with 2ml FC buffer at 500g for 
5min. The supernatant was poured off and the cell pellet was resuspended 
in 500µl acquisition buffer composed of 1% BSA and 0.1% (w/v) sodium 
azide in PBS. The cells were kept on ice until analysis. The data were 
acquired using a BD FACSCanto™ II Flow Cytometer (BD, Oxford) within 
12 hours. 
An unstained control with no primary or secondary antibodies was used as a 
negative control to determine background autofluorescence. Unstained cells 
were resuspended and washed, as described for stained samples. This 
control was used to set the voltage level for the scatter and fluorescence 
channels. 
Undiffrentiated hESCs (day 0 of differentiation) served as a negative 
control. NHKs were used as a positive control to set up cytometer alignment 
and to remove spectral overlap. 
 
5.2.11 Quantitative PCR 
A detailed protocol is described in section 2.2.8. RNA samples were collected 
at day 7, 14 and 30 of differentiation from 3 independently performed 
experiments (n=3 biological replicates). In addition, for all genes of interest, 
quantitative PCR was performed with cDNA from undifferentiated KCL-002 
hESC colonies. Copy numbers of all genes of interest were expressed as a 
ratio against GAPDH copy numbers and then extrapolated against copy 
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numbers in undifferentiated hESCs, which were taken to equal 1. The 
Primer3 website (http://frodo.wi.mit.edu/) was used to design the primers. 
The optimal annealing and extension temperature of the DNA Polymerase 
contained in the SYBR® Green PCR Master Mix (Roche) is 60°C, hence 
primers had to be chosen that were compatible with reagents to be used. 
Primers were designed with a maximum product size of 250 base pairs (bp). 
Specificity of the primer pairs for relevant genes was verified by performing 
nucleotide alignment searches using BLAST. All primers pairs were 
obtained from Sigma. The primers and positive cDNA samples for standard 
curve derivations are shown in Table 15. 
 
5.2.12 Population Doubling assay 
Putative keratinocyte precursors (pKPCs) obtained at day 25 were 
subcultured on type IV collagen-coated 6-well plates (BD Biosciences) in 
DKSFM at a density of 5,000 cells per well. The cells in the duplicate plates 
were harvested and counted every 24 hours for 25 days and the results were 
plotted on a log-linear scale.  
The population-doubling time was determined by identifying a cell number 
along the exponential phase of the curve, tracing the curve until that 





Gene Acronym Primer sequence Tm (°C) Positive control cDNA 






Whole human skin 
Keratin 18 KRT18 Forward: 





Whole human skin 






















Table 15 Primers used in quantitative PCR reactions in co-culture set of experiments.  
Tm = melting temperature. * These cDNA samples were used to derive standard curves for 







5.3.1 Direct PA6 co-culture supports KCL-002 differentiation 
into early epidermal precursors 
5.3.1.1 Comparison of direct co-culture methods using 
morphological criteria 
The rationale behind comparing different co-culture methods was to 
establish which approach most efficiently preserves the viability of hESC 
colonies, while still supporting a satisfactory level of SDIA promoted by PA6 
stromal cells. The results are presented in Figure 27. The morphology of 
hESC colonies suggested that the fixation method was too aggressive for the 
KCL-002 cell line and that the residual PFA had toxic effects on hESCs, 
resulting in increased cell death. Live co-culture also had detrimental effects 
on hESCs proliferation. In general, live co-culture is sub-optimal due to the 
increased difficulty of separating of potential epidermal precursors from 
PA6 feeders. Mitomycin C-treated PA6 feeder layers appeared to be the 
most effective in maintaining survival and proliferation of hESCs. 
Therefore, for my subsequent experiment mitomycin C-treatment of PA6 
cells was chosen as the preferred co-culture method. 
Having chosen the method for direct co-culture differentiation approach, the 






Figure 27 Comparison of different methods for direct co-culture of the KCL-
002 hESC line with the PA6 stromal cell line based on morphological criteria 
at 2 time points: day 4 (time point 1) and day 7 (time point 2).   
The top horizontal panel shows the three methods tested: fixation with 4% PFA (A), 
inactivation with mitomycin C (B) and live co-culture (C). 1A and 2A: In 4% PFA treated 
PA6 feeder-layer apparent toxic effects on KCL-002 hESC colonies resulted in icreased cell 
death; 1B and 2B: Mitomycin C inactivation of PA6 cells appears to encourage hESC 
colony growth and expansion; 1C and 2C: Live co-culture with PA6 feeders is detrimental 
to hESCs with decreased cell surivival and proliferation. Scale bar=100µm. 
 
5.3.1.2 Expression of epidermal markers 
In order to assess the ability of the KCL-002 hESC line to undergo 
epidermal differentiation during direct co-culture with the PA6 stromal cell 
line, differentiating colonies were tested for the presence of keratins by 
immunocytochemistry. Immunofluorescence analysis at day 14 showed that 
the colonies were positive for simple epithelial keratin 18, while some basal 
keratin 5 expression was also observed (Figure 28). This suggests that the 
early ectodermal precursors have started developing into a more defined 
epidermal population. Following enrichment and subculture, the expanded 
progenitors formed homogenous populations of pKPCs positive for keratin 
14 at day 21 (Figure 29). These results confirm that the KCL-002 hESC line 
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could undergo epidermal differentiation in response to SDIA of PA6 cells. 
The next aim was to see if growth factors within the medium conditioned by 
PA6 cells could exhibit a similar level of SDIA on KCL-002 hESCs. 
$
Figure 28 Morphology and expression of epidermal markers in colonies at day 
14 of the direct co-culture protocol. 
A: At day 14 elevated cells can be seen forming a meshwork-type pattern on top of 
inactivated PA6 stromal cells; B: No primary antibody negative control; C: Keratin 5 
expression (red) is occasionally detectable within the differentiating cell population; D: The 
majority of the cells (>80%) is strongly positive for keratin 18 staining (green); yellow 
staining indicates an overlap in keratin 18 (green) and keratin 5 (red) expression. The 




Figure 29 Homogenous population of keratin 14 positive pKPCs obtained at 
day 21 of the direct co-culture differentiation protocol. 
A: Morphology of pKPCS showing cells of similar size and shape; B: Immunocytochemistry 
of pKPCs shows that most cells stain brightly positive for keratin 14 expression. Insert 
shows a no primary antibody negative control. Scale bars= 50µm. 
 
5.3.2 Growth factors within PA6 CM enable KCL-002 
differentiation into early epidermal precursors 
5.3.2.1 Expression of epidermal markers 
In order to assess the ability of growth factors within PA6 CM to induce 
epidermal differentiation from hESCs, the presence of epidermal proteins 
was examined. When PA6 CM and type IV collagen were used as inducers of 
epidermal differentiation, similar results were obtained to the direct co-
culture method. At day 4 of the differentiation protocol, the majority of the 
cells are positive for simple epithelial keratin 18 and residual nuclear Sox-2 
expression was observed by immunofluorescence microscopy (Figure 30). At 
day 7, no Sox-2 expression was detected and the number of keratin 18 
positive cells had decreased significantly. In addition, a few cells expressing 
basal keratin 14 could be detected (Figure 30,-$ By day 14, small colonies 
expressing keratin 14 began to form with some colonies still expressing 
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keratin 18 (Figure 31). Most cells at this stage were also positive for "6-
integrin expression. Following the rapid adhesion enrichment approach, 
only cells expressing high levels of $1-integrin remained (Figure 32). These 
cells were also positive for keratin 14 and formed small colonies of highly 
proliferative cells. When cultured in DKSFM, these colonies expanded into 
epithelial-like colonies which stained positive for keratin 14. However, after 
2-3 passages, a high number of binucleated cells with altered structures and 
accumulation of autophagic vacuoles within cytoplasm was seen, indicating 
early cellular senescence (Figure 33). Consequently, the cells could not be 
expanded past this point. Therefore, an alternative approach relying on 
indirect co-culture was exploited. 
 
Figure 30 Expression of epidermal differentiation markers in cells treated 
with PA6 CM at different time points of differentiation  
1: Day 4; 2: Day 7.  
A: Sox-2; B: Keratin 18; C: Keratin 14. At day 4, Sox2 expression can still be detected (1A), 
cca 80% of cells stain positive for keratin 18 (1B), while no keratin 14 expression could be 
detected (1C). At day 7, no Sox-2 positive cells were seen (2A) and the percentage of keratin 
18 postive cells has decreased to cca 50% (2B), while a few cells expressing keratin 14 could 





Figure 31 Expression of epidermal differentiation markers in cells treated 
with PA6 CM at day 14 of differentiation protocol.  
A: Residual keratin 18 positivity could be detected in cca 10% of cells; B: Small colonies 




Figure 32 Morphology and expression of epidermal differentiation markers in 
a population of expanded pKPCs.  
A: Following the enrichment procedure, only rapidly adhering cells remain; B: These cells 
grow into much larger colonies; C: Rapidly-adhering cells form small colonies positive for 
keratin 14 (green); D: The resultant colonies are homogenously positive for keratin 14 
(green) with some keratin 18 (red) expression. Scale bar = 100 !m in A and B, and 50!m. in 




Figure 33 Cellular senescence within the population of pKPCs obtained in the 
differentiation protocol using PA6 CM.  
A: Severely altered morphology, accumulation of autophagic vacuoles (yellow arrow) and 
the presence of binucleated cells (red arrow) are indicative of early cellular senescence; B: 
Immunofluorescence analysis shows highly dysmorphic heterogenous keratin 14-positive 
pKPCs (green). Scale bar=50!m. 
$
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Figure 34 Representative images of no primary antibody negative controls 





5.3.3 Indirect co-culture protocol (Transwell Systems) supports 
efficient differentiation of KCL-002 towards epidermal cell 
lineages  
5.3.3.1 Morphology and expression of epidermal differentiation 
markers 
The efficiency of the indirect co-culture method was initially confirmed by 
morphology of the differentiating cells and immunofluorescence analysis for 
epidermal marker proteins. The cells displayed similar morphological 
characteristics as in the direct co-culture protocol (Figure 35). By day 4, 
colonies begin to flatten and a meshwork pattern of elevated cells was seen 
at day 7. When subcultured on type IV collagen, rapidly-adhering cells were 
seen forming uniform colonies which underwent further expansion. Large 
sheets of pKPCs positive for basal keratin 14 formed at day 14 as indicated 
by immunofluorescence analysis (Figure 36). However, these cells still 
maintained expression of simple epithelial keratin 18. Some holoclone-like 
colonies could be observed in those further cultures, which expressed 
cytoplasmic keratin 14 and nuclear transcription factor p63 (Figure 37). 
These pKPCs could be further expanded up to 5 passages while maintaining 
keratin 14 expression. In order to compare the efficiency of epidermal 
differentiation between the two protocols (PA6 CM vs. indirect co-culture) 




Figure 35 Morphology of differentiating hESC colonies in the indirect co-
culture method. 
A: Day 4- Colonies begin to flatten and elevated cells can be seen; B: Day 7- Meshwork-
type pattern of elevated cells is formed; C: Day 14- Following the enrichment procedure, 
rapidly-adhering cells form colonies composed of mostly round cells; D: Day 21- Large 





Figure 36 Expression of epidermal markers keratins 14 and 18 at day 14 of 
differentiation in the indirect co-culture protocol.  
A: Keratin 14 (green); B: Keratin 18 (red); C: Merged image; D: No primary antibody 
negative control. Scale bar=50!m. 
 
 
Figure 37 Some holoclone-like colonies can be detected by 
immunocytochemistry at day 18. 
A: These colonies stain positively for keratin 14 (red) and p63 (green); B: No primary 




5.3.3.2 Quantification of immunofluorescence data and 
statistical analysis 
Quantification of immunofluorescence positivity for keratin 14 protein 
expression was carried out to compare the efficiency of epidermal 
differentiation in PA6 CM vs. indirect co-culture methods (Figure 38). By 
Day 14, about 45% more keratin 14-positive cells were detected in indirect 
co-culture vs. the PA6 CM protocol (65% vs. 19%). By Day 21, approximately 
15% more keratin 14-positive cells were observed in indirect co-culture 
method compared to PA6 CM protocol (77.5% vs. 62%). Statistical analysis 
confirmed a significant difference between the efficiency of production of 
keratin 14 positive cells at both time points. Unpaired two-tailed Students' 
t-test gave the values p=0.0002 and p=0.0172 at days 14 and 21, 
respectively. These data suggest a high efficiency for the indirect co-culture 
differentiation protocol and therefore, epidermal marker changes in the time 






Figure 38 Comparison of PA6 CM vs. indirect co-culture protocol by 
immunofluorescence staining.  
Percentage of keratin 14-positive cells as calculated per 3 independent fields of 100 DAPI-
positive cells. n=3. Values expressed as mean ± SEM. A significant difference in keratin 14 
protein expression was observed when the two differentiation methods were compared. 
Unpaired two-tailed Students' t-test 
**** p<0.0001, **p<0.01 
 
 
5.3.3.3 Keratin 14 expression changes during indirect co-culture 
differentiation 
In order to validate the presence of keratin 14 protein in the differentiating 
cell population, flow cytometry analysis was performed at Day 0 
(undifferentiated hESCs negative control), 14, 21 and 30 of differentiation. 
This showed a progressive increase in keratin 14 expression (Figure 39). At 
Day 15, 55.59% were positive for keratin 14, while at days 25 and 30 the 
number of positive cells increased to 65.36 and 70.52%, respectively. It is 
worth noting, however, that keratin 14 expression at day 30 of 
differentiation still has not reached the same level as that in a positive 
control sample (NHKs) (Figure 39E), suggesting that not all the cells have 
obtained a basal epidermal phenotype. Nevertheless, the results obtained by 
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flow cytometry are in agreement with the data from the 
immunofluorescence analysis. The next step was to confirm the presence of 
epidermal markers at the mRNA level. 
 
Figure 39 Flow cytometry for keratin 14 expression during the course of 
differentiation in the indirect co-culture protocol.  
Vertical axis: Cell count. Horizontal axis: Alexa Fluor 488 intensity. A: Day 0 (negative 





5.3.3.4 Quantitative PCR results 
Quantitative PCR was performed at Day 7, 14 and 30 of differentiation in 
order to monitor efficiency of the differentiation protocol (Figure 40). Nanog 
was used to monitor the presence of undifferentiated hESCs, keratin 18 was 
used as a marker of early ectodermal differentiation, keratin 14 gene 
expression was assessed as a marker of a more mature epidermal fate, and 
involucrin as a marker of terminal differentiation. Gene expression for 
keratin 14 increased 17.03 fold at day 14 and 190.71 fold at day 30 when 
compared to undifferentiated hESCs. Keratin 18 expression increased 13.63 
fold by day 7 days and then went down progressively to 7.40 and 4.19 at 
days 14 and 30, respectively. In addition, some involucrin gene expression 
could be detected at day 30 (3.72 fold increase as compared to 
undifferentiated hESCs). Expression of the pluripotency gene Nanog went 
down by 0.527 at day 7 and disappeared completely in the later stages of 
differentiation. 
 
5.3.3.5 Population doubling assay 
A population doubling assay was carried out to establish the number of 
divisions that pKPCs were capable of undergoing before reaching 
senescence. The assay revealed that pKPCs could undergo approximately 9 
population doublings before reaching senescence (Figure 41). An 





Figure 40 Gene expression changes during the course of differentiation in the 
indirect co-culture protocol.  
The graphs show gene expression ratios for 4 genes of interest at 3 different time points as 
normalized to the appropriate gene expression ratio in undifferentiated hESCs. Expression 
of each gene was compared to housekeeping (GAPDH) gene expression. A: Nanog; B: 
keratin 18; C: involucrin; D: keratin 14. Values are expressed as mean±SD. n=3.  
 
 
Figure 41 Population doublings of pKPCs obtained in the indirect co-culture 
differentiation protocol plotted against the number of days in culture.  
Only 9 population doublings were observed before the cells entered senescence. 




5.3.3.6 Technical discussion 
A potential technical limitation of the differentiation study using PA6 
stromal cell line co-culture is the fact that pKPCs obtained were cultured 
under feeder-free conditions in the presence of DKSFM. It is pausible that 
these conditions were suboptimal for further expansion of epidermal 
progenitors. Therefore, an alternative method of culture on inactivated 3T3 
fibroblasts feeder-layer, as described by Rheinwald and Green, could have 




The results described in this set of experiments indicate that both direct co-
culture with PA6 cells and the growth factors secreted by the stromal cells 
can induce epidermal commitment of hESCs. The most efficient 
differentiation was achieved under indirect co-culture conditions with over 
75% of differentiated progeny expressing the basal keratin 14 marker. 
Therefore, the data demonstrated that SDIA promoted by mesenchymal 
stromal feeders and type IV collagen is able to mimic the effects of 
embryonic mesodermal stimulation and direct hESCs differentiation 
towards keratinocyte lineages in vitro. 
The first suggestion that SDIA promoted by stromal cell line could direct  
differentiation of ESCs towards epidermal fate came as a side result of a 
study aimed at inducing dopaminergic differentiation from ESCs (Kawasaki 
et al., 2000).  In that study, the authors showed that BMP-4 treatment could 
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successfully divert ectodermal differentiation promoted by SDIA to non-
neural ectoderm, resulting in expression of the epidermal markers E-
cadherin and keratin 14. 
 
5.4.1 Direct co-culture with PA6 stromal cells for inducing 
epidermal differentiation of hESCs 
The direct co-culture method has previously been successfully exploited to 
derive a homogenous population of ectodermal precursors from hESCs 
(Aberdam et al., 2008). In this approach, a stable somatic ectodermal cell 
population that was 100% positive for keratin 18 was obtained. The authors 
suggested that derivation of such a primitive ectodermal population is 
particularly useful for designing in vitro models to recapitulate early 
embryonic epidermogenesis and lineage specification and can also serve as a 
potential source for epidermal stem cells. However, lentiviral transduction 
with &Np63 construct was required to induce the production of putative 
epidermal progenitors, limiting the potential applicability for clinical 
therapy. 
More importantly, significant levels of mRNA for simple epithelial keratins 
have been well documented in hESCs (Bhattacharya et al., 2004, Liu et al., 
2006a, Cai et al., 2006, Schwartz et al., 2005). A meta analysis of hESC 
transcriptome (http://amazonia.montp.inserm.fr/) initially suggested that 
simple epithelial keratins are under-expressed in undifferentiated hESCs 
(Assou et al., 2007). However, later this finding was explained by the fact 
that during spontaneous differentiation large differentiated cells, typically 
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found at the borders of the colonies accumulate increased amount of 
keratins 8 and 18 (Maurer et al., 2008). The expression of keratins 8 and 18 
has been suggested to reflect the epithelial nature of undifferentiated 
hESCs and explain various characteristics of hESCs, such as the flattened 
epithelial phenotype of colonies (Maurer et al., 2008). Therefore, the overall 
efficiency of epidermal differentiation from hESCs cannot be accurately 
assessed by keratin 18 expression alone.  
Therefore, the first aim of my set of experiments was to adapt and replicate 
the direct co-culture method for the KCL-002 hESC line and evaluate the 
efficiency of epidermal differentiation by expression of basal keratin 14 as 
opposed to simple epithelial keratin 18. 
First, the existing protocol (Aberdam et al., 2008) had to be optimized for 
the KCL-002 hESC line, and morphological observations suggested 
mitomycin C treatment of PA6 cells was the method of choice for direct co-
culture with KCL-002 hESCs. Mitomycin C inactivation appeared to 
preserve viability of hESCs, while still enabling SDIA promoted by PA6 
cells. This observation is in agreement with previous reports on the effects 
of mitomycin C on SDIA (Vazin et al., 2008). When expression of the basal 
epidermal keratin 14 protein was evaluated by immunocytochemistry, a 
homogenous population of pKPCs was observed. Therefore, direct co-culture 
with mitomycin C-inactivated PA6 cells was able to induce efficient 
epidermal differentiation of the KCL-002 hESC line. 
However, despite producing keratin 14-positive cells, the PA6 co-culture 
method has some drawbacks. The main disadvantage of a direct co-culture 
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method is that it makes it difficult to isolate the potential target cells while 
maintaining their homogeneity. This in turn makes full characterization 
challenging. Furthermore, direct co-culture with animal cells renders any 
clinical application impossible and a feeder-free system would presumably 
be required for use in any human cell-based therapy.  
 
5.4.2 Conditioned medium enriched in PA6-secreted growth 
factors in promoting epidermal differentiation of hESCs 
Given the methodological concerns outlined above, the use of PA6 CM 
enriched in soluble growth factors secreted by stromal cells could offer a 
good alternative if efficient differentiation was achieved. Moreover, previous 
reports have suggested that PA6 CM might indeed promote the same level 
of SDIA as intact PA6 cells (Schwartz et al., 2005, Morizane et al., 2006, 
Vazin et al., 2009, Vazin et al., 2008, Swistowska et al., 2010). With regards 
to epidermal differentiation, growth factors secreted by the PA6 stromal 
cells, in combination with type IV collagen as substrate, were examined for 
their potential to induce epidermal differentiation from hESCs. As 
evaluated by immunocytochemisty, differentiating cells begin to express 
minimal amounts of keratin 14 protein by day 7, while by day 14 
approximately 20% of differentiating colonies expressed keratin 14 along 
with keratin 18 expression. This suggests that the ectodermal progenitors 
obtained at this stage have started to acquire a more defined epidermal fate. 
The cells enriched for $1-integrin expression continued to proliferate and by 
day 21 formed large epithelial-like colonies, almost two-third of which were 
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positive for keratin 14 expression. However, these pKPCs could only be 
maintained for up to 2-3 passages, after which the cells started showing 
signs of early senescence. Furthermore, these cells could not be expanded 
making any potential application impossible. 
Therefore, even though soluble growth factors within PA6 CM appear to be 
sufficient to induce some epidermal differentiation and production of keratin 
14-positive cells, the putative paracrine effects are insufficient for 
generation of a functional keratinocyte from hESCs. It is very likely that a 
lack of cellular signalling and/or incorrect temporal exposure to growth 
factors hinders the differentiation of highly proliferative precursors. 
 
5.4.3 Indirect co-culture method using permeable support 
Transwell systems as an inducer of epidermal differentiation 
from hESCs 
As an alternative method, indirect co-culture that relies on the use of 
permeable Transwell support Systems was evaluated for its potential to 
induce differentiation of hESCs towards epidermal lineages. Transwell 
Systems provide a more suitable microenvironment for differentiation as 
well as more accurate temporal induction with the secreted growth factors. 
During the course of differentiation the cells progressively acquire 
epithelial-like morphology. By day 7, undifferentiated colonies change 
morphology into much flatter and more spread-out looking cells. After a 
further 7 days elevated cells can be seen forming a meshwork-type pattern. 
When these cells were enriched based on rapid adherence to type IV 
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collagen and subcultured in DKSFM, the expanded population was mainly 
composed of round cells. 
Immunofluorescence analysis indicated that this approach allows for large 
keratin 14 and 5-positive epithelial sheets to be formed (77.5% positive for 
keratin 14). These sheets could be further subcultured on type IV collagen 
substrate and form holoclone-like colonies with some p63-positive cells, 
indicating the presence of highly proliferative epidermal progenitors. 
As discussed in Chapter 1, in order to achieve efficient epidermal 
differentiation of hESCs, it is vital to closely replicate epidermal 
morphogenesis. In vivo well-defined changes in gene expression accompany 
epidermal morphogenesis and stratification (Fuchs and Green, 1980). 
Therefore, gene expression during the course of differentiation was 
monitored by quantitative PCR and appeared to closely mimic epidermal 
morphogenesis in vivo. The expression of the keratin 18 gene, a marker for 
early ectoderm, increases during the first stages of differentiation, 
suggesting that hESCs have successfully acquired ectodermal fate, and then 
decreases steadily indicating that the cells have obtained a more defined 
epidermal fate. At the same time, the expression of the keratin 14 gene 
shows a steady increase and by day 30 it is increased 190-fold compared to 
undifferentiated hESCs. A progressive increase in keratin 14 expression 
was also confirmed by flow cytometry. However, flow cytometry data 
indicated that keratin 14 protein expression does not reach the same level 
as in human primary keratinocyte culture (70.5% in pKPCs versus 92.36% 
in primary keratinocytes). The expression of the involucrin gene at day 30 
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indicates that pKPCs have the capacity to undergo terminal differentiation. 
However, this expression could not be detected by immunocytochemistry 
suggesting that despite gene expression the monolayer culture prevents the 
protein from being assembled properly (Banks-Schlegel and Green, 1981). It 
has been suggested previously that in monolayer cultures, involucrin is only 
synthesized by large cells which would preferentially adopt a suprabasal 
position in response to stratification (Watt and Green, 1982). 
The pKPCs purified on the basis of high surface expression of $1-integrin, 
and as a result of that rapid adhesion to type IV collagen, were capable of 
forming actively growing colonies. This is in agreement with data obtained 
for NHKs enriched in putative epidermal stem cells in vitro (Dong et al., 
2007, Jones and Watt, 1993, Li et al., 1998). As discussed previously, an 
epidermal stem cell is defined by two fundamental qualities: extensive 
capacity for self-renewal and the ability to generate terminally 
differentiated cells. The pKPCs obtained in this differentiation system 
fulfilled both requirements for epidermal stem cells, since they formed 
actively growing colonies that contained, in addition to rapidly adhering 
cells, slowly adhering and involucrin-positive cells. Furthermore, the 
increased number of viable cells compared to direct co-culture and PA6 CM 
methods shows that indirect Transwell co-culture methodology provides a 
milieu that maintains cells adequately.  
Overall, the indirect co-culture method using Transwell inserts was 
significantly more efficient than PA6 CM alone in directing hESCs towards 
epidermal fate. The pKPCs produced under these differentiation conditions 
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displayed increased survival and proliferation potential as well as higher 
levels of keratin 14 protein. The efficiency of the indirect co-culture method 
in enabling hESCs differentiation towards epidermal lineages suggests the 
existence of co-ordinated signalling between the two cell types, which 
stimulates their normal growth and differentiation, as might be observed in 
vivo. 
 
5.4.4 Drawbacks of the indirect co-culture method 
However, despite the effectiveness of this method, pKPCs still exhibited a 
lower expansion potential than primary cultures: only 9 population 
doublings were observed before the cells became senescent. Several previous 
differentiation studies have reported a limited proliferation potential of 
hESC-derived keratinocytes with less than 15 population doublings 
(Aberdam et al., 2007, Green et al., 2003, Ji et al., 2006, Metallo et al., 
2008b). Normal human primary keratinocyte are known to undergo what is 
referred to as “p16 senescence,” which occurs abruptly and with ever 
increasing frequency during serial passage (Dickson et al., 2000, Rheinwald 
et al., 2002). It is well known that keratinocyte lifespan is determined by the 
timing of derepression of the CDKN2A gene, encoding the cell cycle 
inhibitors p16INK4A and p14ARF. Therefore, in order to become immortalized, 
primary keratinocytes must undergo mutations or be engineered to evade 
this mechanism by telomerase catalytic subunit (TERT) expression (Kiyono 
et al., 1998, Dickson et al., 2000, Rheinwald et al., 2002). However, it has 
been shown that hESC-derived keratinocytes cannot in fact be immortalized 
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in that way (Iuchi et al., 2006). This study was followed by a comprehensive 
analysis of three hESC-derived keratinocyte lines for morphology, marker 
expression, growth requirements, motility, and histogenic potential 
(Dabelsteen et al., 2009). The results suggested that despite sharing many 
features with human primary keratinocytes, hESC-derived epidermal cells 
display early p16INK4A , as well as hypermotility and incomplete 
differentiation properties, suggesting that these cells represent an 
incomplete or abnormal form of p63-positive lineage development. It is 
plausible that the lack of in vivo signalling hinders the differentiation 
process and leads to the production of seemingly abnormal phenotypes.  
Furthermore, even though the indirect co-culture method avoids any direct 
contact between the two cell types, it still relies on ill-defined animal-based 
components to induce epidermal differentiation from hESCs. Potential 
immunogenic factors such as sialic acid or Neu5Gc (Martin et al., 2005, 
Sakamoto et al., 2007) and animal pathogens are still able to pass through 
the pore of Transwell inserts and contaminate the resulting culture. 
Therefore, a defined and xeno-free epidermal differentiation method would 
be required to comply with GMP reluations for clinical applications. 
 
5.4.5 Divergent effects of PA6 stromal cells on ESCs 
differentiation  
Recently, mouse ESCs co-cultured with PA6 cells in the presence of BMP-4 
and retinoic acid were shown to undergo mesodermal differentiation with 
over 90% colonies robustly expressing desmin and nestin, both markers of 
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mesodermal lineages (Torres et al., 2012). The authors have suggested that 
BMP-4 activation of Smad-dependent genes in ESCs can be modulated by 
retinoic acid or co-culture with PA6 stromal cells to direct recruitment of 
activated Smads to specific master genes that control the mesodermal gene 
expression program. Interestingly, the authors reported that they could not 
detect any epithelial cell commitment (Torres et al., 2012). 
The differences in results described in this chapter and those by Torres et 
al. could be explained by intricate differences of methods that could 
influence the fine-tuning of Smad-dependent gene expression, thereby 
influencing stem cell fate. In this context, retinoic acid signalling was 
previously reported to control the duration of BMP-4-triggered 
phosphorylation of Smad1/5/8 (Sheng et al., 2010). It has been reported that 
retinoic acid stimulation of ES/PA6 co-cultures induced efficient 
differentiation of ESCs into spinal cord cell progenitors (Wichterle et al., 
2002). On the other hand, retinoic acid stimulation was shown to induce the 
differentiation of ESCs into mesenchymal and skeletal muscle cells when 
the cells are differentiated as embryoid bodies (Kawaguchi et al., 2005, 
Kennedy et al., 2009). Similarly, BMP-4 was also reported to synergise with 
Activin A to induce the formation of mesendoderm (Vallier et al., 2009). 
Therefore, it is possible that the choice of a particular cell fate is controlled 
by cross-talk between BMP-4-, retinoic acid- and SDIA-activated signalling 
pathways and depends on both the concentration and temporal arrangement 
of these factors. Accordingly, a recent study, which described derivation of 
functional melanocytes from hESCs using BMP-4 and ascorbic acid 
treatment, also evaluated the effect of varying concentrations of BMP-4 on 
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the engagement of hESCs at the earliest stage of cell commitment (Nissan 
et al., 2011). It was shown that the highest concentration (5–0.5µM) directed 
the towards epithelial lineages, while intermediate (0.02–0.004µM) and the 
lowest (0.004-0.0008µM) concentrations led to generation of neural crest and 
neural cells, respectively. In support of this observation, the study described 
in this chapter showed that when high concentration of BMP-4 was applied 
during the earliest stage of differentiation induction, hESCs could be 
directed towards epithelial cell lineages and produce Keratin 14 positive 
epidermal progenitors. 
$
5.4.6 Conclusion and future directions 
The results described in this chapter demonstrate that the sequential 
contribution of mesenchymal inducers can replicate in vitro the effects of 
embryonic mesodermal stimulation and encourage epidermal differentiation 
from hESCs. SDIA promoted by growth factors secreted by PA6 cells can 
direct hESCs towards ectodermal lineages, while BMP-4 is able to 
antagonize neural fate, leading to development of non-neural ectoderm. 
Subsequent induction with type IV collagen and appropriate culture 
medium encourages further differentiation to epidermal precursors. 
Despite the efficiency of this method, several drawbacks hinder its clinical 
potential. Therefore, alternative methods should be exploited. Such methods 
should be able to replicate normal epidermal morphogenesis by mimicking 







Extracellular matrix produced by normal human dermal fibroblasts has the 
potential to serve as an efficient inducer of epidermal differentiation by 
mimicking the natural keratinocyte environment, i.e. basement membrane 
of human skin, in combination with appropriate differentiation conditions 
and induction medium. 
 
AIMS: 
1. Optimize the protocol for reproducible ECM production from HDFs 
and characterize the resulting matrix by immunofluorescence 
micriscopy. 
2. Adapt KCL-002 hESCs to grow on native de-cellularized ECM 
produced by HDFs and assess the expression of pluripotency-
associated proteins by immunofluorescence. 
3. Devise tissue culture conditions necessary to promote differentiation 
of pKPCs from undifferentiated hESCs; analyse the expression of 
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marker proteins to confirm progression of differentiation by 
immunofluorescence and flow cytometry and investigate the colony 
forming efficiency and proliferation of pKPCs produced. 
4. Compare the efficiency of HDF-ECM protocol to that of PA6 protocols, 





6.1.1. ECM as a niche for adult skin stem cells 
Adult stem cells, including the ones found in skin, reside within tissue-
specific niches, which maintain their stem cell fate (Scadden 2006; Morrison 
2008). As discussed previously, in epidermis, resident stem cells adhere to a 
specialized sheet-like form of the ECM, the BM. The components of BM 
function to maintain skin homeostasis by balancing the proportion of 
quiescent and actively proliferating cells. ECM is the non-cellular 
component present within all tissues and organs, which provides not only 
essential physical scaffolding for the cellular constituents but also plays a 
crucial role in tissue morphogenesis, differentiation and homeostasis. 
Although, fundamentally, the ECM is composed of the same constituents 
(i.e. water, proteins and polysaccharides), each tissue has an ECM with a 
unique composition and topology that is acquired during tissue development 
through dynamic and reciprocal interactions of various cellular components 
with the evolving microenvironment.  
In the skin, fibroblasts secrete and organize the ECM proteins, which 
provide tissue organization and structural support for keratinocytes, 
regulating cellular functions such as adhesion, migration, growth and 
survival (Buck and Horwitz, 1987, Geiger et al., 2001, Hynes, 1999). Skin 
BM is the fusion of two laminae, basal lamina, composed of the lamina 
densa and lamina lucida, and lamina fibro-reticularis (Paulsson, 1992). The 
lamina densa is a lattice-like structure, which is composed mainly of type IV 
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collagen. The lamina lucida is a region where hemidesmosome complex 
proteins congregate. It is transvered by anchoring filaments. The proteins 
and glycoproteins in this region include the "6 and $4 integrin subunits, 
type XVII collagen, and laminins (predominantly laminin-332) as well as 
tetraspanin and nidogen-entactin (Litjens et al., 2006, Margadant et al., 
2008). The lamina fibro-reticularis underlies the lamina densa and contains 
fine collagen fibrils and anchoring fibrils, which are composed mainly of 
type VII collagen (Sakai et al., 1986, Lunstrum et al., 1986). Fibronectin is 
also located in the DEJ (Couchman et al., 1990) and promotes adhesion and 
migration (O'Keefe et al., 1985) while inhibiting terminal differentiation 
(Adams and Watt, 1989). Basal keratinocytes are anchored to BM via 
integrins which bind ECM components via their extracellular domains: "2$1 
heterdimer is a collagen receptor, "3$1 and "6$4 predominantly bind 
laminin and "v$5 binds vitronectin (Watt and Hertle, 1994, Adams and 
Watt, 1991). Furthermore, there is a marked variation in ECM and integrin 
expression within different regions of the skin as well as at different 
developmental stages (Watt, 2002, Wilhelmsen et al., 2006, Sugawara et al., 
2008, Breitkreutz et al., 2009). This variation in turn creates distinct 
microenvironments that play a role in modulating the properties of different 
cell populations. It is well recognized that ECM creates an important niche 
for adult stem cells, not just in skin but also in other adult tissues (Hall and 
Watt, 1989, Scadden, 2006, Spradling et al., 2001, Watt and Hogan, 2000). 
As discussed previously, a high level of $1 integrin expression is a known 
marker of epidermal stem cells (Jones and Watt, 1993, Jones et al., 1995) 
and can successfully be used to enrich cell cultures for putative stem cells 
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(Dong et al., 2007, Jensen et al., 1999). Therefore, there is a growing 
appreciation that ECM is not inert scaffolding material but an active 
dynamic structure that plays a vital role in all aspects of skin function and 
homeostasis. 
Considering the importance of ECM in tissue development and maintenance 
in vivo, it is plausible that when provided with an appropriate environment 
that closely mimicks the natural skin stem cells niche, the pluripotent stem 
cells would successfully be guided towards epidermal differentiation. 
Clearly, the molecular composition of collagen and other coating matrices 
cannot fulfil this function in isolation.  
 
6.1.2. Biomolecular and biophysical characteristics of ECM 
The ECM is composed of two main classes of macromolecules: proteoglycans 
(PGs) and fibrous proteins (Jarvelainen et al., 2009, Schaefer and Schaefer, 
2010). The main fibrous ECM proteins are collagens, elastins, fibronectins 
and laminins (Alberts et al., 2007). PGs fill the majority of the extracellular 
interstitial space within the tissue in the form of a hydrated gel. Collagen is 
the most abundant fibrous protein within the interstitial ECM. In fact, up to 
30% of the whole body mass is constituted from collagens. Within ECM, 
collagens provide tensile strength, regulate cell adhesion, support 
chemotaxis and migration, and direct tissue development (Rozario and 
DeSimone, 2010). Although within a given tissue, collagen fibres are 
generally a heterogeneous mix of different types, one type of collagen 
usually predominates. Fibroblasts are known to deposit the matrix 
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immediately outside their cell membrane, with the synthesized fibre 
parallel to the major cell axis (De Wever et al., 2008). By exerting tension on 
the matrix, fibroblasts are able to organize collagen fibrils into sheets and 
cables, dramatically influencing the alignment of collagen fibres. The 
collagen fibre alignment, which in turn regulates cellular behaviour, is an 
important consideration. Fibronectin is closely involved in directing the 
organization of the interstitial ECM and also has a crucial role in mediating 
cell attachment and function. Fibronectin can unfold and stretch by cellular 
traction forces (Smith et al., 2007). This process exposes cryptic integrin 
binding sites within the fibronectin molecule, which in turn acts as an 
extracellular mechano-regulator and influences cellular behaviour (Smith et 
al., 2007). Furthermore, fibronectin is also important for cell migration 
during development and, in such a capacity, has been implicated in tumour 
metastasis (Rozario and DeSimone, 2010, Tsang et al., 2010). Thus, the 
tissue ECM is a highly dynamic entity that continuously undergoes 
regulated remodelling, whose precise orchestration is crucial to the 
maintenance of normal function (Egeblad et al., 2010, Kass et al., 2007). 
 
6.1.3 ECM as a mediator of growth factors signalling 
ECM acts as a reservoir of growth factors, which can be released as soluble 
factors to bind their receptors. Extracellular matrix-associated heparan 
sulphate PGs regulate the interaction of several heparin-binding growth 
factors with their respective receptors and, consequently, their biological 
activity (Schlessinger et al., 1995, Jonca et al., 1997). For example, heparan 
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sulphate PGs can function as an extracellular storage place for the heparin-
binding VEGF isoforms (Park et al., 1993). This binding establishes stable 
gradients of growth factors, and ECM degradation can then release these 
growth factors from solid to soluble phase. In addition, some growth factors, 
such as FGF, require binding to ECM (via heparan sulphate cofactor) prior 
to association with their actual signalling receptor (Mohammadi et al., 2005, 
Shi and Massague, 2003). Furthermore, growth factors can bind to ECM 
proteins themselves without the involvement of PGs (Iyer et al., 2007). Both 
fibronectin and vitronectin bind hepatocyte growth factor leading to 
enhanced cell migration (Rahman et al., 2005). Laminin contains multiple 
EGF-like domains, which can be released by proteolysis and, in soluble 
phase, bind to EGFRs and modulate its signalling (Panayotou et al., 1989). 
The key Dpp (a BMP homolog) -binding motif was identified in the C-
terminal domains of the two Drosophila collagen IV subunits (Wang et al., 
2008). ECM can also act as a storage of latent growth factors. The latent 
TGF-$–binding proteins interact with a number of matrix components 
including collagen, fibronectin and fibrillin, thereby incorporating the 
different TGF-$ isoforms into ECM in latent form (Olofsson et al., 1995, 
Unsold et al., 2001). This incorporation is necessary for the subsequent 
effective activation of TGF-$ through degradation of ECM proteins (Gleizes 




6.1.4 ECM in ageing, fibrosis and cancer 
The importance of ECM has been implicated in ageing (Callaghan and 
Wilhelm, 2008), fibrosis (Schultz and Wysocki, 2009) and tumour formation 
(Butcher et al., 2009, Levental et al., 2009). For example, ageing tissue is 
characterized by a thinning of the BM (Callaghan and Wilhelm, 2008). In 
addition, collagen fibres are inappropriately crosslinked which leads to 
tissue stiffening (Robins, 2007). This aberrant mechanical state can severely 
compromise ECM organization, and modify epithelial organization and 
function, potentially promoting age-related diseases such as cancer (Coppe 
et al., 2010, Freund et al., 2010, Sprenger et al., 2008). 
 
6.1.5 Commercial preparations of ECM 
Considering the importance of the ECM to so many fundamental cellular 
processes, extensive research has been devoted to developing a commercially 
viable ECM preparation that could closely mimic its in vivo counterpart. 
Purified preparations or mixtures of ECM proteins have been used to obtain 
2D monolayers (Kuschel et al., 2006). To address the issue of ECM rigidity, 
functionalized polyacrylamide gels crosslinked with reconstituted BM - 
generated from EHS mouse carcinoma (commercially available as 
Matrigel™), collagen type I, fibronectin or ECM peptides – has become a 
standard approach (Johnson et al., 2007, Pelham and Wang, 1997). Yet, 
none of these methods truly recapitulates the in vivo scenario in which ECM 
has a 3D architecture that can be easily remodelled. Type I collagen has 
some useful properties and can be combined with reconstituted BM, purified 
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laminin or fibronectin to reconstitute some of the biological aspects of 
normal and diseased interstitial ECM (Friess, 1998, Gudjonsson et al., 
2002). Moreover, type I collagen readily assembles into a mechanically tense 
network of fibrils that can be oriented, functionally modified, and 
enzymatically or chemically crosslinked and stiffened. Nevertheless, 
collagen gels are quite heterogeneous, and modifying their architecture 
changes their organization, pore size and ligand concentration, thereby 
complicating the interpretation of data generated from experiments 
conducted by using such a scaffold (Johnson et al., 2007). To overcome this 
issue, denuded ECM scaffolds from various tissues have been generated 
(Macchiarini et al., 2008). These scaffolds, when combined with colonies of 
seeded stem cells, can reconstitute normal tissues with reasonable fidelity 
(Lutolf et al., 2009). ECMs have also been isolated and extracted from 
various tissues, such as small intestine, skin (from cadavers), pancreas and 
breast (Rosso et al., 2005), and these ECMs have been used to engineer skin 
grafts (Badylak, 2007), enhance wound healing and to study tumour 
progression. Despite the enormous efforts, however, commercially available 
matrices still do not fully mimic the organizational features of native ECM. 
 
6.1.6 Matrix production from ECM proteins synthesized by 
human fibroblasts 
The goal is to obtain culture dishes entirely coated with a homogenous, 
naturally produced, BM-like matrix by allowing fibroblasts to produce and 
deposit their own ECM while avoiding any extraction or enzymatic 
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procedures that may alter or denature the “natural” native ECM 
constitution and molecular organization. Published methods have described 
the generation of 3D matrices from corneal endothelial and endodermal cells 
(Vlodavsky, 2001), and a similar approach was later applied to both 
established and primary fibroblast cell lines (Beacham et al., 2007, 
Klimanskaya et al., 2005). Fibroblasts require culture for several days at 
high cell density to generate 3D matrices and evolve “3D-matrix adhesions”, 
namely focal and fibrillar adhesions. The former enable firm linkage to 
relatively rigid substrates (Burridge and Chrzanowska-Wodnicka, 1996) and 
co-operate with the latter to generate fibrils from pliable fibronectin (Katz et 
al., 2000). The resulting matrices closely resemble in vivo mesenchymal 
matrices and are composed mainly of fibronectin fibrillar lattices. Arguably, 
such matrices enable more physiologically relevant cell-matrix interactions 
and signalling, and are therefore potentially superior to conventional 2D 
substrates (Cukierman et al., 2001).  
The phenotype of cultured fibroblasts is extremely important for the 
successful preparation of 3D matrix-coated dishes and should be closely 
monitored by cell morphology. The fibroblasts should be well-spread and flat 
under sparse culture conditions. Therefore, the cultures should not be 




6.1.7 HDF-produced matrix as a substrate for epidermal 
differentiation of hESCs 
In this chapter, it was hypothesized that ECM produced by normal HDFs 
could serve as an efficient inducer of epidermal differentiation by mimicking 
the natural keratinocyte environment, i.e. BM of human skin, in 
combination with appropriate differentiation conditions and induction 
medium. 
An additional consideration is that for hESCs culture ECM produced by 
HDFs has a distinct advantage over currently commercially available 
matrices, such as Matrigel (BD). Matrigel is an ECM proteins mixture 
secreted by EHS mouse sarcoma cell and, therefore, the culture of hESCs on 
this substrate cannot be considered fully xeno-free. Therefore, in order to 
further improve culture conditions of the KCL-002 hESC line, 
undifferentiated hESC colonies had to be adapted to grow on HDF-ECM. 
 
6.2 METHODS 
6.2.1 HDF culture 
HDFs were cultured in high-glucose DMEM (Invitrogen) with 10% FBS. 
Culture stocks were maintained at 80% confluence, and subcultured at a 
1:20 dilution approximately once a week. The medium was aspirated and 
the flasks were rinsed with Ca%B and Mg%B-free PBS (Invitrogen). TrypLE™ 
Express (Invitrogen) was added to the flasks and incubated for 5min at 
37°C. After that, culture medium was added and the cell aggregates were 
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broken down by gentle pipetting. The cell suspension was then transfered 
into a 15ml conical tube and centrifuged at 400g for 5min. The medium was 
aspirated and the pellet resuspended in the appropriate volume of culture 
medium according to the desired split ratio. Cells were grown in a 37°C 
incubator at 5% CO? until confluent. 
 
6.2.2 Plating HDFs for matrix deposition 
The cells were collected from a semi-confluent flask by trypsinization and 
resuspended in 10ml of matrix medium. The cells were counted using a 
haematocytometer, and the HDFs were seeded in 24 well plates at a density 
of 107 cells per 200mm% surface area. After 24 hours, the medium was 
replaced with fresh matrix medium containing 500µg/ml of L-ascorbic acid 
(tissue culture tested; Sigma). This addition was made because a high 
concentration of ascorbic acid after the cells have been plated can 
potentially increase the matrix thickness in primary cell cultures (Beacham 
et al., 2007). Ascorbic acid should be freshly prepared just prior to use as a 
1000# stock concentration of 50mg/ml in PBS and then further diluted with 
medium to yield a final working concentration, and then filter-sterilized 
prior to use. After 48hrs, the medium was replaced with fresh matrix 
medium containing 50µg/ml of ascorbic acid. Ascorbic acid degrades over 
time in culture, so a media change was performed every 48hrs for a further 
7 days. At this point matrices, should be at least 10µm thick. At this 
thickness, three-dimensionality should be achieved, and thus they are ready 
to be extracted. 
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6.2.3 Extraction of HDF-derived 3D matrices 
The medium was carefully aspirated and the plates were washed gently 
with PBS by touching the pipette against the dish wall. Pre-warmed 
extraction buffer was then added and the plates were placed at 37°C for 3-5 
min until no intact cells were visualized. The extraction buffer was 
composed of 0.5% (v/v) Triton X-100 and 20mM NH4OH (Sigma) in PBS. 
Cell lysis can be observed using an inverted microscope. PBS was slowly 
added to dilute the cellular debris. This should be carried out gently to 
prevent turbulence that can dislodge the freshly denuded matrix-layer from 
the surface. The diluted cellular debris was then cautiously aspirated 
making sure that the matrix remained hydrated at all times. The wash step 
was repeated twice. The matrix coated plates can be used immediately or 
covered with PBS containing antibiotics, sealed with Parafilm and stored for 
up to 2 weeks at 4°C. 
 
6.2.4 Immunofluorescence analysis to assess the protein 
expression in HDF-produced ECM 
To test for protein expression in the native de-cellularized matrices 
produced by HDFs, the plates were fixed with 4% PFA in PBS for 20min at 
room temperature. ECM is a scaffold mesh of proteins, therefore no 
permeabilization or blocking was necessary. The plates were then washed 
with PBS twice and incubated with primary antibodies for 1 hour at room 
temperature. At the end of this incubation two washes with PBS were 
performed and the plates incubated with secondary antibodies for a further 
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30min. Both primary and secondary antibodies dilutions were done in Ca%B 
and Mg%B PBS. Primary antibodies used in this chapter are outlined in Table 
16. One drop of ProLong Gold antifade reagent with DAPI (Invitrogen) was 
added to simultaneously mount and confirm the absence of nuclei in the 
HDF-ECM produced. To allow for visualization of immunofluorescent 
staining, glass coverslips (13 mm diameter; Scientific Laboratory Services) 
were put on top of the cells in the stained wells. The samples were 
visualised with a fluorescence microscope.  Images were taken with a CCD 
camera, and processed with Photoshop CS5 (Adobe). The immunofluorescent 





Table 16 Primary antibodies used Chapter 6.  








Anti-Keratin 14 Covance Rabbit IgG 1µg/ml Intracellular 
Anti-Keratin 5 Covance Rabbit IgG 1µg/ml Intracellular 
Anti-Keratin 18 Millipore Mouse IgG1 20µg/mL Intracellular 
Anti-Keratin 19 Millipore Mouse IgG1 5µg/ml Intracellular 
Anti-Involucrin 
(SY5) 
Sigma Mouse IgG1 1:100 Intracellular 
Anti-Integrin "6  Abcam Mouse IgG2b 1µg/ml Transmembrane 













Santa Cruz Rabbit IgG 4µg/ml Extracellular 
Anti-Oct3/4 (C-10) Santa Cruz Mouse IgG2b 2µg/ml Intranuclear 
Anti-Nanog Abcam Rabbit IgG 1µg/ml Intranuclear 













Anti-SSEA-4 DSHB Mouse IgG3 1:50 stock Extracellular 
Anti-Fibronectin Sigma Rabbit IgG 1:100 ECM protein 
Anti-Laminin-332 Sigma Rabbit IgG 1:50 ECM protein 
Anti-Collagen IV Sigma Mouse IgG1 1:500 ECM protein 












6.2.5 Adaptation of the KCL-002 hESC line for growth on HDF-
ECM as a substrate 
Undifferentiated colonies grown on Matrigel (BD) were enzymatically 
passaged using dispase, as described previously, and transferred onto native 
de-cellularized HDF-ECM. The cells were grown in mTeSR1 (Stem Cell 
Technologies) and the medium was changed every 2 days. Undifferentiated 
hESCs were grown for up to 3 passages before assessing pluripotency 
marker expression by immunocytochemistry.  
 
6.2.6 Immunocytochemistry for pluripotency marker proteins 
For each marker combination duplicate wells were fixed and stained 
(technical replicates). The immunocytochemistry protocol used for this 
purpose is outlined in detail in Chapter 2 (Section 2.2.7). Primary antibodies 
used in this chapter are described in Table 16. 
 
6.2.7 Alkaline phosphatase staining 
Endogenous alkaline phosphatase activity in hESC cultures was tested 
using the ELF detection assay (ATCC Stem Cell Centre, Teddington, UK), 
according to the manufacturer's instructions. Cleavage of the phosphatase 
substrate generates a very fine precipitate at the site of alkaline 
phosphatase activity. In this assay, the weak blue fluorescence of the 
substrate is converted to intensely fluorescent yellow-green precipitate at 
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the site of enzymatic activity. The excitation/emission of the reaction 
product is 345/530nm and the staining appears yellow-green against a blue 
background when visualized with a Hoechst/DAPI filter. 
hESCs grown on HDF-ECM were fixed with 4% PFA for 10min at room 
temperature and then rinsed in PBS. Permeabilization was done in 0.2% 
Tween-20 in PBS for 10min at room temperature and rinsed in PBS for 
10min. Following the washes, 50!l of the filtered diluted Phosphatase 
Substrate was added to the cells while at the microscope to monitor the 
progress of the reaction. The reaction was usually completed within 30 to 
90s and rarely required longer than 5min. The reaction is stopped by 
submerging the sample in wash buffer (PBS with 25mM EDTA and 5mM 
levamisole, pH 8.0) three times over 15min with gentle agitation. The 
samples were then mounted with the mounting medium supplied with the 
kit. Staining was visualized through a standard Hoechst/DAPI long pass 
filter set, which provides the appropriate UV excitation and transmits 
wavelengths greater than 400nm. With this filter set, the yellow-green 
signal appears very distinct against a blue background.  
 
6.2.8 HDF-ECM differentiation protocol 
The outline of the differentiation protocol is schematically represented in 
Figure 42. Undifferentiated colonies were dissociated with 1 mg/ml dispase 
for 5min at 37˚C, as described previously (section 2.2.5), and cells were 
seeded onto freshly made HDF-ECM at a density of 5-10x10( cells per cm%. 
The cells were grown in mTeSR1 for 4 days before switching to 
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differentiation induction medium (day 11 of differentiation protocol). 
Induction medium was composed of DMEM:Ham’s F-12 medium (at a 1:1 
ratio) (Invitrogen) supplemented with 1µM ATRA (Sigma) and 25ng/ml 
BMP-4 (R&D). ATRA dilutions were performed in DMSO to a stock 
concentration of 10mM. The medium was changed daily for 7 days before 
switching to DKSFM (Invitrogen). After a further 7 days (day 25 of 
differentiation protocol) the culture medium was aspirated and 
differentiated colonies were dissociated with 1mg/ml dispase for 3-5min at 
37°C. The dispase was then aspirated and replaced with DKSFM 
(Invitrogen). The epithelial-like sheets were scraped off with a cell scraper 
and centrifuged at 200g for 5min before being resuspended in DKSFM. The 
cells were replated on dishes pre-coated with type IV collagen and a rapid-
adhesion enrichment method was applied as described previously (section 
4.2.5). The resulting rapidly-adhering cell population was cultured for a 
further week in DKSFM before final analysis. 
The differentiation protocol was independently repeated 3 times with hESCs 
at different passage number (n=3 biological replicates). 
 
 
Figure 42 Schematic representation of the differentiation protocol using 




6.2.9 Subculture, cryopreservation and recovery of pKPCs 
The pKPCs obtained at day 32 of the differentiation protocol were further 
expanded in DKSFM. At this stage cells were subcultured enyzymatically, 
by incubating with TrypLE Express (Invitrogen) at 37°C for 4min. Following 
centrifugation at 300g for 5min, the cells were counted using a 
haemocytometer. The cells were then either seeded at a density of 10,000 
cells/cm2 on gelatin-coated tissue culture plates in DKSFM for further 
expansion, or cryopreserved by re-suspending 106 cells in 1ml of DKSFM 
10% FBS and 10% DMSO. The suspenson was aliquoted into labeled 
cryovials and stored at -80°C overnight before being transferred into a liquid 
nitrogen vapor tank. To recover pKPCs from liquid nitrogen, cryovials were 
quickly thawed in a 37°C waterbath until only a small frozen pellet 
remained. The cryovial was wiped with 70% ethanol to sterilize prior to 
opening. The contents were transferred into a 15ml conical tube and 5ml of 
pre-warmed DKSFM was added dropwise to the tube, gently mixing as the 
medium is added. The cells were centrifuged at 300g for 5min. The medium 
was aspirated and the pellet resuspended in 5ml of DKSFM. Following the 
cell count, 10,000 cells/cm2 were plated on gelatin-coated tissue culture 
plates in DKSFM. 
 
6.2.10 Immunocytochemstry for epidermal differentiation 
markers 
Immunocytochemistry was carried out at days 7, 14, 21 and 25 of the 
differentiation protocol, as described previously in Section 2.2.7. At each 
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time point 3 wells of a 24 well plate were randomly chosen for 
immunocytochemical analysis (3 technical replicates). Primary antibodies 
used in this chapter are outlined in Table 16. 
 
6.2.11 Quantification of immunofluorescence data and statistical 
analysis 
Quantification of immunofluorescence data was performed as described 
previously in section 5.2.9. Two-way Analysis of Variance (ANOVA) 
statistical test was used to compare 3 groups of parametric, unpaired data 
sets. Defining statistically significant differences between groups was 
achieved by applying the Bonferroni post-hoc tests to data analyzed by 
ANOVA. 
 
6.2.12 Direct flow cytometry for the "6-integrin subunit and 
keratin 14  
The cells obtained at day 32 of the differentiation protocol were harvested 
by trypsinization using TrypLE Express (Invitrogen), and centrifuged at 
300g for 5min. The cell suspension was adjusted to a concentration of 0.5-1 
x108 cells/ml in ice-cold FC buffer (1% BSA/PBS) and 100µl of cell 
suspension was added to each sample tube. Polystyrene round-bottom 
12x75mm Falcon tubes (BD) were used for cell staining. A minimum of 1 
x108 cells/per sample was analyzed. Surface antigen staining was performed 
first: as recommended by the supplier, a volume of 20µl of PE-conjugated rat 
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IgG2a anti-CD49f ("6-integrin) antibody (BD Pharmingen, 555736) was 
added per sample. The tubes were vortexed and incubated for 30min at 
room temperature in the dark. The samples were then washed in 2ml FC 
buffer at 300g for 5min. Prior to intracellular staining, the samples were 
fixed and permeabilized. To fix the cells, 100µl of 4% (v/v) PFA in PBS was 
added to each sample tube and kept at 4°C for 10min. The cells were then 
washed with 2ml FC buffer at 500g for 5min. The supernatant was then 
poured off leaving approximately 100µl of buffer containing the cell pellet. 
Permeabilization was done with 500µl ice-cold 0.1% Triton-X 100/PBS on ice 
for 20min. The samples were then washed with 2ml FC buffer at 500g for 
5min. A recommended volume of 10µl/per sample of FITC-conjugated mouse 
IgG3 anti-Keratin 14 antibody (Abcam, ab77684) was added. The tubes were 
vortexed and incubated for 30min at room temperature in the dark and then 
washed with 2ml FC buffer at 500g for 5min. The supernatant was poured 
off and the cell pellet was resuspended in 500µl acquisition buffer composed 
of 1% BSA and 0.1% (w/v) sodium azide in PBS. The cells were kept on ice 
until analysis and data was acquired using a BD Canto flow cytometer 
within 12 hours. 
Isotype controls were used to confirm that the primary antibody binding 
was specific and not a result of non-specific Fc receptor binding or other 
protein interactions. The following isotype controls were used: mouse IgG3 
FITC (BD Pharmigen, 556658) for anti-keratin 14 antibody and rat IgG2a 
PE (BD Pharmigen, 559317) for anti-CD49F antibody. Both isotype control 
antibodies were used at the same concentration (1µg/1 x108 cells) and under 
the same conditions as the test stain. 
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The BD™ CompBeads Sets Anti-Mouse Ig (552843) and Anti-Rat Ig 
(552844) were used as compensation controls. Compensation beads are 
polystyrene microparticles, which are used to optimize fluorescence 
compensation settings for multicolour flow cytometric analyses. The set 
provides two populations of microparticles: the anti-mouse/rat Ig * particles 
that bind any mouse/rat * light chain-bearing immunoglobulin, and the 
negative control (FBS), which has no binding capacity. When mixed together 
with a fluorochrome-conjugated mouse or rat antibody, the beads provide 
distinct positive and negative (background fluorescence) stained 
populations, which can be used to set compensation levels and more 
accurately establish corrections for spectral overlap for double-staining 
analysis.  
The beads were used as follows: 1 full drop (approximately 60µl) of the BD™ 
CompBeads Negative Control (FBS) and 1 drop of the BD™ CompBeads 
anti-mouse or anti-rat Ig beads were added to a tube containg 100µl of FC 
buffer. An optimal amount of each primary antibody to be tested was then 
added into an appropriate tube and incubated for 20mins at room 
temperature in the dark. Next 2ml FC buffer was added to each tube 
followed by centrifugation at 200g for 10min. The supernatant was 
discarded and the bead pellet resuspended in 500µl acquisition buffer. 
Gating was done on the single bead population based on FSC (forward-light 
scatter) and SSC (side-light scatter) characteristics. Flow rate was adjusted 
to 200 events per second. For each given fluorochrome-conjugated antibody 
dot plots were done as appropriate, i.e. an FL1 vs. FL2 dot plot was used to 
set compensation for FITC-conjugated anti-keratin 14 antibody. A quadrant 
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gate was placed such that the negative bead population was in the lower left 
quadrant and the positive bead population was in the upper or lower right 
quadrant, and the compensation values were adjusted until the median 
fluorescence intensity of each population was approximately equal. 
The BD™ CompBeads Negative Control (FBS) was used as a negative 
control to set up the flow cytometer voltage. 
 
6.2.13 Colony forming efficiency (CFE) assay 
The pKPCs obtained at day 25 of the differentiation protocol were harvested 
and plated at a density of 5000 cells/cm% in 3 wells of a 6-well plate coated 
with gelatin. The number of viable cells at the start of the assay was 
determined with Trypan Blue and counted in a haematocytometer chamber. 
The cells were grown in DKSFM with media changes performed every 48 
hours. After 7 days in culture, cells were stained with 0.25% crystal violet 
(Sigma). Colonies, defined as +50 cells, were counted. The colony-forming 
efficiency was calculated according to the following formula (Boyce and 
Ham, 1983): CFE=Number of colonies x 100/Number of live cells plated. 
CFE was calculated separately for each of 3 wells and the mean was 
calculated. The assay was performed in triplicate (technical replicates) on 
pKPCs obtained from 3 independent rounds of differentiation protocols (n=3 
biological replicates) and the results were compared to CFE of NHKs 
(positive control) using Students' t-tests. 
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6.2.14 MTT Proliferation assay 
Proliferation efficiency was calculated using a MTT assay. The MTT assay 
utilizes a colometric reaction secondary to succinate dehydrogenase activity 
in mitochondria and is a sensitive, reliable indirect measure of cell viability 
and proliferation (Mosmann 1983). Intracellular dehydrogenases of actively 
proliferating cells convert the yellow tetrazolium MTT to purple formazan. 
The optical density (O.D.) of the resulting formazan product can be easily 
measured and quantified. 
The differentiated cells at day 25 were seeded at a density of 5000 cells/ml 
in 96-well plates in 200!l DKSFM medium. After 48 hours 10!l of 5mg/ml 
MTT (Sigma) was added to each well and incubated at 37°C for 2.5 hours. 
The crystal formazan product was dissolved by adding 200!l DMSO (Sigma) 
and a further incubation for 15min. O.D. was measured at 570nm with an 
ELISA plate reader, using 620nm filter as a reference wavelength. The MTT 
assay was performed in triplicate (technical replicates) on pKPCs obtained 
in 3 independent rounds of the differentiation protocol (n=3 biological 
replicates). Negative controls were performed with empty wells. The results 
were then compared using Student's t-tests to those obtained with NHKs 






6.3.1. HDF-produced 3D ECM in vitro is similar in composition 
to BM in vivo  
To assess the quality and composition of native ECM produced by HDFs, 
and also to confirm the complete removal of cells from the resulting 
matrices, immunofluorescent analysis for skin BM-specific ECM proteins 
was carried out (Figure 43). Positive immunofluorescent staining revealed 
the presence of a dense meshwork of fibronectin fibres, numerous fine types 
IV and VII collagen fibrils, as well as type I collagen and laminin-332. DAPI 
was used to confirm the absence of HDF nuclei. Figure 44 shows the 
relevant positive and negative controls for characterization of HDF-
produced ECM by immunofluorescence. The next step was to adapt the 
KCL-002 hESC line to grow on these matrices as a substrate. 
 
6.3.2 KCL-002 hESC line maintains pluripotency on HDF-ECM 
To assess the pluripotency of KCL-002 hESC colonies grown on HDF-ECM, 
the cell morphology and expression of pluripotency marker proteins were 
examined. When cultured on HDF-ECM in the presence of mTeSR™1, 
undifferentiated KCL-002 colonies retained their typical undifferentiated 
morphology, notably displaying well-defined colony edges, a tightly packed 
colony and the absence of differentiated cells. The colonies tested positive for 
presence of pluripotency markers Oct-3/4, Tra 1-60, SSEA-4, Nanog and 
Alkaline Phosphotase (Figure 45). These results confirmed that KCL-002 
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hESCs could be cultured on HDF-ECM, providing a rationale for testing the 
efficiency of epidermal differentiation using this substrate. 
 
Figure 43 Characterization of HDF-produced ECM by immunofluorescence. 
A: Laminin-332 (red); B: Collagen type IV (green) and Collagen type I (red); C: Collagen 
type VII (green); D: Fibronectin (green). No HDF nuclei are observed in extracted matrices, 





Figure 44 Relevant controls for immunofluorescent analysis of HDF-produced 
ECM 
A: No anti-laminin 332 primary antibody negative control; B: No anti-collagen type IV 
primary antiody negative control; C: No anti-collagen type VII primary antibody negative 
control; D: No anti-fibronectin primary antibody negative control; E: Collagen type IV 
expression by HDFs prior to matrix extraction ; F: Laminin-332 expression by HDFs prior 
to matrix extraction. Nuclei of HDFs stain blue by DAPI. Scale bar=100!m. 
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6.3.3 Morphology and expression of epidermal markers during 
the course of differentiation protocol 
Epidermal differentiation, utilizing HDF-ECM as a natural substrate and 
BMP-4 together with ATRA, was initially evaluated by morphological 
observations and immunocytochemistry. After 7 days of differentiation 
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induction (Figure 46), the peripheral cells of each colony spread out greatly 
and became flattened, whereas more centrally located cells remained more 
tightly packed and appeared to be fast dividing, continuing to grow 
exponentially until the cultures became confluent. These colonies stained 
positively for extracellular desmosomal marker DSC 2 and cytoplasmic 
keratins 19, 5 and 14. Interestingly, the expression of keratins 5 and 14 was 
more intense in the peripheral cells. By day 25, large sheets of cells with 
more typical epithelial morphology could be observed (Figure 47). A few very 
large and flat cells could be seen at the edges of these putative epithelial 
sheets. Those cells were either only very dimly positive or negative for both 
keratin 14 and p63 expression. On the contrary, the central parts of the 
sheets displayed bright p63 positivity (Figure 47B). When the putative 
epithelial sheets were scrapped off and the cells with a higher replicative 
potential were selected by rapid adhesion to type IV collagen, some rapidly 
adherent cells formed compact colonies brightly positive for p63 
transcription factor expression, as well as keratin 14 (Figure 48). These 
colonies grew into large epithelial-like sheets and retained their morphology 
and keratin 14 and p63 markers expression (Figure 49). Further 
subcultures could be done on gelatin without loss of marker expression for 
another 5 passages. Furthermore, pKPCs could be cryopreverved and 
recovered without the loss of marker expression (Figure 50). These initials 
results suggested that the method was efficient in inducing epidermal 





Figure 45 Expression of pluripotency-associated markers in KCL-002 hESC 
colonies grown on HDF-ECM.  
A: Tra 1-60 (red) positive colony can be seen on fibronectin (green). DAPI nuclear staining 
(blue); B: Nuclear Nanog staining (green) and patches of laminin-332 (red); C: Alkaline 





Figure 46 Morphology and expression of epidermal markers after 7 days of 
induction (day 18 of differentiation). 
A: Morphology of a colony at day 18. The peripheral cells appear spread out and flattened, 
whereas centrally located cells remain tightly packed; B: Keratin 14-positive colonies (red) 
on type IV collagen (green); C: Keratin 5-positive cells (green) begin to appear at the 
periphery; D: Extracellular DSC 2 staining (red) and cytoplasmic keratin 19 (green). Nuclei 





Figure 47 Expression of epidermal markers and morphology of differentiating 
cells at day 25 before enrichment.  
A: Bright nuclear p63 staining (green) can be seen in the central parts of the putative 
epithelial-like sheets. The vast majority of cells are keratin 14-positive (red). Note that the 
large cells at the periphery are only dimly positive for both markers. DAPI nuclear staining 
(blue); B: High magnification of central p63-positive cells. C: No primary antibody negative 





Figure 48 Colony of enriched pKPC population at day 27.  
A: The colony displays an intense positivity for nuclear p63 (green) and cytoplasmic keratin 
14 (red); B: No primary antibody negative control; C: Morphological appearance of the 





Figure 49 Characterization of pKPCs at the end point (day 32) of 
differentiation.  
A: Many brightly p63- (green) and keratin 14-positive (red) cells can be seen. B: DAPI 
staining (blue) confirms the nuclear co-localization of p63. C: Keratin 5 staining (green). D: 
Morphology of epithelial-like sheets. Scale bar=100µm. 
$
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Figure 50 Characterisation of recovered pKPCs showing sustained marker 
expression. 
A: Keratin 5 positivity; B: Tightly packed colonies showing keratin 14 (red) and p63 (green) 
expression. Scale bar=50!m. 
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6.3.4 HDF-ECM protocol supports hESC differentiation into 
epidermal precursors 
In order to evaluate the efficiency of the HDF-ECM protocol, 
immunofluorescent data was quantified and compared to results obtained 
during PA6 stromal cell-induced differentiation (described in Chapter 3). 
The cells positive for keratin 14 were counted against the total number of 
DAPI-positive cells, and the following results were obtained (Figure 51). At 
day 18, 85.1±1.6% of cells were positive for keratin 14 protein expression. By 
day 25 that number increased to 91.7±2.3%. Statistical analysis confirmed a 
significant difference between the efficiency of production of keratin 14 
positive cells at both time points. Two-way ANOVA test and the Bonferroni 
post-hoc test revealed that the HDF-ECM protocol was significantly more 
efficient in producing keratin 14 positive cells compared to both PA6 CM 
and indirect co-culture differentiation protocols. The statistical difference 
after 7 days of induction gave p<0.0001 and p<0.001 in comparison with 
PA6 CM and Transwells protocols, respectively. After 14 days of induction, 
the p values were p<0.0001 and p<0.05 when compared to PA6 CM and 
Transwells protocols, respectively. 
The high efficiency of differentiation on HDF-produced ECM in the presence 







Figure 51 Comparison of epidermal differentiation induced by HDF-ECM vs. 
secreted PA6 growth factors by quantification of immunofluorescent data.  
Percentage of keratin 14-positive cells as calculated per 3 independent fields of 100 DAPI-
positive. n=3. Quantification was done at two different time points, 7 and 14 days post-
induction. Values expressed as mean ± SEM. Significant difference in keratin 14 protein 
expression was observed when the HDF-ECM differentiation method was compared to the 
two methods described in Chapter 3. **** p<0.0001, ***p<0.001, *p<0.05 
 
6.3.5 Expression of epidermal markers is sustained in expanded 
pKPCs 
To quantify the presence of epidermal markers "6-integrin and keratin 14, 
flow cytometry analysis was carried out (Figure 52). At passage 1 (day 32 of 
differentiation protocol), all of the pKPC cells were positive for keratin 14 
with 80.2% also positive for the "6-integrin subunit. When flow cytometry 
was repeated at passage 5, similar results were observed with all cells 
remaining positive for keratin 14 and 77.7% also expressing "6-integrin. 
These results indicate that a homogenous population of keratin 14-positive 
pKPCs is obtained at the end of the HDF-ECM induced epidermal 
differentiation protocol. Furthermore, this population retains epidermal 
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marker expression following passaging and expansion, thus indicating a 
high proliferation potential of the pKPCs obtained. In order to further 
assess the proliferation potential of the resultant pKPC population, 
functional clonogenic and MTT proliferation assays were conducted. 
 
6.3.6 CFE of pKPCs is lower than that of NHKs 
CFE was measured by the ability of a defined number of pKPCs plated to 
form viable colonies composed of a minimum of 50 cells. Cell viability was 
confirmed by staining with crystal blue dye, which binds to DNA. CFE 
assays were carried out in triplicate (n=3) on pKPCs obtained at day 32 in 3 
independent rounds of differentiation and compared to NHKs (Figure 53A). 
The values are presented as mean±SD. After 7 days of culture pKPCs 
formed 6.4±1.3 viable colonies vs. 10.6±0.6 in NHK cultures. Unpaired two-
tailed Students' t-test returned p=0.0453 indicating statistical significance 
(P<0.05) in the difference between the two values. 
 
6.3.7 pKPCs have a high proliferation potential  
Previous differentiation studies reported a low proliferation potential of 
ESC-derived keratinocytes (Aberdam et al., 2007, Green et al., 2003, Ji et 
al., 2006, Metallo et al., 2008b), therefore I sought to examine the potential 




The MTT assay is based on the capacity of mitochondrial dehydrogenase 
enzymes in living cells to convert the yellow water-soluble substrate 
tetrazolium bromide (MTT) into a dark blue insoluble formazan product. 
The optical density (O.D.) of the resulting product can be measured by 
ELISA plate reader at 570nm absorbance. MTT assay was carried out in 
triplicates (n=3) on pKPCs obtained at day 32 in three independent rounds 
of differentiation and compared to NHKs (Figure 53B). The values are 
presented as mean±SD. Unpaired two-tailed Students' t-test was used to 
evaluate statistical significance between the values obtained for pKPCs 
(0.2±0.03) and NHKs (0.2±0.03). The resulting p=0.1543 indicating no 
significant statistical difference between the two cell populations. 
The collective results described in this set of experiments indicate that when 
cultured on HDF-ECM, under appropriate differentiation-inducing culture 
conditions, hESCs can undergo efficient epidermal differentiation. 
 
Figure 52 Flow cytometry for keratin 14 and "6-integrin expression in pKPCs 
at passage 1 (P1) and passage 5 (P5). 
A: negative cells; B: "6-integrin-positive cells; C: Double positive for "6-integrin and 





Figure 53 Colony forming efficiency (A) and Proliferation efficiency (B) of 
pKPCs as compared to NHKs. 
Each assay was performed in triplicate on cells obtained from 3 independent repeats of the 
differentiation protocol (n=3). Values are presented as mean±SD. CFE, Colony forming 
efficiency. O.D., Optical Density.  *p<0.05, ns-not significant i.e. p>0.05. 
 
6.3.8 Technical discussion 
A great improvement in the characterization of the HDF-produced ECM 
would be to perform a protein gel electrophoresis in order to visualize the 
proteins present. It is important to remember, however, that some proteins 
known to be major constituents of the ECM are highly glycosylated. For 
example, N-glycosylation of fibronectin is known to protect the protein from 
proteolytic degradation (Bernard et al., 1982). Therefore, the extracted ECM 
must be treated with glycosidase to remove these covalent modifications. 
The enzymatically digested proteins can be extracted from the surface of the 
culture plate and analysed by SDS-PAGE or two-dimentional 
electrophoresis. An important consideration is that when dealing with 
complex samples, such as HDF-ECM, one-dimensional SDS-PAGE does not 
allow for differential analysis of protein expression, since each band 
revealed on the gel may contain multiple distinct proteins (Mukhopadhyay 
et al., 2001). On the other hand, two-dimensional gels only allow for 
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visualization of proteins of less than 150kDa (Bumke et al., 2003, Lim and 
Bodnar, 2002), and it is well known that several matrix proteins possess 
molecular masses above this value and their masses are often further 
increased by numerous glycosylation events. Therefore, it would be 
beneficial to identify individual proteins by mass spectrometry, a highly 
sensitive method that allows for the efficient identification of proteins in 
complex mixtures (Peng and Gygi, 2001). 
Another technical limitation of this study is the fact that the resulting 
pKPC population was analysed by flow cytometry based on the expression of 
"6-integrin subunit, a commonly used EpSC marker (Li 1998), which is also 
highly expressed in undifferentiated hESCs (Xu et al., 2001). It has been 
shown that over 90% of hESCs grown on Matrigel express "6- and $1-
integrin subunits, while less than 25% of hESCs were found to express the 
$4 subunit (Meng et al., 2010). As discussed previously in section 1.8.4, this 
integrin subunit plays a crucial role in epidermal homeostasis and is 
abundantly found in human keratinocytes as a part of hemidosmosomes 
complex (Watt and Hertle, 1994, Margadant et al., 2010). Therefore, flow 
cytometry analysis for $4-integrin subunit expression would significantly 




In this set of experiments, I aimed to produce ECM from HDFs that would 
closely resemble BM of human skin. In addition, I sought to examine the 
potential of such matrix to support the growth of undifferentiated hESCs. 
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The main aim of this set experiments was to subsequently evaluate the 
efficiency of the HDF-ECM produced as a substrate for in vitro epidermal 
differentiation of hESCs when appropriate differentiation-inducing factors 
(namely BMP-4 and ATRA) were added. Indeed, ECM secreted by normal 
HDFs appears to resemble human skin BM in expression of several key 
proteins as evaluated by immunofluorescence analysis. Furthermore, HDF-
produced matrix was shown to support the growth and proliferation of the 
undifferentiated KCL-002 hESC line in the presence of mTESR medium. 
When hESCs grown on HDF-ECM as a substrate were induced to 
differentiate by treatment with BMP-4 and ATRA, highly proliferative 
pKPCs, positive for the basal keratin 14 protein and p63 transcription 
factor, were obtained. These pKPCs could form large epithelial-like sheets 
when cultured in keratinocyte medium and sustained basal keratin 14 
expression when expanded and passaged. They also displayed a reasonably 
high clonogenic potential and proliferation capacity, comparable to that in 
NHKs. These collective results indicate that by mimicking the natural 
keratinocyte environment, i.e. BM of human skin, ECM produced by normal 
HDFs can serve as an efficient substrate to direct hESCs towards an 
epidermal fate. 
 
6.4.1 ECM produced by HDFs is similar in composition to skin 
BM 
Immunofluorescent analysis of the produced HDF matrices revealed the 
presence of dense meshwork of fibronectin fibres, numerous fine fibrils of 
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types IV and VII collagen, as well as non-organized batches of type I 
collagen and laminin-332, confirming the presence of the key ECM proteins 
of skin BM.  
The BM at the DEJ is known to be composed mainly of type IV and VII 
collagens, several laminins such as laminins-332, -311, and -511, nidogen, 
and perlecan (Marinkovich et al., 1993, Burgeson et al., 1994). Type IV 
collagen is the main component of the lamina densa, while anchoring 
filaments transversing lamina lucida are composed mainly of laminin-332 
(Rousselle et al., 1991). Fibronectin is an important constituent of the DEJ 
(Couchman et al., 1990), which plays an important role in keratinocyte 
proliferation and differentiation (Adams and Watt, 1989), and type VII 
collagen forms anchoring fibrils in the sub-lamina densa region (Sakai et al., 
1986, Lunstrum et al., 1986). Therefore, basic molecular characterization 
confirmed HDF-ECM contains the key ECM proteins that are essential for 
organizing BM of the skin (Inoue, 1989).  
However, one significant difference in the composition of HDF-ECM 
compared to skin BM is the presence of type I collagen in the former. Type I 
collagen is normally found in the interstitial collagen layers of the dermis 
(Junqueira et al., 1983, Meigel et al., 1977), and not in the BM. This 
difference could significantly alter the overall molecular organization of the 
matrix, and in turn affect the proliferation, migration and differentiation of 
the dependant cell population. Furthermore, the thickness of HDF-
synthesized matrices varies between 8 and 20µm (Beacham et al., 2007). 
This is considerably more than the thickness of the BM of human skin (0.5-
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1.0!m) (Inoue, 1989). This feature also has the potential to alter or affect 
the biophysical properties of HDF-ECM and, consequently, the vital 
function of ECM in maintaining the putative EpSC population. 
 
6.4.2 HDF-ECM supports culture and maintenance of pluripotent 
hESCs 
Culturing hESCs on a native de-cellularized matrix produced by fibroblasts 
of human origin could enable a further optimization of hESCs culture 
towards xeno-free conditions. As mentioned previously, Matrigel (Kleinman 
and Martin, 2005, Kleinman et al., 1986) is produced from EHS mouse 
carcinoma and, despite its effectiveness as a substrate for hESCs, culture 
cannot be considered xeno-free. Previously, it has been shown that such 
matrices can indeed support the derivation and propagation of hESCs 
(Klimanskaya et al., 2005). However, that study utilized MEFs for matrix 
derivation. The results described in this chapter show that hESCs can be 
successfully cultured on ECM produced by HDFs while retaining the 
expression of pluripotency-associated proteins. Very recently, an optimized 
general protocol for entirely animal-protein free and feeder-free derivation 
and propagation of hESCs has been developed at King’s College London (Ilic 
et al., 2012). This protocol utilizes native de-cellularized ECM produced by 




6.4.3 HDF-ECM as an inducer of epidermal differentiation of 
hESCs 
The epidermal differentiation protocol utilizing HDF-ECM as a natural 
substrate and synergetic effects of BMP-4 and ATRA is highly efficient in 
producing a homogenous population of keratin 14-positive pKPCs, which 
also express high levels of p63 transcription factor. 
Previously, epidermal differentiation was achieved when murine ESCs were 
seeded on matrix derived from human normal fibroblasts and NIH-3T3 cells 
(Coraux et al., 2003b). Under these conditions, keratin 14-positive cells were 
obtained which formed well-defined epidermal layers with appropriate 
marker expression in an organotypic mouse model. However, the relative 
percentage of keratin 14-positive cells in that study was only 9.8%, 
suggesting that differentiation culture conditions could be improved. 
Recently, refined culture conditions were developed that relied on prolonged 
time- and concentration-dependent application of ATRA and induction of 
BMP signalling (Metallo et al., 2008b); the authors reported that after 5 
weeks of differentiation, 87% of cells expressed keratin 14. 
Therefore, the aim of the set of experiments described in this chapter was to 
effectively combine the appropriate substrate and culture conditions to 
achieve an efficient production of functional epidermal progenitors from 
hESCs. Under these conditions, expression of basal keratins 5 and 14 is first 
detected in the peripheral cells, suggesting that these cells are the first to 
undergo differentiation. After 7 days of induction, cytoplasmic keratins 19, 5 
and 14 can be detected, as well as the transmembranous desmosomal 
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marker DSC2. By day 25, large sheets of typical epithelial morphology could 
be observed. A few very large and flat cells could be seen at the edges of 
these putative epithelial sheets which were probably terminally 
differentiated cells that had lost replicative potential (Watt and Green, 
1981). These cells were either only very dimly positive or negative for both 
keratin 14 and p63 expression. On the contrary, the central parts of the 
sheets displayed bright p63 positivity, indicating the presence of highly 
proliferative keratinocyte precursors. Following enrichment based on rapid 
adherence to type IV collagen, some rapidly adherent cells formed compact 
holoclone-like colonies that were brightly positive for p63 transcription 
factor expression, as well as keratin 14. These colonies were able to expand 
and form continuous large epithelial-like sheets, while maintaining their 
morphology and markers expression.  
Flow cytometry analysis confirmed that pKPCs at passage 1 were 
homogenously positive for keratin 14 expression with 80.2% of the cells also 
positive for the "6 integrin subunit, a suggested marker for EpSCs (Li 
1998), although this marker is not as effective as the $1 integrin subunit in 
enrichment for human epidermal stem cells (Jones and Watt 1993; Jensen 
1999). It is important to note that both "6 and $1 integrins are highly 
expressed in undifferentiated hESCs (Xu et al., 2001), therefore only keratin 
14 / "6 integrin double-positive cells can be considered putative 
keratinocyte-like cells. Homogenous keratin 14 expression was sustained 
after 5 passages, as indicated by a repeated flow cytometry analysis with a 
similar expression of "6 integrin (77.7%). 
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Previously, a limited proliferation potential of hESC-derived keratinocytes 
was reported (Aberdam et al., 2007, Green et al., 2003, Ji et al., 2006, 
Metallo et al., 2008b), and it was suggested that these cells represent an 
incomplete or abnormal form of p63-positive lineage development 
(Dabelsteen et al., 2009). Therefore in order to assess the proliferation 
potential and functionality of pKPCs produced, two assays which examine 
metabolic components that are necessary for cell growth, namely the CFE 
and MTT assays, were carried out. When CFE of pKPCs (6.3±1.3) was 
compared to that of NHKs (10.6±0.6), statistical analysis returned a value of 
p=0.0453. This is considered significant at 95% confidence interval (p<0.05). 
However as the value approaches the critical P value, it can be concluded 
that the clonogenic capacity of pKPCs closely resembles that of NHKs. Cell 
viability and proliferation was measured by the MTT assay and indicated 
that the O.D. for pKPCs at day 25 of differentiation was 0.16±0.03. When 
compared to NHKs (0.24±0.03), the difference was found to be statistically 
insignificant, suggesting a high proliferative capacity of epidermal 
progenitors produced under these conditions. The results of both assays 
suggest that pKPCs obtained on HDF-ECM under conditions described are 
functional, highly proliferative cells with a robust clonogenic capacity. 
 
6.4.4 Conclusion and future work 
In conclusion, the microenvironment provided by HDFs, in combination 
with BMP4 and ATRA, appears to encourage differentiation of hESCs 
towards highly proliferative keratinocyte precursors. These pKPCs retain 
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their morphological and immunocytochemical characteristics for up to 5 
passages. These results are in accordance with the notion that cooperative 
development of the ectodermal and mesodermal layers during embryonic 
development is achieved through reciprocal signalling between these tissues 
(Sengel, 1976). In the coordinated ectodermal-mesodermal interactions, the 
ECM provides structural supports and directs a variety of cellular functions, 
proliferation, migration and differentiation.  
Nevertheless, further functional studies are required to validate the 
potential of these pKPC cells. Of particular importance would be to see how 
these cells would behave when seeded on DED. In a previously published 
mouse model, reconstitution of fully functional epidermal layers as well as 
formation of a dermal compartment underneath was achieved (Coraux 
2003). However, due to the relative inefficiency of the differentiation 
protocol and consequent heterogeneity of the epidermal cell population 
obtained, a continuous epidermis was not observed and only ~20% of the 
skin was well organized. The differentiation protocol described in this 
chapter, however, produced a pure population of keratin 14-positive cells 
and it is expected that DED would provide a favourable environment and 
further epidermal-stimulating cues for pKPCs to form continuous epidermis 
resembling the normal skin epidermis. Under such conditions pKPCs should 
be able to undergo terminal differentiation and stratification and arrange 
into distinct layers of cells at progressive stages of differentiation: with least 






7.1 THE PROMISE AND PROSPECTS OF PLURIPTENT STEM 
CELLS FOR RDEB CELL THERAPY 
Although the molecular basis of RDEB is reasonably well understood, 
effective treatment is still unavailable (Uitto et al., 2010). One potential 
treatment involves engineered allografted skin from normal individuals, 
which is one of the well-established cell therapies for severe burn victims 
(Pham et al., 2007). However, the allografted skin will eventually be 
immunologically rejected due to donor mismatch. Autologous skin cultures 
can also be generated from small pieces of healthy skin isolated from burn 
patients, and are commonly used for enhancing wound healing in instances 
of severe burns (Pham et al., 2007). However, this method cannot be 
implemented in patients with RDEB, because functional type VII collagen 
protein is markedly reduced or absent from all cells of affected individuals, 
i.e. autologous cells still retain the inherent susceptibility to skin fragility. 
Because the primary pathology of RDEB is due to a single gene defect, a 
"cure" would rely upon on the normal production of type VII collagen. 
Therefore, several current research approaches aim to restore collagen VII, 
including cell, gene and recombinant protein therapy (Mavilio et al., 2006, 
Titeux et al., 2010, Ortiz-Urda et al., 2003, Chen et al., 2002, Gache et al., 
2004, Remington et al., 2009), and, more recently, bone marrow 
transplantation (Wagner et al., 2010a, Tolar et al., 2011a). For an optimal 
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approach in treating RDEB, keratinocytes should perhaps be the main cell 
type targeted, because it is the keratinocytes that produce the majority of 
type VII collagen in the skin in vivo (Regauer et al., 1990). That said, 
correction of the BM defect by genetically corrected fibroblasts alone has 
been demonstrated in a mouse model (Ito et al., 2009). With regards to 
keratinocytes, however, long-term success of the treatment is limited by the 
low proliferative capacity of keratinocytes, which renders them ineffective 
as targets for ex vivo gene therapy based on homologous recombination and 
by the low efficiency of targeting the keratinocyte stem cell pool. This might 
be a difficult task to accomplish in vivo because the pool of stem cells in 
normal skin is relatively limited, and, therefore, is likely to be reduced in 
RDEB skin due to constant sub-epidermal blistering and disruption of BM. 
Thus, one goal in developing a sustainable treatment for this disease would 
be to establish a robust approach for the derivation of keratinocyte stem 
cells or epidermal progenitors.  
With this in mind, pluripotent stem cells can be considered the most 
promising cell type. The original derivation of hESCs by Thomson et al. 
(1998) stimulated a flurry of research focused on the potential for derivation 
of clinically useful cell types from hESCs, such as sensory neurons, skeletal 
muscle cells, insulin-producing pancreatic-like cells and others (Zheng et al., 
2006, Puceat, 2008, D'Amour et al., 2005, Segev et al., 2004). These 
differentiation studies culminated in the first clinical trial using hESCs 
targeting spinal cord repair by transplantation of hESC-derived 
oligodendrocytes (Alper, 2009).  
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The discovery that somatic cell types can be reprogrammed to a pluripotent 
state (Takahashi et al., 2007) has encouraged a new wave of pluripotent 
stem cell research with the promise of obtaining iPSCs as a less ethically 
contentious alternative to hESCs. The reprogramming of RDEB-specific 
somatic cells into iPSCs is a promising new approach to establish human 
models for studying disease mechanisms, testing drugs, and developing cell 
therapies. Furthermore, patient-specific RDEB iPSCs can be gene-targeted 
by homologous recombination to correct the COL7A1 gene defect.$ 
An intriguing alternative for skin diseases is the readily available source of 
spontaneously corrected skin cells in the form of revertant mosaicism 
(Almaani et al., 2010, Jonkman et al., 1997, Pasmooij et al., 2010, Pasmooij 
et al., 2007, Pasmooij et al., 2005). Occasionally, patients with different 
forms of EB and other skin diseases display patches of phenotypically 
normal skin where second-site mutations have resulted in restoration of 
protein expression. Somatic reprogramming of keratinocytes from these 
revertant patches and subsequent generation of iPSC-derived epidermal 
progenitors has the potential to provide an unlimited source of patient-
specific autologous cells that can eventually be used for skin grafting or 
transplantation without the need for conditioning or immunosuppression or 
any additional correction of the skin BM genetic defect.  
Therefore, mastering manipulation of pluripotency would provide a proof of 
concept that pluripotent stem cell derivatives may be a source of 




7.2 SUMMARY OF RESULTS 
The studies presented in this thesis have been concerned with, firstly, 
devising clinically- relevant conditions for culture and/or derivation of 
pluripotent stem cells and, secondly, with the attempted derivation of 
epidermal progenitor-like populations of cells from hESCs. 
 
7.2.1 Studies of pluripotent cell culture and derivation 
Feeder-based culture, as currently done in most laboratories, requires 
manual passaging and makes maintenance of human pluripotent stem cells 
in an undifferentiated state extremely labour-intensive and time consuming.  
To overcome this issue, the KCL-002 hESC line was adapted to feeder-free 
growth prior to commencement of differentiation studies. 
Under feeder-free conditions, robust expression of mRNA transcripts of 
pluripotency-associated Nanog and Sox-2 genes was detected. 
Immunocytochemical analysis of KCL-002 colonies also revealed consistent 
expression of pluripotency-associated markers. Undifferentiated cells were 
able to undergo directed differentiation through embryoid body formation in 
vitro, and proved to possess germ layer competence during teratoma assays 
in vivo. Thus, Chapter 2 of this study demonstrated that hESCs can be 
successfully adapted to growth under defined feeder-free culture conditions 
and expanded using enzymatic treatment, allowing for scalability, which in 
turn permits repeated differentiation attempts and their evaluation. 
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In the work described in Chapter 3, I attempted to achieve somatic cell 
reprogramming using whole protein extracts of the KCL-002 hESC line. 
Unfortunately, despite observing colonies with iPSC-like morphology and 
SSEA-4 pluripotency marker expression, I was not able to obtain a fully-
reprogrammed cell population. The possible explanations for this negative 
result are discussed in more detail in Chapter 3, and it remains to be 
determined if indeed the generation of human iPSCs can be achieved using 
this methodology. 
 
7.2.2 Studies regarding the derivation of epidermal progenitors 
from hESCs 
Chapter 4 of this thesis presented data showing that, while a complex 
microenvironment such as DED was able to induce formation of some 
epidermis-like structures from undifferentiated hESCs, the conditions were 
insufficient to promote the development of a continuous pluristratified 
epidermis. It was, therefore, concluded that to achieve the development of a 
fully-formed epidermis, a highly proliferative population of epidermal 
progenitors should be first obtained from hESCs. Consequently, Chapters 5 
and 6 described the evaluation of various differentiation protocols that could 
serve this purpose. 
In data presented in Chapter 5, comparison of different methods relying on 
SDIA exerted by PA6 stromal cells was drawn, and the results suggested 
that indirect co-culture using Transwell systems was most effective in 
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inducing epidermal differentiation of hESCs. However, pKPCs obtained 
displayed a limited proliferative potential which would severely hinder 
further clinical application of these cells. 
These observations are consistent with previous differentiation studies, 
showing that hESC-derived keratinocytes generated fragmented colonies 
formed by scattered noncohesive cells and, more importantly, possessed a 
much lower proliferative potential compared to NHKs (Green et al., 2003; 
Aberdam et al., 2007; Iuchi et al., 2006; Ji et al., 2006; Metallo et al., 2008). 
The differentiation protocol described in Chapter 6, on the other hand, 
showed that the epidermal progenitors produced had a very high 
proliferative capacity, and, therefore, could potentially be used as a 
continuous source of keratinocytes in future therapies for RDEB. It appears 
that the combination of HDF-ECM and synergetic effects of BMP-4 and 
ATRA can generate and sustain a relatively less differentiated population of 
hESC-derived epidermal stem cells or long-live progenitors, compared to the 
minimally proliferating hESC-derived keratinocytes that have been 
previously described. Indeed, the observed holoclone-like colonies and 
clonogenic efficiency assay would suggest that pKPCs obtained under the 
conditions described were enriched in holoclone-forming cells, as opposed to 
the meroclone- and paraclone-forming population of more differentiated 
transient amplifying progenitors (De Luca et al., 2006). 
Collectively, the data support and further emphasise the importance of 
recapitulating epidermal morphogenesis, in particularly the inductive 
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effects of mesenchyme (Sengel, 1976), in vitro in order to achieve efficient 
and reproducible epidermal differentiation from hESCs. 
7.3 RECONCILIATION OF DATA WITH THE PUBLISHED 
LITERATURE 
In the section that follows, I assessed the integration of data presented in 
this thesis with that of published literature in the relevant field. 
 
7.3.1 Evidence for epidermal cell lineage derivation from hES 
cells 
Several studies have demonstrated the possibility for derivation of 
keratinocytes frm hESCs (Aberdam et al., 2007, Green et al., 2003, Ji et al., 
2006, Metallo et al., 2008b), albeit with varying degrees of efficiency, 
reproducibility and clinical potential.  
Recently, the first pre-clinical trial was conducted which utilized epidermal 
progenitors obtained after 40 days of treatment with BMP-4 and ATRA 
(Guenou et al., 2009). These hESC-derived keratinocytes appeared capable 
of forming a pluristratified epidermis, both in vitro  and in vivo, as 
xenografts in immunodeficient mice. The resultant human epidermis was 
shown to persist for at least 3 months, that is, at least three full epidermal 
renewal cycles. These observations imply that initiation of studies and 
possible clinical trials into the repair of human epidermal defects using 




7.3.2 Evidence for generation of RDEB-specific iPSCs 
Recently, successful derivation of RDEB-specific iPSCs has been reported 
(Itoh et al., 2011, Tolar et al., 2011b). While one of these studies suggested 
that these RDEB-iPSCs  could be used to ameliorate the disease through 
differentiation into a haematopoietic lineage (Tolar et al., 2011b), the other 
study showed that RDEB-iPSCs can undergo a directed differentiation into 
fully-functional keratinocytes (Itoh et al., 2011), providing a proof-of-concept 
for potential therapeutic application of these cells. It is worth noting, 
however, that the percentage of keratin 14-positive cells under 
differentiation conditions tested in that study was approximately 70% (Itoh 
et al., 2011), which is significantly lower than that achieved with the 
differentiation protocol described in Chapter 6 of this thesis. More 
importantly, both of these published studies relied on retroviral 
transduction for iPSC generation (Itoh et al., 2011, Tolar et al., 2011b), and 
a variable viral transgene silencing was reported  (Itoh et al., 2011). 
Therefore, further efforts should be directed towards establishing an 
efficient and reproducible protocol for RDEB-specific iPSCs using non-
integrating reprogramming methods. In addition, a parallel comparison 
with hESC-derived epidermal progenitors with those derived from iPSCs 
would be desirable. 
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7.4 FUTURE STUDIES 
7.4.1 Short-term goals 
Immediate studies should be directed to evaluate the capacity of epidermal 
progenitors obtained in the differentiation protocol described in Chapter 6 to 
form continuous pluristratified epidermis with appropriate marker 
expression in organotypic cultures. 
In addition, examination of stage-specific expression of epidermal marker 
genes, particularly p63 transcription factor, would also augment the data. 
 
7.4.2 Long-term goals 
In order to translate the differentiation approach described in Chaper 6 of 
this thesis into a clinical setting, scalability of the differentiation process 
would be required. Automation culture of pluripotent stem cells using 
bioreactors (Come et al., 2008)  and the full automation of cell culture on a 
CompacT SelecT platform capable of producing two billion cells every 2 days 
(Thomas et al., 2009) opens the prospects for large-scale production of 
hESCs. In addition, similar platforms could be designed for differentiation 




7.5 IMPLICATIONS OF THE PRESENT STUDY AND FINAL 
CONCLUSIONS 
Identification of a differentiation protocol that coaxes pluripotent stem cells 
at an undifferentiated stage towards an epidermal lineage, with the 
resulting cell population exhibiting characteristics similar to those of basal 
keratinocytes, opens exciting avenues for a potential cell therapy for RDEB, 
as well as skin grafting in general. 
Despite high demand and the available technology, an adult keratinocyte 
cell bank has not been established. That said, adult keratinocytes might not 
be the most appropriate candidate for cell banking, since the formation of a 
reconstructed epidermis is highly dependent on the age of donors (Youn et 
al., 2004) and the number of cell passages (Fortunel et al., 2003), which is 
generally high in allogeneic cultures. Furthermore, batch-to-batch 
variability would be unavoidable as cells would be obtained from individuals 
with different genetic backgrounds. On the other hand, it might indeed be 
possible to explore the potential of pluripotent stem cells- either of 
embryonic origin or produced by somatic reprogramming- and establish a 
large bank of clinical-grade epidermal progenitors, capable of forming a 
well-differentiated pluristratified epidermis fulfilling the needs of hundreds 
of thousands of patients who may benefit from it. From the studies of BM 
transplantation in RDEB (Kiuru et al., 2010, Wagner et al., 2010a), these 
epidermal progenitors could be administered topically as well as 
systemically to ameliorate skin disease. 
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There are, however, some issues which have to be addressed in order to 
bring the application of these cells closer to the clinical setting. One issue is 
the potential immunogenicity of the epidermal progenitors, although one 
may expect cells displaying characteristics of foetal or embryonic skin to 
have a much better tolerance than adult keratinocytes. The possibility of a 
bank of pluripotent stem cell lines of a wide variety of haplotypes may 
eventually provide a definitive answer. 
Another important concern regarding the potential clinical utility of 
pluripotent stem cells is the risk of teratoma formation. Although a 
teratoma is not in essence malignant, its natural propensity to grow makes 
it potentially dangerous when implanted into an individual and, as such this 
would be unacceptable for an approved cell therapy. Despite confirmation of 
absence of pluripotency-associated markers in the epidermal progenitors 
obtained, the possibility that a rare cell has retained its pluripotent 
characteristics, or that grafting itself can cause dedifferentiation, cannot be 
excluded. However, the superficial placement of the graft for epidermal cell 
therapy would allow for a relatively easy continuous control by monitoring 
appearance of the tissue and its surgical resection in case of an emerging 
problem. 
In conclusion, it is worth noting that most cell types that normally 
participate in the formation of the dermis and epidermis can either already 
be obtained through in vitro differentiation from pluripotent stem cells or 
would likely migrate from the host into a graft. However, differentiation 
protocols for specialized glands and hair follicles remain to be designed. 
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Therefore, a future can be foreseen when reconstructive medicine will make 
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